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CHAPTER 1 
 
INTRODUCTION 
 
Introduction to the Glutamate System 
Glutamate is an amino acid used as the primary excitatory neurotransmitter in the 
central nervous system (CNS) and is essential in many brain functions, including behavior, 
cognition, memory, and learning (Zhou and Danbolt, 2014a). Initial analyses of the molecule 
indicated that it was important for brain metabolism (Krebs, 1935), and researchers identified it’s 
excitatory effect on neurons in the 1950s (Hayashi, 1952, Curtis and Watkins, 1960). Despite 
this revelation, investigators did not recognize glutamate as the primary excitatory 
neurotransmitter of the nervous system until over twenty years later (Watkins and Evans, 1981, 
Fonnum, 1984).  
In the CNS, glutamate is packaged into synaptic vesicles within the axon terminal of 
glutamatergic neurons. Upon the arrival of a propagating action potential at the synaptic 
terminus, the plasma membrane becomes depolarized and glutamate-containing synaptic 
vesicles undergo exocytosis. This Ca2+ dependent process, termed synaptic vesicular fusion, 
then releases glutamate into the synaptic space between two neurons, carrying cellular signals 
from one neuron to another in the form of glutamate (Kandel, 2013). This glutamatergic signal is 
then interpreted by glutamate receptors that are present on most parts of a neuron (dendrites, 
nerve terminals, and cell bodies) but usually with the highest density at postsynaptic densities of 
a synapse. Due to a lack of extracellular enzymes capable to break down glutamate, the only 
way to control this signal is the removal of glutamate from the extracellular space into both 
neurons and glial cells surrounding the synapse (Balcar and Johnston, 1972, Logan and 
Snyder, 1972) via glutamate transporters, also referred to as EAATs, Excitatory Amino Acid 
Transporters). Spatial and temporal regulation of glutamate concentrations within the CNS by 
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glutamate transporters is crucial to for two reasons: 1) a constant low concentration of 
glutamate in the extrasynaptic space allows for a high signal-to-noise ratio resulting in precise 
cellular communication; 2) prolonged high levels of synaptic glutamate and subsequent 
glutamate receptor activation is toxic to neurons (Danbolt, 2001, Mehta et al., 2007).  
The molecules of glutamate transported from the extracellular space into glial cells are 
metabolized into glutamine via glutamine synthetase within the cytosol of glial cells or are 
utilized for cellular metabolism via the tricarboxylic acid cycle. Glial glutamine is then released 
into the extracellular fluid, taken up by neurons and reconverted back into glutamate by 
mitochondrial glutaminase (Daikhin and Yudkoff, 2000). Neuronal glutamate is subsequently 
repackaged into synaptic vesicles via the vesicular glutamate transporter for reuse as a 
neurotransmitter. This cycle of neuronal glutamate release and recycling through glial cells to be 
repackaged in neuronal synaptic vesicles is commonly referred to as the glutamine-glutamate 
cycle (Fonnum, 1993, Westergaard et al., 1995).  
 
Glutamate Receptors 
Molecular cloning was used to identify three different families of glutamate receptors 
(Hollmann et al., 1994, Hollmann and Heinemann, 1994, Borges and Dingledine, 1998, 
Nakanishi et al., 1998, Ozawa et al., 1998). One class of glutamate receptor was found to be 
activated by the glutamate analogue, N-methyl-d-aspartate (NMDA), thus titled NMDA receptor 
(Traynelis et al., 2010), and is comprised of varying combinations of structurally distinct subunits 
(NR1, NR2A, NR2B, NR2C, and NR2D). The second class of glutamate receptor was defined 
by their activation by α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and 
kainate. As with NMDA receptors, AMPA receptors are also comprised of structurally distinct 
subunits (GluR1-4) based on their affinity for AMPA (GluR1-4) or kainate (GluR5-9, KA1-2). 
These two families are glutamate-gated ion channels that allow for the influx of Na+ exclusively 
or both Na+ and Ca2+ ions and are referred to as ionotropic glutamate receptors. Despite both 
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being activated by glutamate, they have distinct activation profiles and dynamics that result in 
differential effects on glutamatergic signaling. AMPA receptors are quickly activated by 
glutamate but also desensitize quickly while NMDA receptors require a depolarized membrane 
potential in addition to binding of the co-agonist, glycine, along with glutamate activation, for the 
conductance of cations; however they have a slower desensitization profile (Tang et al., 1989, 
Ozawa et al., 1998, Traynelis et al., 2010). The third family of glutamate receptors are 
metabotropic glutamate receptors. These receptors (mGluR1-8) are G-protein coupled 
receptors and are subdivided into groups I (mGluR1 and mGluR5, Gq-coupled), II (mGluR2 and 
3, Gi-coupled), and III (mGluR4-8, Gi-coupled) (Niswender and Conn, 2010). Stimulation of 
mGluRs result in activation of intracellular signaling pathways resulting in altered intracellular 
processes, such as receptor trafficking and protein expression (Wan et al., 2011).  
 
Excitatory Amino Acid Transporters 
Due to the need to maintain spatiotemporal control of neuronal signaling, and the need 
to limit excitotoxicity resulting from excessive glutamatergic activation, it is logical that the CNS 
has highly protective systems in place to remove glutamate from the synaptic cleft. As 
mentioned previously, glutamatergic signaling is tightly controlled via proteins called excitatory 
amino acid transporters (EAATs). Following the identification of the glutamine-glutamate cycle, 
numerous research groups began to study how glutamate is removed from the synapse via 
EAATs. They found that the transport process was electrogenic and required ion gradients of K+ 
and Na+ (Fonnum, 1984, Kanner and Schuldiner, 1987, Nicholls and Attwell, 1990). The 
identification and cloning of three types of EAATs showed that the synaptic glutamate removal 
was more intricate than previously believed (Kanai and Hediger, 1992, Pines et al., 1992, Storck 
et al., 1992, Kanai et al., 1993, Danbolt, 1994).   
There are many different protein families capable of transporting glutamate within the 
CNS, including high- and low-affinity glutamate transporters, Na+-independent carriers, and 
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glutamate-cystine exchangers. For the focus of this dissertation, emphasis will be placed on the 
high affinity glutamate transporters (specifically EAAT3); however more information on low 
affinity glutamate transporters, Na+-independent carriers, and glutamate-cystine exchangers can 
be found elsewhere (Erecinska and Silver, 1990, Warr et al., 1999, Flynn and McBean, 2000). 
Currently, there are five distinct high-affinity glutamate transporters that have been identified 
(Saier, 1999, Slotboom et al., 1999). They are titled GLAST (EAAT1), GLT-1 (EAAT2), EAAT3, 
EAAT4, and EAAT5. All are Na+- and K+-coupled and transport both L-glutamate and L- and D-
aspartate. These five glutamate transporter subtypes share roughly 50-60% sequence 
homology and all belong to the SLC1A gene family (Slotboom et al., 1999). Despite being Na+-
coupled, these glutamate transporters are a distinct transporter protein family from other 
neurotransmitter transporters found in the CNS (Borowsky and Hoffman, 1995, Nelson, 1998).  
As the focus here is on SLC1A1/EAAT3, a brief overview pertaining to the localization 
and importance of the other high affinity glutamate transporters will be addressed here with a 
more in depth discussion of EAAT3 to follow. EAAT1 or GLAST (Glutamate ASpartate 
Transporter) is expressed throughout the CNS by astrocytes (Lehre et al., 1995, Schmitt et al., 
1997, Berger and Hediger, 1998), including the retina, where EAAT1 is believed to be the 
primary form of glutamate uptake (Rauen, 2000, Rauen and Wiessner, 2000). EAAT1 null mice 
exhibit normal development; however glutamate homeostasis is compromised in brain regions 
where EAAT1-mediated glutamate uptake predominates (Harada et al., 1998). Behaviorally, 
phenotypes of EAAT1 null mice include abnormal nesting behavior, sociability, alcohol uptake, 
and reward (Watase et al., 1998, Stoffel et al., 2004, Karlsson et al., 2009). Mutations of 
SLC1A3, encoding EAAT1, are rare but have been linked to episodic ataxia, hemiplegia, and 
seizure (Jen et al., 2005, de Vries et al., 2009, Broer and Palacin, 2011). 
GLT-1 (Glutamate Transporter 1) is the primary transporter of glutamate at the 
glutamatergic synapse and was found to be expressed on the membranes of glial cells via 
immunohistochemistry (Danbolt et al., 1992, Hees et al., 1992, Pines et al., 1992) and use of a 
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GLT-1 eGFP BAC reporter mouse (de Vivo et al., 2010). Data from transport analysis studies, 
electrophysiological studies, and ex vivo preparations from GLT-1 knockout mice propose that 
GLT-1 is responsible for ~95% of all glutamate transport in the forebrain (Danbolt et al., 1992, 
Tanaka et al., 1997, Otis and Kavanaugh, 2000, Holmseth et al., 2012). It is therefore argued 
that GLT-1 is the only EAAT that is essential for long-term organism viability under in normal 
conditions (Tanaka et al., 1997, Danbolt, 2001).  In agreement with this hypothesis, young GLT-
1 null mice display hyperactivity, increased susceptibility to seizures, and reduced body weight 
compared to littermate controls By one month of age, the survival rate of GLT-1 deficient mice 
drops to roughly 50% due to the onset of lethal spontaneous seizures (Tanaka et al., 1997) 
believed to be linked to increased synaptic glutamate levels (Mitani and Tanaka, 2003, Takasaki 
et al., 2008). 
EAAT4 is localized primarily to dendrites of cerebellar Purkinje cells, particularly the 
spines (Fairman et al., 1995, Dehnes et al., 1998). It is also reported to be expressed in the 
forebrain (Dehnes et al., 1998, Massie et al., 2008) and in vestibular hair cells (Dalet et al., 
2012). Ablated expression of EAAT4 in mice causes no overt phenotypes; however 
metabotropic glutamate receptor activation is augmented in cerebellar Purkinje cells (Huang et 
al., 2004, Nikkuni et al., 2007).  
As with EAAT1, EAAT5 function is thought to be preferentially expressed in the retina, 
while levels elsewhere in the brain are low (Arriza et al., 1997, Eliasof et al., 1998). Confirmation 
of the exact cellular and subcellular localization of EAAT5 has been difficult due to the lack of a 
null mouse to be used as a negative control in immunohistochemical studies (Holmseth et al., 
2012). As such, more specific information regarding the role and distribution of EAAT5 in the 
CNS is limited.  
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Glutamate Exchangers 
 Another protein involved in the glutamate system is the glutamate-cystine exchanger 
(system xCT). xCT was identified via molecular cloning (Sato et al., 1999) and characterized as 
an electroneutral glutamate-cystine exchanger that exchanges extracellular cystine for 
intracellular glutamate by using the electrochemical gradient of glutamate as a driving force for 
moving a molecule of glutamate into the extracellular space. Currently, localization of xCT is 
unresolved; however reports suggest that the exchanger is expressed at relatively low levels, 
though it may be inducible in response to oxidative stress (Sato et al., 2002, Sato et al., 2004). 
Interest in xCT has increased due to evidence that xCT expression is increased in glioma and 
that excessive extracellular glutamate may have toxic effects enabling increased tissue invasion 
(Sontheimer, 2004, Takeuchi et al., 2013). xCT-deficient mice provide initial evidence that xCT 
plays a role in extracellular glutamate (De Bundel et al., 2011) and redox-imbalance (Sato et al., 
2005) however more work is necessary to resolve xCT’s role in these issues.  
 
Excitatory Amino Acid Transporter 3 
Structure  
 Currently, the structure of EAATs is predicted to be comprised of 8-10 transmembrane 
domains with intracellular N- and C-termini (Figure 1A) (Grunewald and Kanner, 1995, Wahle 
and Stoffel, 1996, Grunewald et al., 1998, Seal and Amara, 1998, Slotboom et al., 1999, Seal et 
al., 2000). Recent crystallization of an aspartate transporter from Pyrococcus horikoshii, GltPh, 
with ~37% sequence homology to mammalian transporters, identified 8 transmembrane helices 
(Yernool et al., 2004, Boudker et al., 2007). Glutamate transport into the cell is an electrogenic 
process and is dependent on electrochemical gradients that exist across the cellular membrane. 
Na+ is necessary for glutamate binding and K+ is required for net transport (Kanner and 
Schuldiner, 1987, Szatkowski et al., 1991). More recent studies utilizing EAAT3 expressed in 
Xenopus laevis oocytes and in mutant CHO cells have shown that the exact stoichiometry of 
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transport is one glutamate cotransported into the cell with three Na+ ions and one H+, while one 
K+ is exchanged out of the cell (Figure 1B) (Zerangue and Kavanaugh, 1996, Levy et al., 1998). 
Stoichiometry of transport of the other high affinity glutamate transporters has not been 
confirmed, but GLAST has been suggested to exhibit similar transport properties as EAAT3 
(Klockner et al., 1993).   
 
Localization 
In the CNS, EAAT3 is expressed broadly but shows higher expression in the 
hippocampus, basal ganglia and cerebellum (Conti et al., 1998b, Kugler and Schmitt, 1999, 
Holmseth et al., 2012). Outside of the brain, EAAT3 is expressed in the intestine, liver, heart, 
skeletal muscle, kidneys, placenta, sciatic nerve, dorsal root ganglion and primary afferent fibers 
terminating in the dorsal spinal horn (Kanai and Hediger, 1992, Velaz-Faircloth et al., 1996, 
Matthews et al., 1998, Tao et al., 2004). Historically, localization of EAAT3 was more arduous 
than GLAST and GLT-1 despite its sequence being published in the same Nature issue as the 
GLT-1 sequence (Kanai and Hediger, 1992, Pines et al., 1992) and about 1 month after 
publication of the GLAST sequence (Storck et al., 1992). This is believed to be a consequence 
of a few different factors, including a low amount of EAAT3 relative to GLT-1 and GLAST 
(Haugeto et al., 1996), and a lack of highly specific antibodies necessary for positive 
identification of an antigen that is expressed at relatively low amounts. Also, contrary to other 
EAATs, a substantial portion of expressed EAAT3 is located in the cytoplasm, rendering it 
difficult to be recognized by antibodies (Conti et al., 1998a, Kugler and Schmitt, 1999) and 
suggesting that EAAT3 can be promptly transported to the plasma membrane (Yang and 
Kilberg, 2002, Sheldon et al., 2006). Creation of a synthetic peptide corresponding to the C-
terminus of EAAT3 enabled localization of the protein (Rothstein et al., 1994) to the neuronal 
cell bodies and dendrites of several types of neurons including glutamatergic and GABAergic 
neurons. Recent studies have also identified EAAT3 expression on dopaminergic neurons 
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(Nafia et al., 2008, Assous et al., 2014) and have shown that EAAT3 rapidly undergoes 
endocytosis in response to the dopaminergic agent, amphetamine (Underhill et al., 2014). A 
study using a postembedding immunogold technique reported that EAAT3 is primarily found on 
the edges of synapses, termed the peri- or extrasynaptic space (He et al., 2000). Despite some 
in vitro reports to the contrary, EAAT3 expression is believed to be completely limited to the 
neurons as Holmseth et al. detected no identifiable EAAT3 in non-neuronal cells using EAAT3 
null mouse verified antibodies in adult rat brain (Holmseth et al., 2012) 
 
Function 
The majority of all glutamate uptake in the CNS is mediated via GLT-1, which is not 
surprising due to it being expressed roughly 100-fold more abundantly than EAAT3 (Holmseth 
et al., 2012). Some suggest that existing estimates of GLT-1’s role in glutamate reuptake may 
be inflated, since EAAT3 antisense knockdown studies indicate that ~20% of striatal and ~40% 
of hippocampal glutamate uptake is mediated via EAAT3 (Rothstein et al., 1996). The ongoing 
hypothesis is the EAAT3 may have a more substantial impact on glutamate exposure in the 
extrasynaptic regions where it is primarily expressed and where it is expected to modulate local 
glutamate receptor activation. This has been shown for both AMPA and NMDA receptors on 
post-synaptic neurons when EAAT3 function has been compromised (Scimemi et al., 2009, 
Jarzylo and Man, 2012, Underhill et al., 2014, Li et al., 2017). Lack of spatial control over 
glutamate release can result in synaptic spillover capable of activating NMDA receptors 
(NMDARs) located on neighboring synapses (Diamond, 2001). EAAT3 was shown to be 
necessary for the control of spillover glutamate activating NR2B-containing NMDARs 
specifically (Scimemi et al., 2009). Further, induction of long-term potentiation appeared to 
decrease EAAT3 activity and further increase local NMDAR activation in hippocampal slice 
electrophysiology experiments (Scimemi et al., 2009). Activation of hippocampal extrasynaptic 
NR2B-containing NMDARs via EAAT3 inhibition also led to the reduction of GluR1 and GluR2 
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via proteasomal degradation in both rat hippocampal and cortical neurons (Jarzylo and Man, 
2012).  
Another primary function of EAAT3 is the uptake of glutamate for the formation of the 
neurotransmitter γ-aminobutyric acid (GABA), providing an intracellular pool of glutamate for 
GABAergic neurons, including the medium spiny neurons (MSNs) of the striatum. (Mathews and 
Diamond, 2003). Pharmacological inhibition of EAAT3 shows that uptake of spillover glutamate 
contributes to inhibitory currents in the CA1 region of rat hippocampus (Stafford et al., 2010). 
Further, pharmacological inhibition of EAAT3 reduces the GABA released by these neurons, as 
well as the subsequent inhibitory currents resulting from GABA release (Sepkuty et al., 2002, 
Mathews and Diamond, 2003). Use of an antisense RNA knockdown strategy also revealed a 
reduction in 3[H]-GABA synthesis rate and an overall ~50% reduction of hippocampal GABA 
(Sepkuty et al., 2002).  
While all EAATs are able to transport L-glutamate and D-aspartate, recent efforts also 
show that EAAT3 is able to transport cysteine under physiological conditions (Watts et al., 
2014). Transport of cysteine into cells, particularly those under increased levels of oxidative 
stress, is thought to be a neuroprotective function of EAAT3, providing a neuronal substrate for 
the synthesis of the anti-oxidant glutathione. The ability of EAAT3 to transport cysteine has 
been established both in cell culture and animal models (Chen and Swanson, 2003, Aoyama et 
al., 2006, Nieoullon et al., 2006, Aoyama et al., 2012, Aoyama and Nakaki, 2013, Assous et al., 
2014). Investigation in aged EAAT3 null mice revealed increased levels of accumulated 
oxidative stress, cortical thinning, and enlarged ventricles (Aoyama et al., 2006). As mentioned 
previously, cell types under high levels of oxidative stress are more susceptible to oxidative 
stress, and 12-month old EAAT3 null mice exhibit almost ~40% loss of their dopaminergic 
neurons (Berman et al., 2011). Treatment with the cell permeable cysteine precursor, N-
acetylcysteine rescued this loss of dopaminergic neurons in the substantia nigra pars compacta 
(Berman et al., 2011).  
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Regulation of glutamate uptake via EAAT3 is thought to occur primarily via intracellular 
signaling modulation affecting trafficking of the transporter to the cell surface. Early efforts 
demonstrated that activation of protein kinase C (PKC) augmented glutamate uptake via 
selective increases in EAAT3 activity while also reducing GLT-1 function (Dowd and Robinson, 
1996, Gonzalez and Robinson, 2004). This phenomenon is due to increased levels of EAAT3 at 
the plasma membrane caused by intracellular activation of the PI3K (phosphoinositide 3-kinase) 
signaling pathway (Krizman-Genda et al., 2005). Platelet derived growth factor (PDGF) is also 
able to augment cell surface expression of EAAT3 in vitro via activation of the same PI3K 
pathway (Sims et al., 2000) The C-terminus of EAAT3 is also believed to interact with regulatory 
cytosolic proteins such as GTRAP3-18, which when physically interacting with EAAT3, inhibits 
glutamate transport (Lin et al., 2001, Butchbach et al., 2002). GTRAP3-18 knock out mice 
exhibited reduced body weight, increased levels of EAAT3 and GSH, and enhanced learning 
and memory in the Morris water maze (Aoyama and Nakaki, 2012, Aoyama et al., 2012). 
Alternatively from the above intracellular pathways, activation of post-synaptic receptors 
including the neurotensin 1, endothelin-1, and ionotropic glutamate receptors also modulate 
EAAT3 cellular localization (Levenson et al., 2002, Najimi et al., 2002, 2005, Waxman et al., 
2007) The ability to regulate the cell membrane level of EAAT3 represents the ability of neurons 
to rapidly induce adaptive changes in the cellular environment that may be useful to control 
potentially excitotoxic events.  
 
EAAT3 in Disease 
Dicarboxylic Aminoaciduria  
 While Slc1a1/EAAT3 is expressed throughout the CNS, it is also the primary transporter 
of epithelial glutamate and aspartate in the kidneys and intestines. Loss of function mutations in 
SLC1A1 have been identified in the human population and lead to dicarboxylic aminoaciduria 
(Bailey et al., 2011). This condition involves partial reabsorption of negatively charged amino  
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A 
B 
Figure 1. Stoichiometry of glutamate transport via EAAT3 and proposed topology of EAAT3 
A. Transport of one glutamate molecule into neurons is coupled to the translocation of three Na+ ions, one 
H+ and counter transport of one K+. EAATs also have an anion current that is gated by glutamate but not 
coupled to transport. 
B.  Proposed two-dimensional topology diagram of EAAT3 based on the crystal structure of the aspartate 
transporter, GltPh. EAATs are proposed to be composed of eight transmembrane (TM) domains with 
intracellular N- and C-termini and two reentrant loops between TM 6-7 and TM 7-8. 
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acids in the kidney which forces affected individuals to expend excessive resources to maintain 
sufficient cellular levels of anionic amino acids. Lack of functional EAAT3 resulting from these 
mutations in SLC1A1 have been suggested to be linked to growth retardation, intellectual 
disability and metabolic dysfunction (Broer, 2008, Bailey et al., 2011, Broer and Palacin, 2011)   
 
Obsessive-Compulsive Disorder 
 Family studies suggest a substantial heritable contribution to obsessive compulsive 
disorder. Genetic association studies have focused on candidate genes in a number of 
neurotransmitter systems, including glutamate, GABA, dopamine, and serotonin (Haber and 
Heilbronner, 2013, Bokor and Anderson, 2014, Ivarsson et al., 2015). Links to the serotonin 
system have primarily been based on the effectiveness of serotonin reuptake inhibitors as the 
primary form of pharmacotherapy; however little other evidence, genetic or otherwise, has 
connected the system to the disorder. More evidence for the role of dopamine in the 
manifestation of OCD symptoms has been reported, primarily via functional imaging and 
positron emission tomography (PET) studies (Denys et al., 2004, Klanker et al., 2013). Recent 
studies have focused more on evidence connecting OCD to abnormalities in the glutamatergic 
system. 
Unlike other neurotransmitter systems, evidence implicating the glutamatergic system in 
OCD has been historically consistent and more robust. Specifics of the involvement of the 
glutamate system and Slc1a1/EAAT3 specifically will be discussed in more depth in the 
following section. Initial interest in SLC1A1 in OCD arose from a genomic scan of early-onset 
OCD patients and immediate family members (Veenstra-VanderWeele et al., 2001). The 
connection between SLC1A1 and the disorder was subsequently strengthened via genetic 
linkage and association studies (Arnold et al., 2006, Dickel et al., 2006). As evidence that 
alteration of SLC1A1/EAAT3 function may affect OCD-relevant behavior and neurobiology 
grows, the link between the glutamate system and OCD becomes more substantial. Due to the 
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complexity of neuropsychiatric disorders, it is possible that many different factors contribute to 
the emergence of OCD; however mounting evidence suggests that pharmacological intervention 
on EAAT3 function may be a novel therapeutic strategy for the treatment of this debilitating 
disorder.  
 
Epilepsy 
 Reduction of EAAT3 mRNA via knockdown strategies increases the susceptibility to 
seizures in rodents, however it is thought to occur via an alternative mechanism, rather than 
failure to clear glutamate from the synapse (Rothstein et al., 1996). Acute reductions in EAAT3 
have been shown to attenuate tonic inhibition capacity of GABAergic neurons where EAAT3 
transport provides a substrate for the synthesis of GABA (Sepkuty et al., 2002). Following 
kainate and methyazoxymethanol-induced seizures, EAAT3 expression is diminished (Simantov 
et al., 1999, Harrington et al., 2007). These data mirror one report in human epilepsy patients, 
where cortical EAAT3 expression was reduced (Rakhade and Loeb, 2008). Interestingly, EAAT3 
null animals have not exhibited phenotypes of increased susceptibility to drug-induced seizures 
(Peghini et al., 1997, Aoyama et al., 2006), perhaps due to a developmental compensatory 
mechanism often observed in animal models of constitutive protein ablation.  
 Alternatively, recent studies using EAAT3 null mice argue that loss of EAAT3 is 
protective in the CA1 region of the hippocampus following pilocarpine-induced status epilepticus 
(Lane et al., 2014). The authors maintain that under the drug-induced epileptic conditions 
utilized, reductions in ATP and reversal of the Na+ electrochemical gradient across the cellular 
membrane cause EAAT3 to release intracellular glutamate back into the neuronal cleft which 
exacerbates glutamatergic signaling dysfunction leading to seizures (Streck et al., 2006, Kovac 
et al., 2012). In this case, a lack of EAAT3 transporting glutamate back into the synaptic cleft 
would be protective against glutamate efflux, leading to reductions in neuronal cell death as 
observed above. The contributions of EAAT3 to epilepsy are currently still under investigation 
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and, due to reports that EAAT3 is a minor regulator of synaptic glutamate relative to GLT-1, it is 
possible that dysfunctional EAAT3 would act as more of a risk factor for the exacerbation of 
epilepsy. Of note, loss-of-function mutations of the EAAT3 are rare in the human population and 
in a recent report, none of the two probands interviewed reported a history of epilepsy (Bailey et 
al., 2011). 
 
Schizophrenia 
 Attempts to understand the underlying pathophysiology of schizophrenia have been 
ongoing for years. Glutamate has been suggested to be associated with the disorder via 
evidence from human post-mortem brain tissue studies (Hu et al., 2015), including reductions in 
EAAT3 transcript in both bipolar and schizophrenia samples (McCullumsmith and Meador-
Woodruff, 2002). EAAT3 was decreased in the caudate nucleus of schizophrenic patients in one 
study (Nudmamud-Thanoi et al., 2007); however other studies report increased EAAT3 in the 
cortical post-mortem tissue via in situ hybridization analyses (Rao et al., 2012) and abnormal 
expression of the EAAT3 regulating protein JWA, the human ortholog of GTRAP3-18 (Bauer et 
al., 2008, Aoyama and Nakaki, 2012). 
 First-line pharmacotherapy of schizophrenia includes treatment with second-generation 
antipsychotics (SGAs), which have been associated with the induction of obsessive-compulsive 
(OC) like symptoms in schizophrenia patients (Lykouras et al., 2003, Fonseka et al., 2014). 
Strengthening the connection to glutamate and to EAAT3 specifically, single nucleotide 
polymorphisms in SLC1A1, the gene encoding EAAT3, have been associated with SGA-
induced OC symptoms (Kwon et al., 2009). This finding was independently replicated in a 
second study, which also reported a significant interaction between SLC1A1 and the gene 
coding for the NR2B NMDA subunit, GRIN2B (Cai et al., 2013).  
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Obsessive-Compulsive Disorder 
Introduction to Obsessive-Compulsive Disorder 
OCD is a chronic, debilitating, and heterogeneous psychiatric disorder affecting between 
1-3% of the worldwide population (Koran, 2000, Kessler et al., 2005, Ruscio et al., 2010). 
Primary symptoms of the disorder include recurrent obsessive and intrusive anxiety-inducing 
thoughts leading to ritualistic repetitive or compulsive behavior performed to mitigate this anxiety 
(Calvocoressi et al., 1998, Monzani et al., 2014). Age of onset for OCD ranges from early 
childhood, with 30-50% of OCD sufferers report onset prior to 10 years of age (Zohar, 1999). 
Based on higher familial recurrence rates and somewhat different patterns of symptoms, some 
clinicians suggest that early-onset OCD may in fact be a distinct form of the disorder (Geller et 
al., 1998, Nakatani et al., 2011).  
 
Treatment 
In spite of the societal costs of OCD, reported to be near to $10 billion in the USA alone 
(Eaton et al., 2008), available treatments are inadequate for the majority of patients. The initial 
recommended treatment for most patients is cognitive behavioral therapy (CBT), which appears 
to be similarly effective in both children and adults, but with the majority of patients showing 
substantial residual symptoms (Franklin and Foa, 2011). CBT techniques include exposure and 
response prevention, where a patient is exposed to anxiety-producing stimuli accompanied by 
the prevention of repetitive behaviors or compulsions that the patient typically performs to 
decrease their anxiety. Efficacy for CBT is slightly greater relative to treatment with serotonin 
reuptake inhibitors (SRIs) in some studies (Barrett et al., 2004), and their therapeutic effects are 
believed to be additive.  
First-line pharmacological treatment of OCD is SRIs (Geller et al., 2003); however, only 
50-60% of patients exhibit adequate response to available treatments (Koran et al., 2007). For 
example, a 20-40% decrease in OCD symptoms may result following SRI therapy (Dougherty et 
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al., 2004), which leaves many with clinically significant residual symptoms. While the 
effectiveness of SRI’s in OCD is empirically validated, evidence for the potential value of 
therapeutics targeting the dopamine and glutamate system has been mounting in recent years. 
Dopamine D2 (and 5-HT2A) receptor blockade in OCD has primarily been studied in the context 
of augmentation, with a recent meta-analysis of 12 placebo-controlled trials revealing significant 
improvement in cases of SRI-resistant OCD patients augmented with atypical antipsychotic 
medications compared to placebo (Dold et al., 2015). These results should be taken cautiously 
due to the heterogeneous nature of the methodology, dosage, inclusion criteria and other 
factors incorporated into the meta-analysis; however it does provide preliminary evidence for the 
use of D2 blockade in OCD as an augmentation therapy, particularly for risperidone (Bloch et al., 
2006, Skapinakis et al., 2007, Dold et al., 2013). A few drugs that target the glutamate system  
have shown promise as an augmentation therapy in OCD. The glutamate-modulating drug 
riluzole, FDA-approved for the treatment of amyotrophic lateral sclerosis, has emerging, 
suggestive evidence for reducing OCD symptoms in pediatric and adult patients (Coric et al., 
2005, Grant et al., 2007, Pittenger et al., 2008). Other drugs targeting the glutamatergic system, 
including agents targeting the NMDA receptor such memantine (Poyurovsky et al., 2005, 
Pasquini and Biondi, 2006, Haghighi et al., 2013) and D-cycloserine (Wilhelm et al., 2008, 
Storch et al., 2016) showed suggestive results when used as augmentation; however more 
thorough investigation is needed to fully understand the therapeutic potential of these 
compounds in OCD.  Other augmentation therapies, such as NMDA receptor antagonists and 
the glutathione precursor, N-acetylcysteine, are also being evaluated, but evidence for their 
utility is limited (Arumugham and Reddy, 2013). 
In some refractory OCD cases, deep brain stimulation (DBS) has also been used (Sturm 
et al., 2003, Goodman et al., 2010). The most common targets for DBS are the anterior limb of 
the internal capsule (VC/VS) (Greenberg et al., 2010), the nucleus accumbens (van den 
Munckhof et al., 2013, Ooms et al., 2014), and the subthalamic nucleus (Mallet et al., 2008). As 
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this field evolves, novel targets and stimulation techniques may be identified, ideally allowing for 
improved therapeutic efficacy while maintaining minimal off-target effects. 
 
Heritability 
As with many neuropsychiatric conditions, the underlying causes of OCD are unknown 
and are likely to involve both genetic and environmental factors. Abundant evidence for a 
heritable component of OCD stems from twin and family studies (Grados and Wilcox, 2007, 
Pauls, 2008). As reviewed elsewhere (Pauls, 2010), OCD symptoms are estimated to be 40-
65% heritable in children and 27-47% heritable in adults (van Grootheest et al., 2005). Family 
studies indicate that OCD is twice as common in first-degree relatives of affected adults and ten 
times as likely in relatives of affected children (Pauls, 2008). These studies support the premise 
that OCD risk is derived from a complex combination of genetic and non-genetic factors. 
 
Genetic analysis of OCD 
Genetic linkage studies have yet to generate genome-wide significant findings for the 
core diagnosis of OCD, likely because of lack of statistical power in limited sample sizes (Hanna 
et al., 2002a, Mathews et al., 2012). The most promising linkage signal is on chromosome 9p24, 
based upon a suggestive linkage peak in the first genome-wide linkage study that was 
subsequently directly replicated in a study targeting only this region (Hanna et al., 2002a, 
Willour et al., 2004a). Another suggestive linkage peak on chromosome 15q14 was identified in 
two genome-wide linkage studies (Shugart et al., 2006). To date, genome-wide association 
studies (GWAS) have been similarly underpowered in OCD (Stewart et al., 2013b, Mattheisen 
et al., 2015). A single polymorphism near BTBD3 reached genome-wide significance in a family-
based subset of one GWAS analysis, but it was only suggestive in the overall sample (Stewart 
et al., 2013b). 
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Candidate genes for OCD have been identified based upon proximity to linkage peaks, 
biomarker findings, and relationship to pharmacological targets. The strongest candidate gene 
association findings in OCD focus on SLC1A1, which encodes the neuronal glutamate 
transporter, EAAT3 (Arnold et al., 2006, Dickel et al., 2006, Stewart et al., 2007, Kwon et al., 
2009, Shugart et al., 2009, Wendland et al., 2009a, Samuels et al., 2011, Stewart et al., 2013b, 
Wu et al., 2013). Interest in SLC1A1 stemmed from its location under the chromosome 9p24 
linkage peak, as well as biomarker studies implicating the glutamate system in OCD. Additional 
candidate genes in the glutamate system have also been studied, including GRIN2B, which 
shows evidence of association in some but not all studies (Arnold et al., 2004, Alonso et al., 
2012, Cai et al., 2013). The other leading candidate gene is the serotonin transporter, SLC6A4, 
with both common and rare variants exhibiting association in some studies (Ozaki et al., 2003, 
Dickel et al., 2007, Grados et al., 2007, Saiz et al., 2008, Wendland et al., 2008), but not all 
(Taylor, 2013). The dopaminergic system (COMT and DRD4) has been implicated via gene 
association studies; however these findings have yet to be replicated (Billett et al., 1998, Pooley 
et al., 2007). A lack of clear susceptibility genes contributes to the difficulty of modeling OCD in 
animals, though this issue is shared by most complex heterogeneous neuropsychiatric 
disorders.  
 
Neurobiology of OCD 
As imaging methods have improved over the last thirty years, our ability to non-
invasively examine neural substrates and brain regions in OCD sufferers has led to significant 
advancement of our understanding of the underlying pathophysiology of the disorder. As will be 
discussed more thoroughly below, neuroimaging analyses led researchers to focus on a cortico-
striatal-thalamo-cortical (CSTC) model (also known as a frontostriatal or corticostriatal model) of 
OCD (Saxena and Rauch, 2000, Maia et al., 2008, Rotge et al., 2008, Ting and Feng, 2011). 
This model has become the predominant model proposed to reflect the important neural regions 
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involved in the pathophysiology of OCD; however recent adaptations have been suggested 
(Milad and Rauch, 2012, Wood and Ahmari, 2015). 
Within the basal ganglia circuitry, the indirect pathway has the capacity to exert inhibitory 
control on excitatory output from the thalamus to the cortex; whereas the direct pathway exerts 
excitatory control (Figure 2). Based on human imaging studies, hyperactivity through the direct 
pathway due to a lower activation threshold may result in subsequent excessive activity of the 
CSTC and manifest itself in the form of repetitive thoughts and behavior (Saxena and Rauch, 
2000).  
 
Structural Neuroimaging 
The most consistent brain regions implicated via structural analyses have been the 
orbitofrontal cortex (OFC), the anterior cingulate cortex (ACC), and the striatum (Pittenger et al., 
2011, Rodman et al., 2012, de Wit et al., 2014). A large MRI study reported reductions in medial 
OFC gray matter (Di Martino et al., 2008) and increased grey matter of the ventral striatum 
(Pujol et al., 2004) in OCD. Meta-analyses have indicated consistent findings of reduced 
volumes of the left ACC and bilateral OFC, and increased thalamic volume relative to control 
samples (Rotge et al., 2009). A separate meta-analysis identified increased bilateral gray matter 
in the striatum as well as reductions in bilateral ACC volume (Radua and Mataix-Cols, 2009). 
Also of note is a study that combined structural imaging and behavioral testing of OCD patients 
and non-affected first degree relatives, demonstrating that impairment on a response-inhibition 
task correlated with reductions in OFC gray matter and increased great matter in the ACC and 
striatum (Menzies et al., 2008). While structural studies have been somewhat inconsistent, 
alterations in the OFC, ACC, and striatum are most frequently reported.  
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Functional Imaging  
In agreement with the structural imaging reports, the most consistently implicated brain 
regions in functional neuroimaging via positron emission tomography (PET) and functional 
magnetic resonance imaging (fMRI), are the OFC, ACC, and the caudate (specifically the head) 
(Rauch and Savage, 1997, Rotge et al., 2008). Hyperactivity is reported in all of these regions at 
baseline and following symptom provocation (Rauch et al., 1997), supporting the model of 
excessive signaling in the CSTC circuitry. In contrast, studies of SRI or CBT treatment 
demonstrate activity reductions in the OFC or caudate following successful treatment (Rauch et 
al., 2002, Nakao et al., 2005). Recent resting-state connectivity analyses using fMRI further 
support the hypothesis of dysfunctional CSTC circuitry, specifically the OFC, ACC, ventral 
striatum, dorsal striatum, putamen, and anterior thalamus (Beucke et al., 2013, Harrison et al., 
2013, Anticevic et al., 2014, Posner et al., 2014). While three of the resting state connectivity 
studies have reported increased connectivity between the OFC and the striatum (Harrison et al., 
2009, Beucke et al., 2013, Harrison et al., 2013), one has reported the opposite (Posner et al., 
2014). Justification for the discrepancy may be that the majority of the subjects in the Posner 
study were clear of medication (either treatment naïve or ~2 years on average without 
medication), along with differing analytical methodologies. 
 
Elevated glutamate in cerebrospinal fluid  
The most direct evidence for glutamatergic dysfunction in OCD comes from studies 
using overlapping samples, where the authors analyzed the glutamate concentrations of 
cerebrospinal fluid (CSF) of drug-naïve adult OCD patients and normal controls. In the first 
study, glutamate concentrations of the OCD patients was significantly elevated relative to  
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Figure 2. Schematics depicting the direct and indirect pathways of the basal ganglia 
Solid arrows depict glutamate (excitatory) pathways and dashed lines depict GABAergic (inhibitory) 
pathways.  
A. In the normally functioning cortico–striato–thalamo–cortical circuit, glutamatergic signals from the 
frontal cortex (specifically, the orbitofrontal cortex (OFC) and anterior cingulate cortex (ACC)) lead to 
excitation in the striatum. Through “direct pathway”, striatal activation increases inhibitory GABA signals 
to the globus pallidus interna (GPi) and the substantia nigra (SNr). This decreases the inhibitory GABA 
output from the GPi and SNr to the thalamus, resulting in excitatory glutamatergic output from the 
thalamus to the frontal cortex. This direct pathway is a positive-feedback loop. In the indirect pathway, 
the striatum inhibits the globus pallidus externa (GPe), which decreases its inhibition of the subthalamic 
nucleus (STN). The STN is then free to excite the GPi and SNr and thereby inhibit the thalamus.  
B. In patients with obsessive–compulsive disorder (OCD), a hypothetical imbalance between the direct 
and indirect pathways results in excess tone in the former over the latter. 
Adapted from Obsessive-compulsive disorder: An integrative genetic and neurobiological perspective 
(Pauls, 2014)	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controls, without any effects of age, sex, or duration of illness (Chakrabarty et al., 2005a). The 
second study, performed on the same samples, used a more in-depth analysis on subjects over 
the age of 15 by also analyzing additional amino acids, as well as autoantibodies against the 
basal ganglia and thalamus. The authors reproduced their initial findings of elevated glutamate, 
and also reported elevated levels of the NMDAR co-agonist, glycine, in OCD patients relative to 
controls (Bhattacharyya et al., 2009). The authors made note that elevations in glycine were 
driven by OCD patients with autoantibodies to the basal ganglia or the thalamus, indicating that 
immune system alteration may be connected to elevations in glutamate and glycine. Despite a 
low number of studies, these results do suggest that alterations in glutamate homeostasis may 
be linked to OCD.  
 
Convergence of Glutamate, SLC1A1/EAAT3, and Obsessive-compulsive disorder 
Based on the efficacy observed in the treatment of OCD and SRIs, the serotonin system 
was the first neurotransmitter system suspected to be involved in OCD. However, a significant 
portion of the OCD patient population display minimal clinical benefit resulting from serotonin-
enhancing drugs (Soomro et al., 2008), while some but not all of refractory cases are improved 
by augmentation with dopamine modulating drugs (Arumugham and Reddy, 2013). Novel 
evidence from genetic analysis, neuroimaging and neurochemical studies, observations from 
animal models, and off-label trials of FDA-approved glutamate-modulating drugs suggest that 
dysregulation of glutamate may be involved in the pathophysiology of OCD.  
First, the prevailing glutamate hypothesis of OCD argues that genes related to the 
glutamatergic system would be feasible candidate genes for the disorder. SLC1A1, the gene 
coding for the neuronal excitatory amino acid transporter, EAAT3, is the most consistently 
implicated OCD candidate gene. SLC1A1 was first identified via genome-wide linkage study of 
the disorder and was subsequently replicated (Hanna et al., 2002a, Willour et al., 2004b).  Soon 
after, a significant genetic association was found with a SNP in the 3’ end of the gene (Arnold et 
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al., 2006, Dickel et al., 2006). While the specific SNPs and haplotypes associated with OCD 
have not been reproduced consistently, the majority of the SNPs have been located in the 3’ 
region of the gene (Arnold et al., 2006, Dickel et al., 2006, Stewart et al., 2007, Kwon et al., 
2009, Shugart et al., 2009, Wendland et al., 2009a, Samuels et al., 2011, Stewart et al., 2013a). 
Interestingly, recent genetic investigations of the gene propose that polymorphisms of SLC1A1 
are associated with de novo obsessive-compulsive symptoms induced via atypical antipsychotic 
treatment in schizophrenia patients (Kwon et al., 2009, Ryu et al., 2011, Schirmbeck et al., 
2012, Cai et al., 2013), suggesting an interaction between the dopamine system and glutamate 
neurotransmission.  
The consistent implication of SLC1A1 in OCD via genetic studies does strengthen the 
hypothesis that the gene is in fact a risk factor for OCD; however limited data provide insight 
into how abnormal expression or function of EAAT3 may be responsible for OCD symptoms. An 
EAAT3 null mouse exhibited cortical neurodegenerative effects and behavioral phenotypes, but 
only at an advanced age and without OCD-relevant behavioral characterization (Peghini et al., 
1997, Aoyama et al., 2006). One of the two studies examining the role of EAAT3 in the CSTC 
circuitry found that exposure to amphetamine triggers endocytosis of EAAT3 from the cell 
membrane, leading to augmented glutamatergic signaling via AMPA and NMDA glutamate 
receptors (Underhill et al., 2014, Li et al., 2017). Additional studies of EAAT3’s role in 
modulating OCD-relevant behavior and circuitry are needed to elucidate its contribution to the 
underlying pathophysiology of OCD-relevant behavior.  
 
Abnormal Regulation of Glutamate in the Central Nervous System 
The primary neurotransmitters in the CSTC circuit are glutamate and GABA (Figure 2). 
The medium spiny neurons (MSNs) of the striatum C receive glutamatergic input via projections 
from the cerebral cortex, thalamus, and hippocampus. MSNs of the striatum, however, are 
GABAergic and act to inhibit the neuronal activity of their targets. These targets include the 
	   24	  
globus pallidus pars interna (GPi), the globus pallidus pars externa (GPe), and the substantia 
nigra pars reticulata (SNr). Neurons in these MSN target regions are themselves GABAergic 
and act to inhibit the their targets, including the subthalamic nucleus (indirect pathway) and 
thalamus (direct pathway). In turn, glutamatergic thalamic neurons innervate the neocortex, 
including the OFC and ACC. As such, the majority of neurons, aside from a subset of 
interneurons, in the CSTC circuit use glutamate or GABA as their primary neurotransmitters. 
Potential excessive activity throughout this circuit could be reflected by increased levels of 
glutamate in brain regions innervated by glutamatergic neurons. In order to test this, they began 
using MRS in order to quantify glutamate in specific brain regions implicated in OCD.  
Use of magnetic resonance spectroscopy allows quantification of tissue levels of a 
number of common brain chemicals, but its ability to analyze glutamatergic concentrations has 
limitations. Currently, all MRS analysis studies of glutamatergic levels have been performed at 
low magnetic strengths. Thus, the subtle molecular differences between glutamate, glutamine, 
and GABA are unable to be resolved. Another caveat is that glutamate is an important 
biosynthetic building block for cellular metabolism, not exclusively for neurotransmission, and 
Glx in different cellular compartments are unable to be differentiated. Most Glx signal in MRS 
studies therefore likely corresponds to intracellular glutamate, which may or may not indicate a 
change in glutamatergic signaling. Despite these technical limitations, alterations in Glx in the 
CSTC circuit have consistently been reported in OCD. Early MRS studies described elevations 
in the caudate Glx that normalized following SRI treatment in pediatric patients (Moore et al., 
1998, Rosenberg et al., 2000, Rosenberg et al., 2001). Decreased ACC Glx was separately 
reported in pediatric patients (Rosenberg et al., 2004). An MRS study in adult women with OCD 
showed that symptom severity was linked to reductions in ACC Glx (Yucel et al., 2008). One 
study in treatment-naïve adults described increased Glx signal in orbitofrontal white matter of 
OCD patients relative to controls that was associated with symptom severity (Whiteside et al., 
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2006); however a similar study reported no Glx differences in the OFC (Bedard and Chantal, 
2011).  
These MRS studies, together with CSF measurement of glutamate, suggests 
glutamatergic dysfunction in the CSTC circuit of OCD patients. These data must be judiciously 
interpreted, however, because many studies had small sample sizes and were unable to 
differentiate glutamate alone from the Glx signal. Due to the limitations of the imaging 
techniques, it is also unclear whether increases in glutamate are due to excessive glutamate 
projection, changes in glutamate release, altered glutamate transport, or changes in glial 
glutamate exchange. Regardless, taken together with the structural neuroimaging findings, 
there is strong evidence that abnormal regulation of the glutamate may be involved in the 
pathophysiology of the disorder.  
 
Mouse Models of Glutamatergic Dysfunction and Repetitive Behavior 
 A broader array of mouse models of compulsive-like behavior will be discussed in 
Chapter 2; therefore only models with alteration of the glutamate system will be addressed here. 
No animal models accurately reproduce the heterogeneous characteristics of OCD 
symptomology. This is an inherent limitation on animal models of most psychiatric disease, but 
this constraint is even more pronounced in OCD, since obsessions are purely subjective, thus 
leaving researchers to examine repetitive behaviors and deficits in neurotransmitter systems 
with strong prior evidence, such as the glutamate system.  
 
D1CT-7 Mice 
One of the first transgenic mouse models relevant to OCD was the D1CT-7 model 
(Campbell et al., 1999) that expresses an intracellular form of cholera toxin under control of the 
dopamine receptor 1 gene (DRD1) promoter. By constricting expression of the toxin to DRD1-
expressing neurons, researchers were able to limit chronic activation of stimulatory G-protein 
	   26	  
(Gs) to the direct pathway of the basal ganglia in an effort to mimic the hypothesis that 
hyperactivity of the direct pathway underlies the pathophysiology of OCD. This model exhibits a 
myriad of compulsive-like behaviors, including perseverance of normal behaviors, repetitive 
nonaggressive biting, and leaping (Campbell et al., 1999). Onset of motor tic-like behavior was 
described in juveniles, with increased prevalence in males (Nordstrom and Burton, 2002), 
reminiscent of the psychiatric disorder Tourette’s Syndrome (TS). While direct evidence of 
glutamatergic dysfunction at baseline was absent, addition of a non-competitive NMDA receptor 
antagonist, resulting in stimulation of cortical-limbic glutamate output, exacerbated compulsive-
like behavior (McGrath et al., 2000). 
 
Sapap3 Null Mice 
One of the most prominent genetic mouse models of repetitive behavior is the Sapap3 
null model. SAPAP3 is a post-synaptic density scaffolding protein that colocalizes to 
glutamatergic synapses within the CSTC circuit. Not only do these mice exhibit increased 
anxiety-like behavior and repetitive behavior, their elevated grooming phenotype responds to 
subchronic levels of SRI administration. Evidence from electrophysiological studies identified 
cortico-striatal glutamatergic signaling dysfunction in Sapap3 nulls, including increased NMDA 
receptor activity and altered NMDA receptor subunit composition (Welch et al., 2007, Wan et al., 
2014). Genetic evidence supporting SAPAP3 in OCD is lacking; however an association was 
identified in a small subset of OCD patients exhibiting grooming symptoms, such as 
trichotillomania (Bienvenu et al., 2009). Despite a weak case for construct validity, Sapap3 nulls 
are a valuable model of repetitive behavior exhibiting face and predictive validity, alongside 
dysfunctional cortical-striatal glutamatergic transmission.  
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Slitrk5 Null Mice 
 Interestingly, ablation of another post-synaptic protein, SLITRK5, also led to a genetic 
model of OCD-relevant behavior. Another SLITRK family member, SLITRK1, was previously 
reported to be associated with TS (Abelson et al., 2005). The function of SLITRK5 is still being 
explored, but it is believed to be important for neuronal survival and synapse formation (Proenca 
et al., 2011). Slitrk5 null mice display excessive grooming and anxiety similar to SAPAP3 null 
mice, and as well as improvement with chronic SRI treatment (Shmelkov et al., 2010b). Notably 
with regards to the glutamate hypothesis, Slitrk5 nulls also showed reduced cortico-striatal 
transmission and increased indirect markers of neuronal activity in the OFC (Shmelkov et al., 
2010b). 
 
Repeated stimulation of OFC-Ventral striatum projections 
  Optogenetic and chemogenetic approaches allow manipulations of the activity of 
specific cell populations with varying degrees of temporal control. Optogenetic techniques take 
advantage of exogenous, light-activated ion channels to activate or silence neurons with 
temporal and cell-type specificity. To test the glutamatergic hyperactivity hypothesis in a specific 
component of the CSTC circuit, Ahmari and colleagues expressed channelrhodopsin-2 (ChR2) 
in the glutamatergic neurons projecting from the OFC to the ventral striatum (VS). Acute 
stimulation had no OCD-relevant behavior consequences; however repeated stimulation of 
OFC-VS glutamatergic neurons over multiple days led to a perseverative grooming behavior 
that persisted even after the cessation of the stimulation protocol (Ahmari et al., 2013). High-
dose chronic (but not acute) SRI administration rescued the observed grooming phenotype and 
normalized the evoked firing rate elicited by optogenetic stimulation. These findings provide yet 
another piece of evidence for the role of CSTC glutamatergic signaling in OCD. 
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Summary of Data Linking OCD and Glutamate 
 The hypothesis that aberrant glutamatergic regulation is connected to the 
pathophysiology of OCD was established near the beginning of the new millennia (Moore et al., 
1998, Rosenberg and Keshavan, 1998). This foundational hypothesis was structured around 
glutamate being the primary neurotransmitter in the CSTC circuit, which was recognized as 
connecting the brain regions consistently implicated in structural and functional neuroimaging 
analyses of the OCD patient population. The hypothesis further proposes that hyperactivity of 
the direct pathway or hypoactivity of the indirect pathway may lead to an overactive CSTC 
circuit that could result in repetitive thoughts and behaviors (Saxena et al., 2001). 
 The first animal model aimed at recapitulating this hardwired hyperactive state of the 
CSTC circuit was the D1CT-7 model, resulting in OCD- and tic-like behavior that was 
exacerbated by NMDA receptor antagonists (Campbell et al., 1999, McGrath et al., 2000). More 
convergent evidence followed, identifying abnormal glutamatergic concentrations in MRS 
studies of specific brain regions in the CSTC circuit (Rosenberg et al., 2000, Rosenberg et al., 
2004) and elevated glutamate concentrations in the CSF of OCD patients (Chakrabarty et al., 
2005a, Bhattacharyya et al., 2009).  
 Due to the accumulating support for glutamatergic dysregulation in OCD, genetic 
analyses focused on potential candidate genes relevant to the glutamate system. The gene with 
the most consistent genetic association to OCD is SLC1A1, coding for the neuronal glutamate 
transporter (EAAT3). EAAT3 is localized on the post-synaptic and extrasynaptic membrane of 
neurons receiving glutamate input, with high levels of expression in cortical and striatal brain 
regions. Another candidate gene with preliminary evidence for association is GRIN2B (Arnold et 
al., 2004), which encodes the NR2B subunit of NMDARs. NR2B-containing NMDARs are also 
predominantly expressed on the extrasynaptic membrane and have been shown to interact with 
EAAT3 (Scimemi et al., 2009, Jarzylo and Man, 2012). Secondly, the increase in evidence 
linking glutamatergic dysfunction with OCD has also coincided with the proliferation of 
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transgenic animal models. Two mouse models relevant to OCD, the Sapap3 and Slitrk5 null 
mouse models not only result in SRI-responsive repetitive behaviors but also exhibit cortico-
striatal glutamatergic signal dysfunction and altered glutamate receptor expression (Welch et 
al., 2007, Shmelkov et al., 2010b, Wan et al., 2011, Wan et al., 2014). These models elicited 
considerable excitement in the field, especially with regard to the glutamate hypothesis; 
however evidence of specific genetic alterations in their corresponding genes in the human 
OCD population are less strong. The first optogenetic mouse model strengthened both the 
hyperactive CSTC circuit and glutamate dysfunction hypotheses by showing that long term 
repeated stimulation of glutamatergic OFC projections innervating the ventral striatum led to the 
emergence of SRI-responsive repetitive grooming and evoked firing (Ahmari et al., 2013). 
  There are many difficulties with accurately modeling neuropsychiatric disorders in 
mouse models. Direct translation of genetic abnormalities identified in the OCD patient 
population into animal models is limited due to a lack of known rare genetic variants that elicit a 
large effect, as well as the inability of genome-wide association studies to identify common 
variants that reach genome-wide significance. However, findings in transgenic and optogenetic 
animal models have furthered our understanding of potential mechanisms linked to the CSTC 
circuit and repetitive- or compulsive-like behavior.  With these caveats in mind, my thesis 
research focused on taking advantage of the most replicated genetic evidence in the field, 
suggesting that altered expression or function of Slc1a1/EAAT3, a neuronal glutamate 
transporter prominently expressed in the CSTC circuit, is linked to the underlying 
pathophysiology of OCD. The goal of this research was to investigate the consequences of 
altered Slc1a1/EAAT3 expression in an OCD-relevant behavioral context and to provide novel 
insights into the generation of rationally designed therapeutics aimed at improving the unmet 
therapeutic needs of the OCD patient population. 
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Specific Aims 
 The research presented herein was undertaken in an effort to understand the OCD-
relevant consequences of reduced Slc1a1/EAAT3 expression and to further our knowledge of 
the functional role that EAAT3 plays in OCD-implicated neurocircuitry.  
 
1) Characterize the biochemical effects of reduced Slc1a1/EAAT3 expression in the 
Slc1a1-STOP mouse model. 
2) Identify baseline behavioral deficits resulting from reduced Slc1a1/EAAT3 expression 
in the Slc1a1-STOP mouse model. 
3) Pharmacologically probe OCD-implicated brain circuitry in the Slc1a1-STOP mouse 
model in order to evaluate the effect of reduced Slc1a1/EAAT3 expression on striatum-
dependent repetitive behavior. 
4) Examine and localize the effects of Slc1a1/EAAT3 loss on cortico-striatal circuits.  
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CHAPTER 2 
 
RODENT MODELS OF OBSESSIVE-COMPULSIVE BEHAVIOR 
As published in: Rodent Models of Obsessive Compulsive Disorder: Evaluating Validity 
to Interpret Emerging Neurobiology. Neuroscience (2016) 
Isaac Zike, Tim Xu, Natalie Hong, Jeremy Veenstra-VanderWeele 
 
Abstract 
 
Obsessive Compulsive Disorder (OCD) is a heterogeneous neuropsychiatric disorder 
with unknown molecular underpinnings. Progress in neuroimaging has linked the cortico-striatal-
thalamo-cortical (CSTC) circuit within the brain to the symptomatic obsessions and compulsions 
of OCD patients. Genetic and non-genetic risk factors have also been identified resulting in 
animal models created using transgenic, immunological, pharmacological, and optogenetic 
tools. These models enable researchers to manipulate known OCD risk factors such as genes, 
or for the ability to perturb specific neurocircuitry implicated in the disorder and examine 
behavioral, biochemical, and electrophysiological responses.  These model systems are 
essential to hypothesis testing however they have inherent limitations and are unable to fully 
reproduce the human condition. With the end goal of further understanding the molecular 
mechanisms underlying OCD-relevant behavior in rodents potentially leading to novel 
intervention strategies, relatively rigorous validation criteria (predictive, face, and construct) may 
be used to evaluate their utility with respect to how well they mirror the human disorder. 
Currently, assessment of available models has shown that no single model is likely to 
substantially encompass all validation criteria. As new molecular and genetic findings as well as 
novel technologies emerge, intricate dissection of implicated genes and circuits may be utilized 
to create models more representative of the human condition in preference of manipulations 
that elicit OCD-relevant behavior in rodents.  
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Introduction 
Obsessive compulsive disorder (OCD) is a common, chronic condition characterized by 
persistent, intrusive obsessions, repetitive behavior, and anxiety (Calvocoressi et al., 1998). The 
disorder affects 1-3% of the population and is among the top ten causes of disability worldwide 
(Kessler et al., 2005, Koran et al., 2007, Michael S. Ritsner, 2007). First line forms of therapy 
include serotonin reuptake inhibitors (SRIs) and cognitive behavioral therapy; however, only 50-
60% of patients show adequate response to available treatments (Koran et al., 2007). For 
example, a 20-40% decrease in OCD symptoms may result following SRI therapy (Dougherty et 
al., 2004), which leaves many with clinically significant residual symptoms. In some refractory 
OCD cases, deep brain stimulation (DBS) has also been used as a treatment alternative (Sturm 
et al., 2003, Goodman et al., 2010). Other augmentation therapies, such as antipsychotics and 
glutamatergic agents, are also being evaluated but have limited evidence for their utility 
(Arumugham and Reddy, 2013). 
Ideally, more effective therapeutics would emerge from an understanding of the etiology 
of OCD. As with many neuropsychiatric conditions, the underlying causes of OCD are unknown 
and likely to involve both genetic and environmental factors. Hypotheses based on genetic and 
neuroimaging data have led researchers to create animal models that recapitulate the hallmarks 
of the disorder, with the aim of probing the underlying neurobiology. Here, we will discuss the 
growing number of proposed rodent models of OCD, including pharmacologically-induced, 
genetic, and optogenetic animal models, with a focus on assessment of the validity of the model 
in relation to knowledge of the human condition. Building upon the initial data on validity, we will 
describe the emerging understanding of neurobiological mechanisms in each model. Finally, we 
will discuss the approaches to take growing knowledge from these rodent models and translate 
it into novel treatments that can be applied in patients with OCD.  
  
	   33	  
Genetic and non-genetic factors likely contribute to OCD risk 
To understand the validity of rodent models, we must first understand the risk factors 
that may contribute to OCD. Abundant evidence for a heritable component of OCD stems from 
twin and family studies (Grados and Wilcox, 2007, Pauls, 2008). As reviewed elsewhere (Pauls, 
2010), OCD symptoms are estimated to be 40-65% heritable in children and 27-47% heritable in 
adults (van Grootheest et al., 2005). Family studies indicate that OCD is twice as common in 
first-degree relatives of affected adults and ten times as likely in relatives of affected children 
(Pauls, 2008). These studies support the premise that OCD risk is derived from a complex 
combination of genetic and non-genetic factors. 
Genetic linkage studies have yet to generate genome-wide significant findings for the 
core diagnosis of OCD, likely because of lack of statistical power in limited sample sizes (Hanna 
et al., 2002a, Mathews et al., 2012). The most promising linkage signal is on chromosome 9p24, 
based upon a suggestive linkage peak in the first genome-wide linkage study that was 
subsequently directly replicated in a study targeting only this region (Hanna et al., 2002a, 
Willour et al., 2004a). Another suggestive linkage peak on chromosome 15q14 was identified in 
two genome-wide linkage studies (Shugart et al., 2006). Genome-wide association studies 
(GWAS) have been similarly underpowered, to date, in OCD (Stewart et al., 2013b, Mattheisen 
et al., 2015). A single polymorphism near BTBD3 reached genome-wide significance in a family-
based subset of one GWAS analysis, but was only suggestive in the overall sample (Stewart et 
al., 2013b). 
Candidate genes for OCD have been identified based upon proximity to linkage peaks, 
biomarker findings, and relationship to pharmacological targets. The strongest candidate gene 
association findings in OCD focus on the SLC1A1, which encodes the neuronal glutamate 
transporter, EAAT3 (Arnold et al., 2006, Dickel et al., 2006, Stewart et al., 2007, Kwon et al., 
2009, Shugart et al., 2009, Wendland et al., 2009a, Samuels et al., 2011, Stewart et al., 2013b, 
Wu et al., 2013). Interest in SLC1A1 stemmed from its location under the chromosome 9p24 
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linkage peak, as well as biomarker studies implicating the glutamate system in OCD. Elevated 
cerebrospinal fluid glutamate levels in two studies (Chakrabarty et al., 2005b, Bhattacharyya et 
al., 2009) are matched by increased glutamatergic signal in magnetic resonance spectroscopy 
studies in OCD (Moore et al., 1998, Rosenberg et al., 2000). Additional candidate genes in the 
glutamate system have also been studied, including GRIN2B, which shows evidence of 
association in some but not all studies (Arnold et al., 2004, Alonso et al., 2012, Cai et al., 2013). 
The other leading candidate gene is the serotonin transporter, SLC6A4, with both common and 
rare variants exhibiting association in some studies (Ozaki et al., 2003, Dickel et al., 2007, 
Grados et al., 2007, Saiz et al., 2008, Wendland et al., 2008), but not all (Taylor, 2013). The 
dopaminergic system (COMT and DRD4) has also been implicated via gene association 
studies; however these findings have yet to be replicated (Billett et al., 1998, Pooley et al., 
2007). A lack of clear susceptibility genes contributes to the difficulty of modeling OCD in 
animals, though this issue is shared by most complex heterogeneous neuropsychiatric 
disorders.  
Apart from genetics, autoimmunity has also received considerable attention as a 
potential risk factor for OCD. Observation of neuropsychiatric manifestations co-occuring with 
rheumatic fever and Sydenham’s chorea lead to the description of Pediatric Autoimmune 
Neuropsychiatric Disorders Associated with Streptococcal infections (PANDAS). As reviewed 
elsewhere (Williams and Swedo, 2015), children with this presentation may develop 
compulsions, tics, or other psychiatric symptoms very rapidly following an infection. Emerging 
data suggest that non-streptococcal infections may also serve as triggers for symptoms, leading 
to the more recent description of Pediatric Acute-onset Neuropsychiatric Syndrome (Chang et 
al., 2015). Anti-brain antibodies, including antibodies to the basal ganglia, have been identified 
in some cases of PANDAS, but with little evidence that antibodies consistently separate cases 
from controls or increase with symptom exacerbations (Pavone et al., 2004, Singer et al., 2004, 
Singer et al., 2005, Morris-Berry et al., 2013). In contrast, studies in the larger population of 
	   35	  
patients with idiopathic OCD have more consistently reported elevated anti-basal ganglia 
antibodies in serum, as supported by a recent meta-analysis (Pearlman et al., 2014), as well as 
one study in cerebrospinal fluid (Bhattacharyya et al., 2009). It is not clear, however, whether 
and how these antibodies might be causally connected to the pathophysiology of OCD.  
 
Basal ganglia circuitry is implicated in OCD 
Evidence from neuroimaging studies has consistently implicated the basal ganglia as 
being involved in the development of OCD, specifically the cortico-striatal-thalamo-cortical 
(CSTC) loop (Saxena and Rauch, 2000, Ting and Feng, 2011). The most consistently 
implicated basal ganglia subregions in OCD patients are the caudate nucleus and the putamen, 
which make up the human striatum (Rauch et al., 2001, Rosenberg et al., 2001). Structural 
neuroimaging studies have consistently demonstrated abnormalities in caudate volume in OCD 
(Radua and Mataix-Cols, 2009, Radua et al., 2010). Functional imaging studies have also 
identified hyperactivity in cortico-striatal circuits, both at baseline and after symptom provocation 
(Menzies et al., 2008). The caudate is extrinsically innervated primarily by excitatory inputs 
originating from the cerebral cortex, the thalamus, and the substatia nigra pars compacta 
(Parent and Hazrati, 1995). Many studies have found that increased activity within the cortex, 
specifically the anterior cingulate (ACC) and orbitofrontal cortex (OFC) are seen in OCD 
patients (Chamberlain et al., 2008, MacMaster et al., 2008, Menzies et al., 2008). These 
studies, along with further meta-analysis of functional neuroimaging data in OCD patients 
(Whiteside et al., 2004, Whiteside et al., 2006), suggest that there is a functional abnormality 
resulting in hyperactivity of the basal-ganglia loop. A common model of this increased CSTC 
signaling suggests that it could arise from hyperactivity of the direct-pathway or by hypoactivity 
of the indirect pathway resulting in repetitive and compulsive behaviors (Ting and Feng, 2011).  
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Validation of mouse models relevant to OCD 
Rodent models allow hypothesis testing via manipulation of OCD risk factors, as well as 
stimulation or inhibition of the circuitry implicated in OCD. The ability to perform such 
experimental manipulations is also accompanied by immediate access to the brain that allows 
for detailed probing of molecular and circuitry changes that may underlie the pathophysiology of 
OCD. Unfortunately, behavioral assessment in rodents is limited to compulsive-like behaviors, 
since obsessions are an internal experience that can only be measured via self-report. Animal 
studies aimed at eliciting OCD-relevant behaviors through the use of pharmacological, 
transgenic, immunologic, and optogenetic tools have resulted in a wide range of behavioral 
phenotypes with varying degrees of similarity to compulsive behaviors in the human population. 
Biochemical and electrophysiological analyses of the underlying cells and circuits believed to be 
involved in OCD are beginning to provide data that may enable researchers to develop novel 
therapeutics closer to the pathophysiology of the disorder.  
Model systems are necessary to test hypotheses and probe the underlying neurobiology, 
but models are inherently limited and cannot fully recapitulate the human disorder. To assess 
the potential utility of a given model, three criteria are typically used, as first described by Willner 
in 1991: 1) construct validity, 2) face validity, and 3) predictive validity (Willner, 1991). By using 
these criteria to assess how well an animal model mirrors the human condition, we can better 
contextualize the significance of resulting findings, potentially allowing us to target our attempts 
at translation to subgroups of the human population that may more clearly map onto the risk 
factor, behavioral profile, or circuitry implicated in the rodent.  
 
Construct Validity 
The first and likely most important criterion for assessing animal model validity is 
construct validity. This is best understood in the context of genetic models, where a putative 
OCD risk gene is manipulated in mice to observe its behavioral and neurobiological 
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consequences. Similarly, an immunological trigger, such as the antibodies that have been 
detected in some cases of Pediatric Autoimmune Neuropsychiatric Disorders Associated with 
Streptococcal infections (PANDAS), could allow direct transfer into an animal model (Swedo, 
2002, Snider and Swedo, 2004). Drug-induced worsening of OCD symptoms, such has been 
reported with the anti-migraine 5-HT1B/D agonists (Koran et al., 2001a) and psychostimulants 
(Varley et al., 2001, Bloch et al., 2009), may also provide construct validity. Since these drugs 
seem to exacerbate but not cause OCD, this approach to validity may not work independently 
from another risk factor, as discussed in the predictive validity section below.  
 Since circuitry is better defined than risk factors, could circuits be a source of construct 
validity? Or does this represent face or predictive validity? Often, validation criterion may 
overlap, as is the case when thinking about brain circuitry. The differentiation between the 
validity criteria when it comes to brain circuits may come down to experimental design. If 
alteration of circuit activity is the foundation of the animal model, as is the case in some recent 
optogenetic work, then construct validity may be supported. Conversely, for genetic models that 
result in electrophysiological changes in brain regions implicated in OCD, the circuitry findings 
may be better classified as face validity, as described below.  
 
Face Validity 
The second criterion, face validity, is usually based on the emergence of observable 
behaviors reminiscent of compulsive behavior, since OCD is a behaviorally defined disorder. 
The most commonly observed rodent behavior that supports face validity is excessive 
grooming, which corresponds to an increase in a behavior that follows a stereotyped pattern 
even in wildtype mice (Welch et al., 2007, Shmelkov et al., 2010a, Ahmari et al., 2013); although 
the stereotyped pattern itself may also be distorted in some models. In contrast, other models 
lead to a novel stereotyped, repetitive pattern of behavior, as is seen with dopaminergic 
(quinpirole) and serotonergic (8-OHDPAT) agonists that induce perseverative locomotor 
	   38	  
behavior in the Y-maze or open field chambers (Yadin et al., 1991, Szechtman et al., 1998). 
Other measures, such as reversal learning or prepulse inhibition deficits, parallel findings that 
are not explicitly diagnostic but are instead thought to underlie the symptoms of OCD, such as 
cognitive rigidity or motor inhibition deficits (Chamberlain et al., 2006, Remijnse et al., 2006, Gu 
et al., 2008, Valerius et al., 2008, Andersen et al., 2010, Ahmari et al., 2012, Bissonette and 
Powell, 2012, Brigman et al., 2012, Remijnse et al., 2013, Hatalova et al., 2014, Zhang et al., 
2015).  
Face validity may also be established in animal models by identifying alterations in 
putative biomarkers that mirror those previously identified in the human OCD population. As 
reviewed above, several such biomarkers could be used to assess a rodent model of OCD, 
such as abnormal caudate volume (Radua and Mataix-Cols, 2009, Radua et al., 2010), 
hyperactivity in the cortico-striatal circuit (Menzies et al., 2008), increased glutamate 
concentrations in the caudate (Moore et al., 1998, Whiteside et al., 2006, Starck et al., 2008), 
and elevated cerebrospinal fluid glutamate levels (Chakrabarty et al., 2005a). Identification of 
other abnormalities in previously hypothesized neurotransmitter system, such as serotonin, 
dopamine, or glutamate (Dickel et al., 2007, Taylor et al., 2010, Pittenger et al., 2011), could 
also be asserted to represent face validity, but we must be careful not to stretch too far in 
assessing what “looks like” our conception of OCD.  
 
Predictive Validity 
Predictive validity of animal models of OCD may be determined in a few ways. 
Unfortunately, there is no straightforward way to model the cognitive behavioral therapy that 
should be the first-line treatment in OCD; however compulsive-like behaviors may be rescued or 
protected against through the administration of SRIs, as these are the first line medications. 
Additionally, response to SRIs in OCD requires several weeks of administration, which could be 
used to add specificity, as has been suggested in a few models that show response to chronic 
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or sub-chronic but not acute dosing. Adjunctive medications, such as atypical antipsychotics, 
which have some evidence of benefit in OCD, may also be expected to improve compulsive-like 
behavior, though this may be less specific since they also benefit tics in the human population. 
Invasive treatments, such capsulotomy or high frequency stimulation (HFS) protocols similar to 
deep brain stimulation (DBS), have shown benefit in SRI-resistant OCD and could be used to 
assess predictive validity with a clearer relationship to any observed changes in circuitry 
(Greenberg et al., 2006). From the opposite perspective, common anxiolytics or antidepressants 
that are ineffective in people suffering from OCD, including benzodiazepines and noradrenergic 
reuptake inhibitors (NRIs), should be expected to be ineffective in rescuing the behavioral 
phenotypes observed in a valid mouse model of OCD. One challenge for the field is that many 
people with OCD show only modest or even minimal response to available treatments, and lack 
of predictive validity could indicate that a model corresponds to this subset – the precise group 
that we would most like to help. 
 One question is how to conceptualize drugs that appear to worsen OCD symptoms. 
When administered to wildtype animals, these drugs may provide support for construct validity; 
although there is little evidence for drugs inducing persistent OCD symptoms once the drug has 
been stopped. In contrast, within an existing model of an OCD risk factor, a drug targeting the 
serotonin or dopamine system may be a way to reveal the worsened symptoms that have been 
reported with certain drugs in OCD patients, including clozapine, stimulants, and sumatriptan 
and its analogs (Broocks et al., 1998, Koran et al., 2001b, Gross-Isseroff et al., 2004, Bloch et 
al., 2009, Fonseka et al., 2014). Ultimately, assessing a given model does not necessarily 
require checking off each box in the three types of validity but instead assessing the overall 
strength of the data and carefully drawing boundaries around the human population that it 
models. For example, if clozapine were used to induce repetitive behavior and CSTC circuit 
abnormalities in a particular inbred strain of mouse, then the initial step in translation would  
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Figure 3. Evaluating Mouse Models of OCD-Relevant Behavior and Neurobiology 
The most commonly used criteria to evaluate rodent models of Obsessive Compulsive Disorder are: 1) 
construct validity, 2) face validity, and 3) predictive validity. Each criterion contains exclusive 
components (grooming behavior for face validity or behavioral response to serotonin reuptake inhibitors 
for predictive validity). Some findings, such as the implication of cortico-striatal circuitry, may contribute 
to validation in any one of the three domains, depending upon context. For example, an optogenetic 
mouse model was constructed via chronic stimulation of cortical inputs to the striatum (Ahmari et al., 
2013). Abnormal corticostriatal signaling is seen in a couple of genetic mouse models (Welch et al., 
2007, Shmelkov et al., 2010), a form of face validity paralleling human neuroimaging findings. Finally, a 
different optogenetic paradigm seeks predictive validity by rescuing compulsive-like behavior by 
stimulating a cortico-striatal circuit (Burguiere et al., 2013). 
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target the human population that experiences treatment-emergent compulsions while taking 
clozapine.  
Genetic Mouse Models 
Sapap3 Null Mice 
At the time of the initial description of OCD-related phenotypes in mice lacking Sapap3, 
(Sap90/PSD-95 associated protein 3) (Welch et al., 2007, Burguiere et al., 2013), no genetic 
data were available to examine its potential involvement in OCD. A subsequent study identified 
rare amino acid variants in the human Sapap3 ortholog, DLGAP3 (Discs, Large (Drosophila) 
Homolog-Associated Protein 3), in OCD and trichotillomania populations; although the degree to 
which these variants contribute to OCD risk remains somewhat unclear (Zuchner et al., 2009). 
Another association study found nominally significant association with a number of common 
polymorphisms and haplotypes in individuals with a grooming disorder (trichotillomania, 
excoriation, or nail-biting) in addition to OCD, but not in OCD alone (Bienvenu et al., 2009). 
Additionally, the largest genome-wide association study in OCD found some suggestive but not 
significant evidence of association with another DLGAP family member, DLGAP1 (Stewart et 
al., 2013b). Collectively, these individual pieces of data provide plausible hints of construct 
validity without replicated evidence of involvement of DLGAP3 in human OCD. 
The face validity and predictive validity of the Sapap3 null mouse is quite appealing and 
provided an example for subsequent studies of putatively compulsive-like behavior. Between 4-
6 months, Sapap3-null mice exhibit a perseverative grooming phenotype that results in open 
skin wounds, as well as increased anxiety-like behavior, which together parallel the common co-
occurrence of maladaptive repetitive behavior and anxiety in human OCD. It is also possible, 
however, to argue that increased, self-injurious grooming in the mouse maps less well onto the 
cleaning symptoms commonly seen in OCD, such as compulsive hand-washing, and more 
neatly onto the OC-spectrum conditions of trichotillomania or excoriation/skin-picking. Without 
access to “obsessions” that may drive the grooming behavior, it is impossible to clearly separate 
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these possibilities. It may be most useful, then, to conceptualize this mouse as a model of OC-
spectrum behavior. Importantly, the excessive grooming is alleviated by sub-chronic (6 days), 
but not acute administration of fluoxetine, an SRI. It is important to note that chronic 
administration of SRIs for a month or more is necessary to achieve efficacy in the human OCD 
population; however differences in brain circuitry in mice compared to humans could underlie 
this difference. 
SAPAP3 (SAP90/PSD95-associated protein 3 or DLGAP3) is a post-synaptic scaffolding 
protein that interacts with Post Synaptic Density Protein 95 and Shank protein families 
(Takeuchi et al., 1997), and is highly expressed within glutamatergic synapses of the striatum, 
providing plausibility for its involvement in OCD risk (Saxena and Rauch, 2000, Welch et al., 
2007, Menzies et al., 2008, Ting and Feng, 2011). The initial characterization of Sapap3 null 
mice demonstrated cortico-striatal glutamatergic transmission abnormalities, including defective 
synaptic transmission and reduction in in N-methyl-D-aspartate (NMDA) and alpha-amino-3-
hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) glutamate receptor function (Welch et al., 
2007). Further electrophysiological work with this model has revealed that loss of SAPAP3 
enhances AMPA receptor endocytosis via an mGlu5-dependent mechanism (Wan et al., 2011). 
Interestingly, it was also found that constitutive and induced deletion of Mc4r, the gene coding 
for the melanocortin 4 receptor (MC4R) was able to rescue the elevated grooming phenotype 
and normalize the striatal signaling abnormalities of the Sapap3-null mouse (Xu et al., 2013). 
MC4R impacts feeding behavior and polymorphisms within the gene, MC4R, are the most 
common cause of hyperphagia and morbid obesity (Farooqi, 2008). Prior work with MC4R 
showed that stimulation of the receptor resulted in a compulsive-like grooming phenotype 
(Alvaro et al., 2003) and led the researchers to hypothesize that deletion of Mc4r within Sapap3-
null mice may rescue the previously described grooming phenotype. At this point it is not 
understood how links between obesity or metabolism and compulsive behavior may be 
impactful, this double knockout of Sapap3 and Mc4R is useful to show that intervention resulting 
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in the amelioration of striatal signaling abnormalities may be capable of rescuing OCD-relevant 
behavioral phenotypes as observed in the Sapap3-null mouse.  Additional defects in inhibitory 
neurotransmission of Sapap3-null mice have also been identified, including reductions of 
parvalbumin-positive fast spiking interneurons, resulting in abnormalities in a learning related 
behavioral task that will be discussed in future sections (Burguiere et al., 2013), further 
supporting the hypothesis of dysfunctional neurotransmission within the cortico-striatal circuit in 
this model. As the first genetic mouse model to be described with SRI-responsive, striatally-
dependent repetitive behavior, the Sapap3 null mouse has already begun to yield insights that 
could potentially translate into human OC-spectrum disorders. In the absence of clear genetic 
data, however, it remains difficult to assess whether findings in this mouse offer a direct parallel 
to human OCD. 
  
Slitrk5 Null Mice 
Interest in the SLIT (slit guidance ligand)- and TRK (trunk)-like (Slitrk) gene family 
initially emerged from a chromosomal translocation and follow-up rare variant association study 
linking Slitrk1 and Tourette’s syndrome (Abelson et al., 2005), with support in some but not all 
subsequent studies (Keen-Kim et al., 2006, Scharf et al., 2008, Miranda et al., 2009, O'Roak et 
al., 2010, Karagiannidis et al., 2012, Ozomaro et al., 2013). SLITRKs are single-transmembrane 
proteins containing two extracellular leucine-rich repeat domains, similar to SLIT proteins, and a 
carboxy-terminal domain similar to tyrosine kinase receptors (Proenca et al., 2011). Like SLIT 
proteins, SLITRK proteins are widely expressed throughout the brain and are believed to direct 
neurite outgrowth. Tic-like or compulsive-like behavior has not been described in Slitrk1-null 
mice, but these animals do exhibit increased anxiety-like behaviors and elevated norepinephrine 
levels in the prefrontal cortex and nucleus accumbens (Katayama et al., 2010). On the other 
hand, knockout of another SLITRK family member, Slitrk5, resulted in a phenotype similar to 
that previously described in the Sapap3 null mice. It is unclear whether genetic association data 
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at SLITRK1 should be seen as contributing to construct validity of Slitrk5 null mice as a model of 
OC-spectrum behavior. Similarly, a recent genome-wide study in OCD found suggestive 
association near PTPRD (protein tyrosine phosphatase, receptor type D), which encodes a 
member of the receptor protein tyrosine phosphatase family that interacts with SLITRK3, 
providing more circumstantial evidence for involvement of this protein family, if not SLITRK5 
itself. 
Shmelkov and colleagues (2010) developed and characterized a Slitrk5-null mouse that 
displayed face-validity in the form of elevated grooming resulting in facial hair loss and skin 
lesion by three months of age (Shmelkov et al., 2010b). It is also of note that hemizygous Slitrk5 
mice developed similar lesions but with a delayed onset at seven to nine months of age, which 
has not been reported in the Sapap3 heterozygous animals. Slitrk5-null mice also displayed 
increased anxiety-like behaviors in the elevated plus maze and open-field test. With regards to 
predictive-validity, chronic treatment with the SRI, fluoxetine, reversed the elevated grooming 
phenotype in Slitrk5-nulls; although the consequences of acute treatment were not shown.  
The Slitrk5 null animals also showed biochemical and structural findings in the CSTC 
circuit implicated in OCD. Increased FosB immunoreactivity in the OFC in these animals may 
parallel functional imaging finding in OCD (Chamberlain et al., 2008). Similarly, they show 
decreased striatal volume that may parallel reports of reduced striatal volume relative to whole-
brain measurements in OCD patients (Rosenberg et al., 1997). As with the Sapap3 null, 
defective neurotransmission was measured in striatal slice preparations from Slitrk5 null mice, 
linking abnormalities in brain regions previously implicated in OCD to this model. As an almost 
direct parallel to the established pattern of validation in the Sapap3 null mouse, the Slitrk5 null 
mouse model shows SRI-sensitive, excessive grooming behavior in the context of altered 
corticostriatal structure and function. Again, more genetic data will be needed to evaluate 
whether this provides a direct model of OCD or OC-spectrum risk; however it is possible that 
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insights from this model will translate to SRI-dependent repetitive behavior across species, 
regardless of whether this particular genetic mechanism underlies OCD itself. 
 
HoxB8 Null Mice 
HOXB8 is a component of the mammalian Hox (Homeobox-containing) complex, a 
family of 39 transcription factors important in determining the anteroposterior axis during 
development (Capecchi, 1997). In contrast to the above models, where some genetic data, 
albeit limited, point to potential genetic involvement in OCD or OC-spectrum disorders, no data 
implicate HOXB8 or its gene family in the human disorder. On the other hand, Greer and 
Capecchi (2002) noted that HoxB8-null mice show excessive grooming resulting in extensive 
hair loss and skin lesions (Greer and Capecchi, 2002). HoxB8-null animals self-groom 
excessively and also have increased social grooming of control animals. A subsequent report 
from another group using a different Hoxb8 null mouse line suggested that deficits in spinal cord 
function led to changes in sensitivity to pain, potentially underlying the excessive, self-injurious 
grooming behavior (Holstege et al., 2008). A follow-up study conducted by the Capecchi group 
in the original Hoxb8 null mice, however, clearly demonstrated that central nervous system 
function was responsible for excessive grooming in these animals (Holstege et al., 2008, Chen 
et al., 2010). Remarkably, targeted knockout of Hoxb8 in the hematopoietic system alone was 
found to induce excessive grooming in these mice, and bone marrow transplant resulted in 
rescue of the grooming phenotype in Hoxb8 null animals. Taken together, these findings 
suggest that dysfunction resulting from peripherally-derived microglia accounts for compulsive-
like grooming in these animals.  
While the latest study on targeted Hoxb8 knockout ruled out peripheral nervous system 
(PNS) defects as the cause of the grooming phenotype, the broad expression of Hoxb8 in 
microglia of the brain prevents straightforward localization of the implicated brain region(s). As 
noted above, this model lacks clear construct validity, and predictive validity has not been 
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assessed with an SRI rescue experiment. Despite this, the novelty of microglial involvement in 
excessive grooming provides an interesting new direction for potential treatment of compulsive-
like behavior. As noted above, immune or autoimmune mechanisms have been explored in 
OCD; although without conclusive data tying a particular mechanism to emerging symptoms 
(Swedo, 2002, Martino et al., 2009). Intravenous immunoglobulin or plasmopheresis have been 
explored for treatment of Streptococcal infection-associated compulsive behaviors (Snider and 
Swedo, 2004); however, no current treatments have targeted the monocyte lineages leading to 
microglia. The Hoxb8 null model, then, may be an example of a genetic mouse model limited to 
face validity that nevertheless generates a very novel hypothesis about OCD risk or treatment. 
Without construct or predictive validity at the outset, however, translational studies targeting 
peripherally-derived microglia seem quite risky and should likely be reserved for truly refractory 
OCD unless more data emerge implicating this mechanism in a subgroup of patients with OCD. 
 
Slc1a1/EAAT3 null mice 
As a counter example to these three mouse models that show compulsive-like behavior 
but without strong construct validity, the neuronal glutamate transporter gene SLC1A1 (Solute 
Carrier Family 1 Member 1) has the most genetic evidence to date, but behavioral assessment 
of mice lacking Slc1a1 has not suggested altered compulsive-like behavior, to date. As noted 
above, both linkage and association data point to SLC1A1 in OCD, particularly in males with 
early-onset symptoms (Veenstra-VanderWeele et al., 2001, Hanna et al., 2002b, Willour et al., 
2004b, Arnold et al., 2006, Dickel et al., 2006, Stewart et al., 2007, Shugart et al., 2009, 
Wendland et al., 2009b, Samuels et al., 2011). Adding circumstantial evidence, a recent study 
of 3 patients with dicarboxylic aminoaciduria identified rare loss-of-function mutations in 
SLC1A1, with one of the probands reporting long-standing checking and hand-washing 
behaviors that could be OCD-related but were not formally evaluated (Bailey et al., 2011). 
Slc1a1 mRNA and its corresponding protein, EAAT3 (Excitatory Amino Acid Transporter 3), are 
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strongly expressed in the cortico-striatal regions implicated in OCD (Nieoullon et al., 2006). 
EAAT3 is also involved in mediating neuronal cysteine transport, an essential rate-limiting step 
in the synthesis of the antioxidant glutathione (Aoyama et al., 2006, Aoyama and Nakaki, 2013).  
Initial publication of an Slc1a1/EAAT3 null mouse suggested little behavioral relevance 
to OCD (Peghini et al., 1997), with the only significant change being decreased spontaneous 
open-field locomotor activity. Subsequent studies with the EAAT3 null mouse focused on the 
potential neurodegenerative effects associated with the loss of neuronal cysteine transport. 
Aoyama et al. (2006) reported reduced neuronal glutathione levels and age-dependent 
neurodegeneration, shown by cortical thinning and enlarged ventricles. As they aged, EAAT3 
null mice were observed to show increased aggression and to appear disheveled. At eleven 
months of age, but not at two months of age, EAAT3 null mice showed hippocampal atrophy 
and declines in learning on the Morris water maze (Aoyama et al., 2006). The available data, 
then, certainly do not suggest face validity for the EAAT3 null animals in relation to OCD. A lack 
of face validity in these mice is not surprising, as the majority of genetic evidence suggests that 
increased SLC1A1/EAAT3 expression, rather than decreased expression, as in the null animals, 
would be predicted from the OCD-associated polymorphisms (Wendland et al., 2009b). By not 
creating a transgenic model accurately reproducing the genetic changes in Slc1a1 predicted to 
result from common OCD-associated SNPs, construct validity of the EAAT3 null mice is limited 
at best. Further work to evaluate the impact of Slc1a1/EAAT3 should focus on modeling 
increased expression. Alternatively, face validity could potentially be demonstrated by 
attenuation of pharmacologically- or genetically-mediated compulsive-like behaviors in mice with 
diminished EAAT3 expression.  
 
Other genetic manipulations also lead to increased grooming 
Excessive grooming is a common behavioral phenotype described in these mouse 
models of compulsive-like behavior, but it is not exclusive to OCD-like mouse models. One early 
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mouse model created to mimic the hypothesized hyperactivity of the direct basal ganglia 
pathways postulated to underlie obsessive and compulsive behavior in humans, is the DICT-7 
transgenic mouse (Campbell et al., 1999). These mice express cholera toxin (CT) in dopamine 
receptor 1 expressing neurons, resulting in potentiation of CSTC circuitry, providing limited 
construct validity to the model. While face validity of this model is supported via increased 
anxiety-like and repetitive behaviors, any measures exploring predictive validity with SRIs are 
absent. Notably, this model is a precursor to the use of optogenetics to affect the activity of 
neuronal activity in implicated circuitry as in the Ahmari model evaluated below. Many other 
genetic manipulations similarly generate increased levels of grooming, especially those related 
to autism spectrum disorders (ASD), where one hallmark of the disorder is excessive repetitive 
behavior that may or may not be OCD-like (Jacob et al., 2009). ASD-related models, including 
the Cntnap2 null, Neurexin1 null, Shank3 null, and Integrin beta 3 null, are primarily based on 
genes that have been associated with ASD and other neurodevelopmental disorders (Etherton 
et al., 2009, Carter et al., 2011, Peca et al., 2011, Penagarikano et al., 2011). The Cntnap2 null 
and the Shank3 null mice also show altered striatal structure or function, supporting relevance 
to OCD despite construct validity primarily related to ASD. Although the construct validity of 
these models specifically to OCD may be tenuous, the above genetic models thought to be 
most relevant to OCD are also lacking in either construct or face validity. Importantly, none of 
the ASD genetic models have been evaluated for response to SRIs, which limits evaluation of 
predictive validity. On the other hand, the Cntnap2 null mouse does show decreased grooming 
with a non-sedating dose of risperidone, an atypical antipsychotic medication frequently used in 
ASD but also used as an adjunctive medication in OCD (Bloch et al., 2006). Overall, the 
emerging pattern of increased grooming in genetic mouse models suggests that this species-
typical repetitive behavior may be a useful readout for altered corticostriatal signaling, 
regardless of whether the model is most relevant to OCD or ASD (Kalueff et al., 2016).  
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Immunological Models 
Alternative models aimed at understanding the potential role of the immune system and 
the induction abnormal neuropsychiatric behavior may also be a fruitful path in relation to OCD. 
One model with potential construct validity is based on the observation that streptococcal 
infections may induce obsessive-compulsive behavior and tics in children, as noted above 
(Swedo et al., 1998). Mouse models intended to mimic PANDAS have shown mixed results. 
The primary hypothesis of these investigations is that immune response to streptococcal 
infection would alter neuronal function and lead to the induction of repetitive behavior 
reminiscent of those reported in PANDAS. Since mice are not naturally infected with group A 
beta-hemolytic streptococcus pyogenes (GABHS) it is challenging to develop a direct model of 
the human pathophysiology. An alternative would be to transfer antibodies or sera from human 
patients into mice; although this also has challenges due to the differences between protein 
antigens across species. 
The first attempt at a PANDAS model used repeated injection of a GABHS homogenate 
together with Freund’s adjuvant to generate an immune response (Hoffman et al., 2004).  In 
comparison to animals injected with adjuvant alone, sera from these GABHS-exposed mice 
showed greater immunoreactivity to the globus pallidus and thalamus with the CSTC loop 
implicated in OCD; however the strongest finding was greater immunoreactivity to the deep 
cerebellar nuclei (DCN) (Hoffman et al., 2004). Animals with enhanced immunoreactivity to the 
DCN exhibited increased rearing behavior in the open field arena and in hole board tests 
compared to controls and to GABHS-immunized mice without increased DCN immunoreactivity. 
A follow-up study from the same group tested if passive transfer of antibodies from GABHS-
immunized animals to non-immunized animals was capable of inducing similar behavioral 
disturbances (Yaddanapudi et al., 2010). Increased rearing behavior was again observed in the 
open-field, and a more extensive behavioral evaluation also demonstrated reduced aggression 
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and social interaction in resident-intruder behavioral tasks, as well as motor coordination 
deficits. In theory, the rearing behavior observed in this model could represent a repetitive, 
compulsive-like behavior, but rearing is also an exploratory behavior that may indicate 
decreased anxiety-like behavior or increased exploratory drive. Motor coordination deficits and 
broad changes in emotional reactivity are sometimes reported in PANDAS, but this seems less 
relevant to OCD symptoms in particular (Swedo et al., 1998). Evaluating predictive validity in a 
PANDAS model is a little challenging, since serotonin reuptake inhibitors have not been 
explicitly tested in this subpopulation of OCD. 
Rats have also been utilized in the creation of a rodent PANDAS model. The goal of the 
researchers was to create an animal model that duplicated the behavioral, pharmacological, and 
immunological phenotypes of streptococcal-related neuropsychiatric disorders. Male rats 
exposed to GAS (Group A streptococcus) antigen had impaired motor symptoms (food 
manipulation and beam walking) while also exhibiting elevated induced-grooming, which was 
rescued by dopamine D2 antagonist and SRI administration respectively (Brimberg et al., 2012). 
As previously described in the mouse PANDAS model, the GAS-exposed rats had increased 
levels of immunoreactivity in the previously implicated OCD-relevant basal ganglia circuit. This 
study was also able to show the sera isolated from the GAS exposed rats reacts with both D1 
and D2 dopamine receptors, providing face validity based on the implication of the dopamine 
system in both PANDAS and OCD. The model exhibits relatively strong construct validity 
specifically for PANDAS while it’s face validity may be more reminiscent of disorders such as 
Sydenham Chorea, in which patients display both motor and compulsive or tic-like symptoms. 
The predictive validity of the model is more tenuous when looked at specifically with regards to 
OCD. Administration of dopamine D2 receptor antagonists rescued the motor phenotype 
however dopamine D2 receptor antagonists in OCD have been utilized primarily as 
augmentation therapy to SRIs in OCD (Li et al., 2005), in contrast to the standalone manner 
they were used in this model. As noted previously, SRI’s are the preeminent form of 
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pharmacological therapy used in the treatment of OCD however they typically require weeks of 
administration prior to observable efficacy and in this rat PANDAS model, three days of SRI 
treatment attenuated the compulsive-like phenotypes. It is debatable how much predictive 
validity that this provides due to the differing timelines for onset of efficacy when framed 
specifically for OCD and the lack of studies evaluating the effectiveness of SRIs in the PANDAS 
subpopulation. A follow up study from the same group expanded on the previous rat PANDAS 
findings by asking if intra-striatal passive transfer of isolated antibodies of GAS-exposed rats 
was able to induce similar behavioral abnormalities observed above. In this study, rats striatally 
infused with IgG purified from Group A streptococcus-exposed rats (GAS-I), took longer to 
traverse a narrow beam however no induced-grooming phenotypes emerged relative to naïve 
rats or those infused with total IgG from adjuvant-exposed rats (Lotan et al., 2014).  
Interestingly, the GAS-I rats did exhibit increased marble burying behavior compared to Control-
I and naïve rats, which had been previously observed in GAS-exposed rats but not published. 
Face validity of elevated marble burying is uncertain due to benzodiazepines being able to 
attenuate the behavior in wild-type mice (Nicolas et al., 2006) despite their ineffectiveness in the 
human OCD population (Crockett et al., 2004). Taken together, this expanded PANDAS model 
was able to reproduce some of the behavioral abnormalities previously published and further 
identify behavioral phenotypes that may be relevant to OCD while isolating a specific brain 
region where autoantibodies produced following Group A streptococcus exposure may be 
exerting their pathogenicity. 
Injecting sera from human patients with PANDAS into rodents may be a more valid 
approach, given that mice are not typically infected with GABHS; although species differences 
could also distort patterns of immunoreactivity. One study infused sera isolated from patients 
with PANDAS or Tourette syndrome into either the ventral or ventrolateral striatum of rats. They 
found no behavioral abnormalities and concluded that antibody reactivity in the striatum was 
unlikely to mediate the behaviors observed in PANDAS (Loiselle et al., 2004). The body of 
	   52	  
literature on immunological models of OCD is quite small and difficult to evaluate at this point 
because of the limitation of studies using GABHS in rodents. On the other hand, interest in 
immune-mediated mechanisms continues to grow in light of the growing literature on PANDAS 
and PANS as well as the rescue of the excessive grooming behavior in the Hoxb8 null mouse 
by bone marrow transplantation.  
 
Pharmacological Models 
Pharmacological models of OCD-relevant behavior are based on drug-induced 
behavioral phenotypes reminiscent of OCD behaviors observed in human patients (e.g., 
perseveration, compulsive checking). In the models evaluated, drugs that affect previously 
implicated neurotransmitter systems drive the OCD-relevant behavior. Due to numerous reports 
of alterations of both the dopaminergic and serotonergic system in people with OCD (Denys et 
al., 2004, Fineberg et al., 2012), it is reasonable to believe that manipulation of these 
neurotransmitter systems could lead to OCD-relevant behaviors in rodents. It is unclear, 
however, exactly how dopamine and serotonin are involved in the underlying pathogenesis of 
the disorder, thus the validity of each model must be carefully evaluated when making 
conclusions from these data, with predictive validity becoming even more important. In contrast, 
two drug classes have been reported to exacerbate or trigger OCD in the human population. 
One of these, the 5-HT1B agonist drugs in the triptan class, has led to a pharmacological model, 
as described below. The other, atypical antipsychotic drugs, with clozapine as the primary 
offender (Fonseka et al., 2014), has not yet been examined as a potential trigger of compulsive-
like behavior in rodents. 
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OH-DPAT induced decrease in spontaneous alternation 
One of the initial drugs to be studied in relation to compulsive-like behavior was 8-
hydroxy-2-(di-n-propylamino)-tetraline (8-OH-DPAT), a serotonin 5-HT1A receptor agonist that 
also has some activity at 5-HT7 (Yadin et al., 1991). Of note, no compulsive-like response has 
been described in humans in response to 5-HT1A agonists, such as buspirone, so construct 
validity is limited to the general implication of the serotonin system in OCD. Acute administration 
of 8-OH-DPAT to rats results in a decrease in spontaneous alternation behavior in the T-maze. 
Instead of spontaneously switching the arm that is entered, rats who receive the drug tend to 
return repeatedly to the same arm, which may parallel the perseverative behavior often 
observed in OCD but could also indicate defects in working memory (Dek et al., 2015). Chronic 
fluoxetine prevents this drug-induced behavior, potentially providing predictive validity; whereas 
desipramine does not, providing evidence of specificity (Fernandez-Guasti et al., 2003). 
Importantly, however, diminution of serotonin receptor-mediated behavior with chronic 
administration of a serotonin reuptake inhibitor is expected due to receptor down-regulation in 
the context of tonic increases in extracellular serotonin levels. It is difficult, therefore, to know 
whether this truly indicates predictive validity or whether it simply represents an expected 
homeostatic mechanism. An alternative approach to predictive validity would be to parallel 
neuromodulatory treatments in OCD. Both bilateral lesions and bilateral low-frequency 
stimulation of the thalamic reticular nucleus diminished perseverative response to 8-OH-DPAT; 
although high-frequency stimulation, which more clearly parallels the response to deep brain 
stimulation in OCD, had no effect (Andrade et al., 2009, Andrade et al., 2010). More recent work 
suggests that 8-OH-DPAT may also induce perseverative behavior in other contexts, including 
returning repeatedly to the same location in an open field arena, which has been described as 
“compulsive checking” behavior (Alkhatib et al., 2013). Overall, despite interesting data, this 
model is challenged by difficulties in establishing clear validation in any of the three domains. 
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Quinpirole induced “compulsive checking” 
Chronic administration of the D2/3 receptor agonist quinpirole to rats results in a 
perseverative exploration phenotype also described as “compulsive checking” behavior 
(Szechtman et al., 1998). This model has some degree of construct validity with regard to the 
dopamine system generally, since stimulant drugs and dopamine agonists can lead to repetitive 
behaviors, or frank compulsive behavior, in some contexts, such as with treatment of 
Parkinson’s disease or attention deficit hyperactivity disorder (Borcherding et al., 1990, 
Djamshidian et al., 2011, Weintraub et al., 2015). On the other hand, stimulants do not appear 
to be a common cause of worsening in OCD patients themselves and may even lead to 
improvements in some patients (Insel et al., 1983). The quinpirole model uses an open field 
chamber containing four small cubes, and rats receiving 5 or more weeks of drug treatment 
show more rapid and excessive returns to preferred objects, as well as ritual-like motor 
behaviors, in comparison to rats receiving vehicle injections (Szechtman et al., 1998). Chronic 
treatment with clomipramine, an SRI in the tricyclic class, delayed but did not eliminate this 
behavior. High frequency stimulation and temporary inactivation of the subthalamic nucleus 
(STN) was able to attenuate this compulsive-like behavior (Winter et al., 2008), paralleling one 
of the most common neuromodulatory targets in OCD (Mallet et al., 2002, Fontaine et al., 2004). 
Similarly, high-frequency stimulation of the OCD-linked nucleus accumbens, another common 
target in OCD (Sturm et al., 2003, Greenberg et al., 2006, Rauch et al., 2006), also reduced 
quinpirole-induced checking (Mundt et al., 2009). In sum, the predictive validity of this model is 
impressive, with interesting behavioral parallels to OCD as well, but the construct validity is 
more difficult to evaluate. 
 
RU24969 induced repetitive circling and prepulse inhibition deficits 
Serotonin 5-HT1B receptor agonist drugs, such as sumatriptan, are used to treat 
migraines and have been reported to worsen OCD in some patients (Koran et al., 2001a, Gross-
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Isseroff et al., 2004). Based upon this observation, treatment with the 5-HT1B agonist RU24969, 
which also has some activity at 5-HT1A, has been examined as a possible construct valid 
pharmacological model of OCD. Acute treatment with RU24969 in mice results in a dramatic 
increase in activity, and this activity is dominated by perseverative circling around the perimeter 
of an open field chamber (Shanahan et al., 2009). Direct injection of a 5-HT1B antagonist 
demonstrated that 5-HT1B in the OFC is necessary for this perseverative circling response 
(Shanahan et al., 2009, Shanahan et al., 2011), paralleling neuroimaging data implicating the 
OFC in OCD (Menzies et al., 2008). Furthermore, RU24969 treatment results in prepulse 
inhibition (PPI) deficits that may parallel data in OCD, as well as in a number of other 
neuropsychiatric conditions, (Swerdlow et al., 1993, Shanahan et al., 2009, Ahmari et al., 2012). 
Chronic treatment but not acute treatment with fluoxetine, but not desipramine, rescued both the 
repetitive circling behavior and the PPI deficits (Shanahan et al., 2009). This provides some 
degree of predictive validity but with the same challenge of circularity when examining 5-HT 
receptor response after chronically increasing extracellular 5-HT with an SRI. Considering all of 
the evidence, RU24969 treatment is one of the most convincing pharmacologically-induced 
models due to the most impressive construct validity, coupled with some evidence for both face 
and predictive validity.  
 
Neonatal clomipramine  
Neonatal exposure to fluoxetine has previously been described to lead to long-term 
increases in anxiety-like behavior in mice (Ansorge et al., 2004), supporting the possibility that 
such exposure could also lead to risk of compulsive-like behavior. No epidemiological studies 
have yet examined this hypothesis in human studies, but the Andersen lab administered 
clomipramine, an SRI in the tricyclic class, to rat pups from postnatal day 9-16, followed by 
assessment of relevant behaviors in adulthood (Andersen et al., 2010). Exposed rats showed 
increased anxiety-like behavior on the elevated plus maze, increased marble burying, and 
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increased “hoarding” of food pellets at the bottom of the cage, as well as deficits in OCD-
relevant cognitive tasks (spontaneous alternation, reversal learning, and working memory-
related tasks). All of the above behaviors are evocative of symptoms or cognitive deficits 
observed in OCD patients (Krebs and Heyman, 2015). They also reported increased 5-HT2C 
receptor mRNA in the OFC and dopamine D2 receptor mRNA in the striatum of experimental 
rats compared to controls, providing some parallel to neuroimaging studies in OCD (Remijnse et 
al., 2006, Menzies et al., 2008). This developmental model shows the broadest range of OCD-
relevant phenotypes with perhaps greater face validity than any other model described to date, 
but it lacks construct and predictive validity at this point. These intriguing findings, however, 
raise the possibility that early life programming, either via pharmacological exposure or via 
genetics, may result in adaptive changes in OCD-relevant brain regions that lead to later 
emergence of compulsive-like behavior.  
 
Optogenetic Mouse Models  
As both human neuroimaging data and electrophysiology data from genetic mouse 
models continue to refine our understanding of the underlying circuitry, optogenetic approaches 
can be used to test these hypotheses by directly stimulating or inhibiting components of the 
cortico-striatal-thalamo-cortical network. By taking an alternative approach from targeting genes 
identified from OCD genetic studies, the optogenetic approach may point to circuitry-based 
treatment options such as repetitive transcranial stimulation or deep brain stimulation, rather 
than focusing on a molecular understanding or potential pharmacological treatments. These 
techniques permit alteration of neural activity with brain region, genetic, and temporal precision. 
Optogenetic technology has recently been used to in two separate studies in an attempt to 1) 
rescue OC-relevant behaviors in a previously studied genetic mouse model via stimulation of 
neurons projecting from the lateral OFC to striatum, and 2) induce compulsive-like behaviors 
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using optogenetic stimulation of neurons projecting from the OFC to the ventral medial striatum 
(VMS). Whether used in conjunction with previously validated transgenic models or on their 
own, optogenetic tools may revolutionize the study of disease-relevant circuits in animal models 
of OCD. 
Optogenetic induction of excessive grooming behavior 
Ahmari and colleagues used optogenetics to test circuitry-based hypotheses about 
compulsive behavior (Ahmari et al., 2013). Rather than focusing on a genetic or immune 
hypothesis of OCD risk, they focused on the intermediate phenotype of hyperactivation of the 
OFC and VMS in OCD (Insel and Winslow, 1992, Rosenberg and Hanna, 2000, Pauls et al., 
2014), matched by the observation that deep brain stimulation of the ventral striatum is effective 
in reducing OCD symptoms in some patients (Rodriguez-Romaguera et al., 2012). Based upon 
these lines of evidence in humans with OCD, they hypothesized that increasing signaling from 
the OFC to the VMS would result in increased compulsive-like behavior in mice. The 
optogenetic approach is very different from genetic manipulations that attempt to establish 
construct validity by linking to the most proximal cause of OCD risk. Instead, this type of 
experiment may be thought to primarily examine the plausibility of the cortico-striatal-thalamo-
cortical circuit hypothesis of OCD. Remarkably, however, whereas the results may not directly 
inform our understanding of the proximal risk factors contributing to OCD risk, the results 
suggest that manipulation of this circuit could be used to understand the dysfunction that 
generates compulsive-like behavior, and potentially to develop new treatments based upon this 
understanding. 
Ahmari and colleagues introduced the light-sensitive cation channel, Channelrhodopsin 
via viral injection to the OFC. They then applied light stimulation in the VMS to establish 
specificity for the OFC-VMS circuit. Contrary to the initial hypothesis, acute OFC-VMS 
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hyperstimulation did not increase repetitive behavior. In contrast, repeated hyperstimulation of 
the OFC-VMS projection generated a progressive increase in grooming, which persisted for two 
weeks after the stimulation was stopped. No self-injury was described in these animals, but the 
increase in grooming suggests that the OFC projection to the VMS can alter this species-typical 
stereotyped behavior that is also increased in genetic models with face and predictive validity 
for OCD. Importantly, electrophysiologic measurements were also taken and a progressive 
increase in light-evoked firing was observed with repeated stimulation, paralleling the increase 
in repetitive grooming behavior.  
Moving beyond testing the plausibility of the CSTC hypothesis, they then examined 
whether an SRI could rescue the induced grooming. Remarkably, treatment with two weeks of 
fluoxetine following a seven-day optogenetic stimulation protocol was able to normalize light-
evoked neuronal activity and attenuate grooming behavior, providing evidence of predictive 
validity. Taken as a whole, these data move beyond establishing plausibility for altered 
corticostriatal signaling as an intermediate phenotype in compulsive-like behavior. The increase 
in VMS response to light-induced activity with repeated hyperstimulation suggests that plasticity 
at OFC-VMS synapses induces long-lasting alterations that prime the OFC-VMS synapses, 
resulting in a reduced activation threshold during subsequent bouts of stimulation. Increased 
OFC-VMS activity may transmit information through the CSTC circuit, leading to multiple 
downstream events that generate a repetitive pattern of behavior. The combination of construct, 
face, and predictive validity make this model very appealing for further dissecting the impact on 
local microcircuits in the VMS, downstream effects on CSTC signaling, as well as the molecular 
events underlying the observed synaptic plasticity, with the possibility that other manipulations, 
beyond SRIs, could also rescue the altered corticostriatal signaling and compulsive-like 
behavior. 
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Optogenetic rescue in Sapap3 null mice 
Burguire and colleagues (2013) used optogenetics to take the opposite approach. 
Rather than using inducing compulsive-like behavior, they evaluated the ability of circuit 
manipulation to rescue compulsive-like behavior in the Sapap3 null mouse model. They first 
designed a novel delayed conditioning task to achieve temporal and conditioned control over 
the previously described excessive grooming phenotype. They presented a tone followed by an 
unconditioned stimulus of a water drop delivered to the nose, which induced grooming behavior 
in both the wildtype and the Sapap3 null mice. Probe trials, with the tone presented alone 
without the water drop, were interspersed with conditioning trials. In mid-training, both wildtype 
and Sapap3 null mice showed grooming response to the tone alone, but later in training this 
was suppressed in the wildtype but not the mutant mice. This suggests that Sapap3 null mice 
are unable to inhibit their conditioned grooming response to the tone, even after observing only 
intermittent presentation of the unconditioned water drop stimulus. In parallel, they found that 
medium spiny neuron activity was higher in the Sapap3 null animals late in the training period 
when the response pattern diverged. Interestingly, they noted a decrease in striatal parvalbumin 
positive (PV+) interneurons in the Sapap3 null animals, suggesting that defective inhibition could 
account for the electrophysiological and behavioral defects.  
To assess whether cortical input could be used to rescue inhibition deficits in the 
striatum, Burguire and colleagues used optogenetics to stimulate axon terminals of the lateral 
orbitofrontal cortex (l-OFC) within the striatum, based on previous findings implicating these 
regions in OCD (Chamberlain et al., 2005, Remijnse et al., 2006, Chamberlain et al., 2008). 
Remarkably, activation of l-OFC input to the striatum in the Sapap3 null mice was able to 
attenuate their elevated MSN activity late in training, presumably by enhanced feed-forward 
inhibition driven by cortical activation of fast-spiking striatal interneurons. Beyond the 
electrophysiological rescue, they also found that optogenetic stimulation rescued the tone-
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response inhibition deficits observed in the mutants. Even outside the context of the delayed 
conditioning task, they found that optogenetic activation of l-OFC input to the striatum 
decreased compulsive-like grooming in the mutant mice. Importantly, this optogenetic rescue 
makes use of l-OFC input to striatum, despite no clear evidence that l-OFC activity is defective 
in the Sapap3 null mice (Burguiere et al., 2013). Such an approach could be paralleled by deep 
brain stimulation in the human population, where the manipulation depends upon an 
understanding of the circuits implicated in OCD, without knowing specifically what node in the 
circuit may be dysfunctional in an individual patient. This idea could be further tested by 
extending this optogenetic paradigm to other mouse models with compulsive-like grooming 
behavior due to other genetic manipulations, such as the Slitrk5 or Hoxb8 null mice.  
At first glance, these two optogenetic studies seem to have conflicting results. One is 
able to rescue elicit compulsive-like behavior, whereas the other rescues it, despite activating 
similar brain regions. It is important to note that there are some fundamental differences. 
Burguire and colleagues (2013) took advantage of a genetic knockout mouse model with 
established repetitive behavioral phenotypes that result from abnormal neural activity resulting 
from the genetic manipulation. In contrast, Ahmari and colleagues (2013) used wild-type mice 
that had undergone normal neural development prior to introduction of the channelrhodopsin 
and stimulation of the OFC-VMS circuit. Initial work characterizing the Sapap3-null mouse 
showed abnormal cortico-striatal function that may be a result of abnormal neural development 
(Welch et al., 2007), suggesting that the circuits in the two studies may be fundamentally 
different at the onset. Secondly, the stimulation protocols are actually quite different, with 
different stimulation durations in either the lateral OFC and primarily dorsal striatum (Burguire) 
or the medial OFC and ventral striatum (Ahmari). These are distinctly separate cell populations 
that were previously posited to have alternative roles in the pathophysiology of the disorder 
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(Milad and Rauch, 2012). Clearly, more work will be needed to better understand the stimulus 
pattern, subregion, and cell type specificity in relation to compulsive-like behavior. 
 
Discussion and Future Directions 
The primary limitation across rodent models of OCD is the lack of clear risk factors that 
would support construct validity. At least one model in each of the four major categories 
reviewed here shows both face and predictive validity, but construct validity is considerably 
more challenging. The genetic category is likely the easiest domain to establish construct 
validity, but the field is limited by the lack of power in OCD linkage and genome-wide 
association studies. The published genetic models with increased grooming that responds to 
SRI treatment are limited to circumstantial genetic evidence supporting their potential 
involvement in OCD in the human population. Conversely, those genes with the strongest 
support in the OCD literature have not yet been adequately evaluated in rodent models, either 
for compulsive-like behavior or even in relation to their function in the circuits implicated in OCD. 
Beyond genetic linkage and association studies, no postmortem studies have been published to 
date in OCD, leaving us without the RNA, protein, or cellular profiles that have guided 
development of animal models in schizophrenia or autism spectrum disorder (Berg et al., 2015, 
Brown et al., 2015). 
Construct validity is harder to establish for immunological, pharmacological, or 
optogenetic studies. PANDAS and PANS are exciting clinical syndromes that are poorly 
understood and offer technical challenges for rodent models. Our knowledge of pharmacological 
triggers is primarily limited to triptans and atypical antipsychotics, but these are not thought to 
cause OCD itself but typically to worsen symptoms, and even then only in a subset of patients. 
The circuitry-based models are perhaps the most exciting and can offer us an opportunity to test 
hypotheses based upon intermediate phenotypes in OCD, rather than requiring a clear 
understanding of the original factors that contributed to risk in an individual. It may be difficult to 
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assess construct validity in these models, but they seem to offer substantial promise for 
understanding how the circuitry implicated in OCD works, even if they do not directly model the 
disorder itself. We must be careful, however, to not over-interpret models based upon 
expressing a foreign, light-sensitive protein in an ectopic pattern and then stimulating neurons in 
a temporal pattern that would not typically occur in the brain. 
The difficulty in establishing construct validity also complicates our understanding of the 
most valid behavioral or cognitive tests that are relevant to OCD. If we had several genes 
clearly implicated in OCD with mouse models that mimic the human risk variant, we would be 
able to survey the phenotypes in those animals to understand the true range of “OCD-like” 
behavior in the rodent. Just as OCD is often difficult to diagnose in the human population, some 
of those animals would likely be engaging in subtle rituals or compulsive-like behaviors that we 
may not anticipate or detect without extensive characterization. In the absence of construct valid 
models to serve as examples, we are restricted to behaviors that fit our expectations for how 
compulsivity might present in a rodent. In this context, a broad assessment that includes both 
spontaneous behaviors, such as grooming, as well as cognitive measures reported to be 
abnormal in OCD (Dittrich and Johansen, 2013), is important to better understand the strengths 
and limitations of a given model. None of the genetic models have had a significant assessment 
of cognitive function reported to date; although the conditioned-grooming assay in the Sapap3 
model begins to move toward an understanding of cognitive function in these animals, albeit 
only in the context of the already identified grooming phenotype. Some intermediate phenotypes 
identified in OCD, such as reversal learning deficits or impaired prepulse inhibition, can be 
assessed across species; although no single cognitive or sensory gating measure is specific for 
OCD to the exclusion of other neuropsychiatric disorders. 
In contrast to the challenges in understanding the risk factors and molecular etiology of 
OCD, neuroimaging has made significant progress in identifying affected brain regions through 
the use of continually advancing techniques. Likewise, the use of deep brain stimulation points 
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to brain regions or tracts that are likely to at least reflect downstream consequences of the 
pathophysiology of OCD. This understanding of brain regions and circuits has become one of 
the key arguments for the validity of particular genetic or pharmacological models, rather than 
the construct being modeled. Abnormalities in the OFC or the striatum, or corticostriatal 
signaling specifically, are reassuring findings across models, but we should be particularly 
excited to see more specific findings arise, such as the decrease in fast-spiking striatal 
interneurons in the Sapap3 null mice. Even in the absence of construct or predictive validity, the 
sheer novelty of the Hoxb8 microglia rescue raises the possibility that an animal model will 
transform our understanding of OCD pathophysiology, even if just in a small subset of the 
overall population. 
When assessing the available models, a few conclusions can be drawn. First, no single 
model is likely to be all-encompassing, with each model likely corresponding to a subset of the 
disorder and potentially to a particular symptom type or cognitive deficit. Second, excessive 
grooming is a species-appropriate, stereotyped behavior that seems particularly sensitive to 
perturbations that affect the CSTC circuit implicated in OCD and may be a very useful readout 
across models. Importantly, rodent grooming also increases in novel or stressful environments 
(Hammamieh et al., 2012, Xu et al., 2015), and anxiolytic response to SRIs may therefore 
complicate assessment of predictive validity specific to compulsive-like behavior. Third, 
emerging techniques to manipulate specific circuits offer the possibility of working back and 
forth between genetic, immunological, and pharmacological models that perturb specific circuits, 
and optogenetic models that can evaluate whether an observed change in circuit function is 
necessary and specific to generate the observed compulsive-like behavior, with optogenetic 
rescue of the Sapap3 null mice as the pioneering example. The rapid advance in technologies 
to develop and study rodent models is moving forward at an astonishing pace, and we may 
expect more genetic models to emerge that may force us to test construct validity after 
observing a rodent phenotype, as in the Sapap3 and Slitrk5 null mice. We can also expect that 
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optogenetic findings will direct the attention of human neuroimaging studies to specific circuits 
or nodes that may otherwise have been ignored. Ideally, however, we will also continue to 
pursue models with explicit construct validity in order to maintain a focus on factors that impact 
upon OCD risk in humans, rather than the myriad of manipulations that may generate 
compulsive-like behavior in rodents. 
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CHAPTER 3 
 
BEHAVIORAL ASSESSMENT OF EAAT3 INHIBITORS IN 
IN VIVO MODELS OF GLUTAMATERGIC AND BASAL GANGLIA DYSFUNCTION 
 
Introduction 
 
 In the past two decades, investigation into the etiology of obsessive-compulsive disorder 
(OCD) has converged upon the cortical-striatal-thalamo-cortical (CSTC) circuit and the 
glutamatergic system. OCD is a debilitating neuropsychiatric condition characterized by 
persistent, intrusive obsessions, repetitive behavior, and anxiety (Calvocoressi et al., 1998). 
OCD has a worldwide prevalence rate of 2% and is tenth in the World Health Organization’s 
ranking of the leading causes of disability (Michael S. Ritsner, 2007). Serotonin reuptake 
inhibitors (SRIs) are the primary form of pharmacotherapy; however only 50-60% of patients 
show adequate response (Koran et al., 2007). A mean 20-40% decrease in OCD symptoms are 
observed following SRI therapy (Dougherty et al., 2004), which leaves many with clinically 
significant residual symptoms. Recent evidence in the field suggests that further efforts focused 
on the glutamatergic system could yield rationally designed therapeutics needed to address the 
underlying pathophysiology of the disorder. 
 The ability to non-invasively investigate neural structures, activity, and chemical 
substrates within the brain with neuroimaging techniques has revolutionized our understanding 
of neuropsychiatric disease. Collective interpretation of the studies in OCD suggests that 
dysfunction of the CSTC circuit, including hyperactivity of the direct pathway or hypoactivity of 
the indirect pathway, may underlie the manifestation of OCD (Saxena and Rauch, 2000, Maia et 
al., 2008, Rotge et al., 2008, Ting and Feng, 2011). Structural analyses via magnetic resonance 
imaging (MRI) identified abnormalities within the CSTC circuit, including reductions in grey 
matter of the orbitofrontal cortex (OFC) (Di Martino et al., 2008), and increased grey matter in 
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the ventral striatum (Pujol et al., 2004). Structural alterations in gray matter volume of structures 
within the CSTC also correlated with cognitive impairment in OCD patients relative to non-
affected first-degree relatives (Menzies et al., 2008). Functional imaging analysis identified 
hyperactive states of the OFC, ACC, and the caudate at baseline and following symptom 
provocation in OCD patients (Rauch et al., 1997), as well as reductions in the activity of the 
OFC and caudate following treatment (Rauch et al., 2002, Nakao et al., 2005). The CSTC circuit 
dysfunction hypothesis is also supported by resting-state connectivity analyses with functional 
MRI indicating increased connectivity between the OFC, ACC, striatum, and thalamus, 
(Harrison et al., 2009, Beucke et al., 2013, Anticevic et al., 2014). 
 With glutamate being the major excitatory neurotransmitter in the CSTC circuit, studies 
aimed at identifying alterations in the glutamatergic system have also been performed in the 
OCD patient population. Via proton magnetic resonance spectroscopy (1H-MRS), abnormalities 
in a cumulative glutamate signal, Glx (summation of glutamate, glutamine, and GABA), are 
found in the caudate and ACC of pediatric and adult patients irrespective of their treatment 
history (Rosenberg et al., 2000, Rosenberg et al., 2004, Starck et al., 2008, Yucel et al., 2008). 
The elevation in Glx levels from 1H-MRS analysis corresponds to data from two studies 
describing increased glutamate in the cerebrospinal fluid of OCD patients (Chakrabarty et al., 
2005a, Bhattacharyya et al., 2009).  
 Many insights into the underlying causes of psychiatric disorders originate from genetic 
investigation of the patient population. Linkage analysis supported a preliminary link between 
OCD and the chromosome 9p24, which included SLC1A1 (Hanna et al., 2002b, Willour et al., 
2004b). This piqued researcher’s interest in SLC1A1 as it codes for the neuronal glutamate 
transporter, excitatory amino acid transporter 3 (EAAT3). Ensuing genetic analysis identified 
significant genetic association of SLC1A1 and OCD (Arnold et al., 2006, Dickel et al., 2006), 
which has been consistently replicated (Stewart et al., 2007, Shugart et al., 2009, Wendland et 
al., 2009a, Samuels et al., 2011, Stewart et al., 2013b). The most common OCD-associated 
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polymorphism, rs301430C, affects SLC1A1 expression by leading to increases in the encoded 
protein, EAAT3. The C-allele is also linked to increased SLC1A1 expression in lymphoblastoid 
cells, human post-mortem brain, and in a luciferase reporter assay (Wendland et al., 2009a). 
When taken together, this suggests that OCD-susceptibility may result from increased SLC1A1 
expression and that inhibition of EAAT3 function may be therapeutic.  
 To examine the hypothesis that increased SLC1A1/EAAT3 expression may contribute to 
glutamatergic dysfunction within the OCD-linked CSTC circuit, we utilized two EAAT3 inhibitors 
(NBI-59159 and 2-CFoDA) in two distinct in vivo models of OCD-relevant repetitive behavior 
and basal ganglia dysfunction. The first model, Sapap3 null mice, exhibits excessive self-
injurious grooming behavior and glutamatergic signaling dysfunction at the cortical-striatal 
synapse (Welch et al., 2007). As an alternative to the Sapap3 null transgenic model, 
amphetamine was used to behaviorally probe the CSTC circuit. Amphetamine challenge leads 
excessive dopamine release in the striatum and robust hyperlocomotor behavior. Utilization of 
these two in vivo EAAT3 inhibitors, NBI-59159 and 2-CFoDA, allows us to translate findings 
from human genetic studies into in vivo assessment of how reductions in the activity of EAAT3, 
the protein coded for by the most consistently replicated OCD-associated gene, SLC1A1, 
affects repetitive behavior in OCD-relevant mouse models. 
  
Methods 
Mice 
 SAPAP3 null mice were donated from the Feng Lab (Massachusetts Institute of 
Technology, Cambridge, MA). The colony was maintained via heterozygous breeding to ensure 
littermate controls for all behavioral experiments. SAPAP3 null mice used for experiments were 
maintained on a C57BL/6J background and aged 4-6 months to ensure emergence of repetitive 
grooming phenotype. All mice used for intracerebellar ventricular (ICV) and direct striatal 2-
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CFoDA injection studies were wildtype C57BL/6J mice obtained from The Jackson Laboratory 
(Stock #000664) aged 12-16 weeks. 
 
Immunoblotting Studies  
Brains were harvested from mice following rapid decapitation. Brains were immediately 
placed on an ice-cold metal platform, and the striatum was dissected. Dissected tissue was 
placed into 3 mL of homogenization buffer [130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl2, 1.2 mM 
MgSO4, 1.2 mM KH2PO4, 10 mM Hepes (pH 7.4), 10 mM glucose, ascorbic acid, and 0.32 M 
sucrose] and homogenized using a Potter Elvehjem homogenizer (Wheaton, Millville, NJ, USA). 
Protein concentrations of all samples were determined by a bicinchoninic acid (BCA) protein 
assay (Thermo Fisher Scientific). Equal amounts of protein were incubated with Laemmli 
sample buffer for 10 min at room temperature and analyzed by using SDS/PAGE and Western 
blotting. EAAT3 protein was visualized in samples blotted to Immobilon-P PVDF membrane 
(EMD Millipore, Billerica, MA, USA) by using a rabbit anti-EAAC1/EAAT3 antibody (EAAC11-A, 
1:1,000 dilution; Alpha Diagnostics, San Antonio, TX, USA). β-actin was visualized by using a 
mouse anti–β-actin antibody (A5316, 1:10,000 dilution; Sigma-Aldrich, St. Louis, MO, USA) as a 
loading control. Appropriate HRP-conjugated, secondary antibodies were obtained from GE 
Healthcare Life Sciences (Pittsburgh, PA, USA). Secondary antibody labeling was detected by 
using Amersham ECL Prime Western Blotting Detection Reagents and visualized via 
chemiluminescence using FluorChem M System (Protein Simple, San Jose, CA, USA). Multiple 
exposures were obtained to ensure linearity of band detection. Western blots were quantified by 
using NIH ImageJ software.  
 
Synaptosomal Cysteine Transport Assays 
Brains were harvested from mice following rapid decapitation and immediately placed on 
an ice-cold metal platform so that striatum could be dissected. Striatal tissue samples were 
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placed into 3 mL of homogenization buffer [130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl2, 1.2 mM 
MgSO4, 1.2 mM KH2PO4, 10 mM Hepes (pH 7.4), 10 mM glucose, ascorbic acid, and 0.32 M 
sucrose] and homogenized by using a Potter-Elvehjem homogenizer (Wheaton). Homogenates 
were centrifuged at 500 × g at 4 °C for 10 min. Supernatants were removed and centrifuged at 
12,000 × g at 4 °C for 10 min. The resulting synaptosome-enriched pellets were then 
resuspended in 2.5 mL of assay buffer [130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl2, 1.2 mM 
MgSO4, 1.2 mM KH2PO4, 10 mM Hepes (pH 7.4), 10 mM glucose and ascorbic acid], and 
protein concentrations were determined by using the bicinchoninic acid (BCA) Protein Assay 
(Thermo Fisher Scientific). This material (hereafter called synaptosomes) was then diluted to 30 
µg of total protein per 100 µL. Synaptosomes were incubated with 200 uM [35 S]-cysteine 
(Perkin-Elmer, Waltham, MA, USA) (1% labeled and 99% unlabeled). Assays were terminated 
by rapid filtration over 0.3% polyethyleneimine-soaked GF/B glass microfiber filters (Whatman, 
GE Life Science) and washed three times with ice-cold Krebs-Ringers-Hepes buffer [130 mM 
NaCl, 1.3 mM KCl, 2.2 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, and 10 mM Hepes (pH 
7.4)]. Filters placed into scintillation vials with 7 mL of Ecoscint H (National Diagnostics, Atlanta, 
GA, USA) scintillation fluid, shaken overnight at room temperature, and then radioactivity was 
quantified by using a TriCarb 2900TR scintillation counter (Perkin-Elmer). Specific [35 S]-
cysteine transport was assayed in triplicate for all samples.  
 
Spontaneous Grooming 
Mice were placed alone in an empty novel cage and allowed to habituate for 30 minutes. 
Mouse behavior was then recorded for 10 minutes. Total time spent grooming was manually 
decoded by an observer blind to genotype. For NBI-159 grooming studies, mice were pretreated 
with NBI-59159 (5 mg/kg, IP), 30 minutes prior to testing. 
 
Guide Cannula Implantation  
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 Mice were anesthetized with isoflurane (5% for induction, 2% for maintenance during 
surgery) and placed in a stereotaxic frame using mouse-specific ear bars (Kopf Instruments, 
Tujunga, CA). A guide cannula (CMA7) was lower through a skull burr hole to rest above the 
injection site (ICV AP 0.0 mm, M/L ±0.75 mm, DV -1.5 mm; Striatal injection AP +0.5 mm, ML 
±1.5 mm, DV -2.5 mm; all measurements relative to bregma) and secured to the skull using 
glass ionomer cement (Instech Solomon, Plymouth Meeting, PA). Mice received post-op care 
daily (5 mg/kg Ketoprofen, Sigma, St. Louis, MO) and were allowed to recover for one week 
prior to behavioral testing.  
 
2-CFoDA Injection  
 Mice were anesthetized with isoflurane (5% for induction, 2% for maintenance during 
injection) and placed in a stereotaxic frame using mouse-specific ear bars (Kopf Instruments, 
Tujunga, CA). Injection cannula was connected to a 5 uL Hamilton syringe (Hamilton, Reno, 
NV) placed into a nano-syringe pump (KDS310, KD Scientific, Holliston, MA).The injection 
cannula was front loaded with the 1 uL of the desired concentration of 2-CFoDA then inserted to 
into the guide cannula. The injection cannula extended ventrally from the guide cannula (ICV 
0.5 mm; Striatal 1.0 mm) to reach the desired injection coordinates in lateral ventricles for ICV 
injection (AP 0.0 mm, M/L ±0.75 mm, DV -2.0 mm) and dorsal medial striatum (AP +0.5 mm, ML 
±1.5 mm, DV -3.5 mm). A total of 1 uL of 2-CFoDA was infused at a rate of 0.5 uL/min. The 
injection cannula was left in place for 10 minutes after completion of infusion to eliminate 
backflow then removed from the guide cannula. This process was then repeated on the 
contralateral side. Following bilateral 2-CFoDA infusion, mice were immediately placed into 
locomotor chambers for amphetamine induced locomotion assays.  
 
Amphetamine Induced Locomotion 
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Locomotor activity in the open field was measured by using 27 x 27 x 20.5 cm chambers 
(Med Associates) placed within light- and air-controlled sound-attenuating boxes (64 x 45 x 42 
cm). Locomotion was detected by interruption of infrared beams by the body of the mouse (16 
photocells in each horizontal axis located 1 cm above the activity chamber floor, as well as 16 
photocells elevated 4 cm above the chamber floor to detect rearing and jumping behaviors). 
Data were collected and analyzed by Med Associates Activity Monitor software. Mice were 
acclimated to the activity chambers during a 30-min session 2–3 d before data recording began. 
On day 1 of the experimental sequence, mice were weighed, infused with 2-CFoDA, then 
placed into activity chambers, and activity was monitored for 60 min. The mice were then 
removed from the activity chambers and received an intraperitoneal injection of 0.9% saline or 
amphetamine (Sigma-Aldrich) (3 mg/kg) Mice were returned to the activity chambers and 
locomotor activity was recorded for 75 min. Mice were returned to their home cage for a week to 
allow for drug wash out then given alternative treatment. Time course data were analyzed by 
using non-linear curve line fit analysis and cumulative measures of behavior (i.e., total distance 
traveled) during the entire 75-minute period following amphetamine administration.  
 
Statistical Analysis 
Data were analyzed using Prism (GraphPad, La Jolla, CA, USA). Two-tailed, unpaired 
Student t-test or two-way ANOVA with Sidak’s post-tests were used to analyze the primary data, 
except for locomotor data, which was analyzed using non-linear curve fit analysis. Specific 
statistical analyses for each data set are described in results and in the figure legends.  In the 
text and figures, all data are reported as the mean ± standard error of the mean. Bar graphs 
depict the mean ± standard error of the mean.  
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Results 
Loss of SAPAP3 Expression Affects Expression But Not Function of EAAT3  
 To investigate the hypothesis that abnormal expression and or function of Slc1a1/EAAT3 
may contribute to OCD-relevant repetitive behaviors in mouse models of glutamatergic 
dysfunction, the SAPAP3 null mouse model was utilized (Welch et al., 2007). Immunoblots of 
striatal synaptosome preparations revealed an increase of EAAT3 in SAPAP3 nulls relative to 
wildtype (WT) controls (Figure 4a and b, P=0.011, n=4 per genotype). We next examined 
EAAT3 function via striatal synaptosome transport assays (Nieoullon et al., 2006) to assess if 
EAAT3 function mirrored the observed elevation in EAAT3 expression. Because EAAT3 is the 
primary source for neuronal cysteine (Aoyama et al., 2012, Watts et al., 2014), [35S]-cysteine 
(200 uM) was used as the substrate for EAAT3 synaptosome uptake assays. A significant effect 
of the EAAT inhibitor TBOA (100 uM) and a trend level genotype effect were observed in 
synaptosomes prepared from SAPAP3 null mouse striatum relative to WT synaptosomes 
(Figure 4c, Two-way ANOVA; TBOA F(1,20)=14.55, P=0.001; genotype F(1,20)=3.8 P=0.06, 
n=2 per genotype). These data indicate that loss of SAPAP3 affects EAAT3 expression; 
however this change may not be matched by a change in the functional capabilities of the 
transporter in SAPAP3 null mice.  
 
Pharmocological Inhibition of EAAT3 Does Not Rescue OCD-relevant Grooming Behavior 
in SAPAP3 Null Mice 
 With the evidence from immunoblots that EAAT3 showed increased expression in the 
striatum of SAPAP3 null mice (Figure 4a), we next wanted to determine if pretreatment with an 
EAAT3 inhibitor, NBI-59159, would attenuate the repetitive grooming behavior observed in 
SAPAP3 null mice (Welch et al., 2007).  (S)-4-(9Hfluoren-2-ylamino)-2-amino-4-oxobutanoic 
acid (NBI-59159) (Supplementary Figure 1) was reported to show an in vitro preference for 
EAAT3 over EAAT2 in HEK cells, yielding IC50 values of 0.09 uM for EAAT3 and 1.4 uM for  
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Figure 4. Sapap3 null mice express increased levels of striatal EAAT3 however protein function 
is unaffected.  
(A) Representative immunoblot from striatal synaptosome preparations from SAPAP3 null (Lane 2 and 
4) and wildtype (WT) (Lane 1 and 3) mice. EAAT3 (top band) was the protein of interest and actin 
(bottom band) was the loading control. 
(B) EAAT3 protein expression is elevated in striatal synaptosome preparations from SAPAP3 null mice 
relative to WT controls. (unpaired t-test, t= 3.26, *P=0.011, n=5 per genotype. Figure is representative 
of 3 separate experiments). Average protein expression is demonstrated in bar graph. 
(C) EAAT3 function assayed via cysteine uptake is unchanged in Sapap3 null mice relative to WT 
controls (Two-way ANOVA; genotype F(1,20)=3.83, ^P=0.64; TBOA F(1,20)=14.55, ***P=0.001; n=2 
per genotype).  
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GLT-1 (Greenfield et al., 2005). Prior behavioral assessment of NBI-59159 suggested that 
pretreatment of mice with the EAAT3 inhibitor prior to challenge with amphetamine attenuated 
the locomotor response to the psychostimulant amphetamine; however the behavioral effect 
was modest and published without experimental detail (Supplementary Figure 2) (Dunlop and 
Marquis, 2006). For this experiment in SAPAP3 null mice, we pretreated SAPAP3 null and WT 
littermate controls with 5 mg/kg NBI-59159 (intraperitoneal, IP), 60 minutes prior to manual 
scoring of time spent grooming over a 10-minute observation period. Following pretreatment 
with either NBi-59159 or saline, no effect of NBI-59159 on overall time spent grooming was 
observed in SAPAP3 null or WT mice (Figure 5a, Two-way ANOVA; genotype F(1,46)=35.41, 
****P<0.0001; NBI-59159 F(1,46)=0.66, P=0.42). We did observe a main effect of genotype and 
a stark increase in time spent grooming by SAPAP3 null mice relative to WT controls regardless 
of their pretreatment condition (Figure 5a, Sidak’s multiple comparison test; **P<0.01).  
 
Basal Ganglia Dependent Amphetamine-Induced Locomotion is Unaffected by 
Intracerebellar Ventricular Delivery of an EAAT3 Inhibitor 
One of the most consistently identified biomarkers in studies examining the OCD patient 
population is glutamatergic dysfunction in the CSTC circuit. In order to probe one component of 
this circuit pharmacologically and induce elevated levels of striatal dopamine release, we 
challenged WT mice with the psychostimulant, amphetamine. As mentioned previously, 
systemic challenge of low to moderate dose amphetamine causes a hyperlocomotor behavioral 
response due to increased dopamine and glutamate release in the striatum (Yates et al., 2007). 
Prior work with the EAAT3 inhibitor NBI-59159 showed that pretreatment with the EAAT3 
inhibitor attenuated the psychostimulant induced locomotor response (Supplementary Figure 2). 
Due to the unavailability of larger amounts of NBI-59159, we transitioned to using a novel 
EAAT3 inhibitor, 2-CFoDA (Supplementary Figure 1). As with NBI-59159, 2-CFoDA inhibits all  
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Figure 5. Pretreatment with the EAAT3 inhibitor, NBI-59159, has no affect on grooming 
behavior in wildtype or SAPAP3 null mice 
(A) 60 minute pretreatment with the EAAT3 inhibitor, NBI-59159, did not affect grooming behavior in 
wildtype (WT) or SAPAP3 null mice (Two-way ANOVA, genotype F(1,46)=35.41, ****P<0.0001; NBI-
59159 F(1,46)=0.66, P=0.42; Sidak’s multiple comparison test; **P<0.01) 
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EAATs, but is reported to be the most potent at EAAT3 (in vitro IC50=0.09 uM vs 20 uM 
and 1.44 uM for GLT-1 and GLAST respectively) (Ye, 2009). Effects of 2-CFoDA were never 
before characterized in vivo so in order to maximize our experimental capabilities with the 
inhibitor, we first implanted guide cannula into the lateral ventricles of WT mice so that the 
EAAT3 inhibitor could be delivered via intracerebroventricular (ICV) injection (Supplementary 
Figure 3). Following two weeks of recovery, the mice were pretreated with one of four 
pretreatment conditions (saline, 0.1 mg/ml 2-CFoDA, 1 mg/ml 2-CFoDA, or 5 mg/ml 2-CFoDA, 
all 1 uL volume). Sixty minutes following pretreatment, mice were challenged with amphetamine 
(3 mg/kg, IP) and their locomotor behavior was assessed. Following acute amphetamine 
challenge, no changes in amphetamine induced locomotor behavior were observed at any of 
the doses of 2-CFoDA relative to saline (Figure 6a-d). Analysis via non-linear curve fit of the 
data resulted in overlapping curve fits for all comparisons except 0.1 mg/ml 2-CFoDA (Figure 
6a-c), which revealed higher activity in comparison to the saline control. Further analysis 
performed by calculating the area under the locomotor curves following amphetamine challenge 
from the two groups indicated that their overall activity was not different from one another, or the 
other 2-CFoDA doses (Figure 6d, One-way ANOVA; F(3,28)=0.92, P=0.45). Due to the 
previously uncharacterized nature of 2-CFoDA in vivo, it is difficult to assess the effectiveness of 
the inhibitor in this behavioral context, as many of the variables important for effective drug 
action of 2-CFoDA in the CNS are unknown.  
 
Basal Ganglia Dependent Amphetamine-Induced Locomotion is Attenuated by Direct 
Striatal Delivery of High Dose 2-CFoDA  
 We were unable to ascertain if inhibition of EAAT3 was ineffective in altering the 
locomotor response to amphetamine via ICV delivery, or if 2-CFoDA was unable to reach its site 
of action. We therefore transitioned to an alternative experimental strategy. As before, the mice  
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Figure 6. Pretreatment with the EAAT3 inhibitor, 2-CFoDA, via intracerebroventricular (ICV) 
injection does not alter amphetamine-induced locomotor behavior 
(A-D) Following acute D-amphetamine challenge (3.0 mg/kg, IP), WT mice treated with the EAAT3 
inhibitor 2-CFoDA (ICV) do not exhibit an altered locomotor response to the psychostimulant. While 
curve fit analysis of 0.1 mg/ml 2-CFoDA vs. saline resulted in different curve fits (A), Area under the 
curve (AUC) analysis of amphetamine locomotor response was unchanged.  
A) 0.1 mg/ml 2-CFoDA pretreatment (Non-linear curve fit analysis T=0-60; F(4,424)=6.151, 
****P<0.0001, n=8 per treatment) 
B) 1.0 mg/ml 2-CFoDA pretreatment (Non-linear curve fit analysis T=0-60; F(4,424)=0.26, P=0.90, n=8 
per treatment) 
C) 5.0 mg/ml 2-CFoDA pretreatment (Non-linear curve fit analysis T=0-60; F(4,424)=0.48, P=0.75, n=8 
per treatment) 
D) Area under the curve analysis of amphetamine induced locomotor response of each 2-CFoDA 
treatment condition relative to saline (One-way ANOVA; F(3,28)=0.92, P=0.45, n=8 per treatment).  	  
A 
D 
B 
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were pretreated with 2-CFoDA (5 or 10 mg/ml, 1 uL volume), then challenged with 
amphetamine (3 mg/kg, IP); however they were now administered the drug directly into the 
striatum (AP +0.52 mm, ML ±1.5 mm, DV -3.5 mm, all relative to bregma) (Supplementary 
Figure 3) via guide and injection cannula prior to amphetamine challenge. At the pretreatment 
dose of 5 mg/ml 2-CFoDA, subtle differences in the locomotor response curve were identified as 
above (Figure 7a, 5 mg/ml, Non-linear curve fit analysis T=0-60; F(4,235)=2.95, P=0.021, n=4 
saline, n=5 2-CFoDA); however further AUC analysis identified no differences in the cumulative 
locomotor response between pretreatment with saline or 5 mg/ml 2-CFoDA (Figure 7b, t-test, 
t=0.54, P=0.61, n=4 saline, n=5 2-CFoDA). At the highest 2-CFoDA pretreatment dose tested 
(10 mg/ml), substantial reductions in locomotor response curves were observed in response to 
direct striatal injection of the EAAT3 inhibitor (Figure 7c, 10 mg/ml, Non-linear curve fit analysis 
T=0-60; F(4,397)=49.12, P<0.0001, n=8 saline, n=7 2-CFoDA). Subsequent area under the 
curve analysis agreed with the non-linear curve fit analysis providing strong evidence of 
reductions in amphetamine-induced locomotor response when pretreated with 2-CFoDA directly 
into the striatum (Figure 7d, t-test, t=3.07, P=0.0089, n=8 saline, n=7 2-CFoDA).  
 
Discussion 
 One of the main difficulties in understanding the underpinnings of heterogeneous 
neuropsychiatric disorders such as obsessive-compulsive disorder is the identification of 
candidate risk genes and putative biomarkers in the patient population that allow for rational 
examination in a pre-clinical context. In the studies described in this chapter, we aimed to 
incorporate two of the most consistent findings in OCD, genetic evidence implicating SLC1A1 in 
OCD (Hanna et al., 2002b, Willour et al., 2004b, Arnold et al., 2006, Dickel et al., 2006, Stewart 
et al., 2007, Kwon et al., 2009, Shugart et al., 2009, Samuels et al., 2011) and glutamatergic 
dysfunction in the CSTC circuit (Rosenberg et al., 2000, Rosenberg et al., 2004, Chakrabarty et 
al., 2005a, Starck et al., 2008, Yucel et al., 2008, Bhattacharyya et al., 2009). Using in vivo  
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Figure 7. Pretreatment with the EAAT3 inhibitor, 2-CFoDA, via direct striatal injection only 
affects amphetamine-induced locomotor response at a high, potentially sedating, dose 
Amphetamine locomotor response curves in mice pretreated with 5 mg/ml 2-CFoDA relative to saline 
pretreated mice are different however, AUC analysis of locomotor curves do not segregate, suggesting 
a lack of an overall effect on amphetamine-induced locomotor behavior at this dose. Locomotor 
response to amphetamine at a high dose of 2-CFoDA (10 mg/ml) does result in separate curve fit 
relative to saline pretreatment and lower AUC for amphetamine locomotor response curves, potentially 
due to off-target sedating effects.   
A) 5 mg/ml 2-CFoDA pretreatment via direct site injection (Non-linear curve fit analysis T=0-60; 
F(4,235)=2.95, *P=0.021, n=4 saline, n=5 2-CFoDA). 
B) Area under the curve analysis of amphetamine induced locomotor response of striatal direct site 
injection of 5 mg/ml 2-CFoDA treatment relative to saline is unchanged (T-test, t=0.54, P=0.61, n=4 
saline, n=5 2-CFoDA). 
C) 10 mg/ml 2-CFoDA pretreatment via direct site injection inhibits the amphetamine induced 
locomotor response (Non-linear curve fit analysis T=0-60; F(4,397)=49.12, ****P<0.0001, n=8 saline, 
n=7 2-CFoDA). 
D) Area under the curve analysis of amphetamine induced locomotor response of striatal direct site 
injection of 10 mg/ml 2-CFoDA treatment relative to saline is reduced (T-test, t=3.07, **P=0.0089, n=8 
saline, n=7 2-CFoDA). 
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EAAT3 inhibitors in mouse models of repetitive behavior and glutamatergic dysfunction enabled 
us to examine whether these convergent findings in the human population may yield potential 
benefit in preclinical models.  
 The SAPAP3 null mouse is a well characterized model of repetitive behavior and 
glutamatergic cortico-striatal dysfunction however no prior studies have investigated the impact 
of SAPAP3 loss on EAAT3. We identified an increase in the striatal expression of EAAT3 in 
SAPAP3 null mice relative to WT controls (Figure 4a-b). This is consistent with prior 
identification of an OCD-associated SLC1A1 polymorphism that results in increased SLC1A1 
expression (Wendland et al., 2009a). In order to determine if this increase in EAAT3 expression 
in SAPAP3 null mice corresponded to increased EAAT3 function, [35S]-cysteine uptake 
experiments were performed. Uptake experiments using striatal synaptosome preparations from 
nulls and WT controls identified only a trend-level genotype effect (Figure 4c); albeit in a small 
sample size. One explanation is that SAPAP3 null mice may express increased levels of 
EAAT3; however this increased expression does not result in elevated increased protein 
function at the synaptic membrane as a significant portion of the transporter is proposed to be 
localized in the cytoplasm of neurons (Conti et al., 1998a, Kugler and Schmitt, 1999).  
Importantly, the sample size was relatively small, and further functional assessment of EAAT3 in 
Sapap3 nulls may identify a main genotype effect once the sample size is expanded.   
 Examination of grooming behavior in potential animal models of OCD is common since 
the behavior has direct correlates to many symptoms observed in the human patient population 
(O'Sullivan et al., 2000). We next took advantage of this to assess if pretreatment of SAPAP3 
null mice with the EAAT3 inhibitor NBI-59159, would lessen their elevated spontaneous 
grooming phenotype. Pretreatment of SAPAP3 null mice and WTs with NBI-59159 (5 mg/kg) 
had no effect on grooming in either genotype regardless of pretreatment condition (Figure 5). 
There are many factors that may help interpret this lack of effectiveness of NBI-59159 to lessen 
the grooming behavior in the null mice. The first is that prior in vivo assessment of the 
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compound in animal models used a shorter pretreatment period (15 min vs 60 min, 
Supplementary Figure 2) (Dunlop and Marquis, 2006) so by the time we performed our 
grooming analysis, the inhibitor may have been metabolized to lower concentrations in the CNS. 
Another potential explanation is that recent investigation of SAPAP3 null mice identified 
increased striatal signaling via mGluR5 (Ade et al., 2016). Due to the proximal localization of the 
mGluR5 to EAAT3 and EAAT3’s ability to limit glutamate availability in a manner that affects 
mGluR5 signaling (Otis et al., 2004), inhibition of EAAT3 function via NBI-59159 administration 
may not lead to reductions in mGluR5 signaling, and therefore we may not observe alterations 
in repetitive behaviors that are linked to increased striatal mGluR5 signaling in SAPAP3 nulls. 
 Ensuing investigation focused on the ability of EAAT3 inhibitors to impact the CSTC 
circuit used a separate compound, 2-CFoDA. 2-CFoDA was synthesized as part of broader 
effort to improve GLT-1 inhibitors and was reported to exhibit an improved inhibitory profile at 
EAAT3 relative to NBI-59159, though the details regarding in vitro inhibition assays used for the 
two compounds were different. Due to a lack of information on the drug metabolism or 
pharmacokinetic properties of 2-CFoDA, we designed our amphetamine-induced locomotion 
experiments so that the mice were initially pretreated with 2-CFoDA via ICV injection in order to 
bypass the blood brain barrier. Our ICV pretreatment of mice with 2-CFoDA did not decrease 
amphetamine-induced locomotor behavior at any of the three doses used (0.1, 1, and 5 mg/ml) 
(Figure 6). Curve fit analysis identified alterations in post amphetamine locomotion in the 0.1 
mg/ml condition relative to saline (Figure 6a). These data suggest that pretreatment with a 
potent EAAT3 inhibitor sixty minutes prior to psychostimulant challenge has no affect on basal 
ganglia dependent behavior; however there are some limitations of the experiment to consider. 
The first caveat is that the CSF of a mouse poorly penetrates the brain tissue, primarily due to 
the limitations of diffusion. The second caveat is that turnover of CSF is rapid in the mouse, 
approximately two hours. Since the pretreatment time of the mice in this experiment was 60 
minutes, half of the total CSF volume will have been removed in that pretreatment period. 
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Thirdly, our knowledge of the mechanism in which 2-CFoDA is metabolized is unknown. All 
previous work with the compound was performed in vitro without any further investigation of its 
in vivo drug metabolism and pharmacokinetic properties. Taken together, whatever portion of 2-
CFoDA that does reach the striatum (without being metabolized or removed from brain CSF 
completely) is still limited by diffusion into the brain tissue. It is more likely than not that the 
results from these experiments do not provide a conclusive resolution to the ability of EAAT3 
inhibitors to impact behavior relevant to glutamatergic dysfunction in the CSTC or OCD.  
 In order to minimize the caveats discussed above, we transitioned to an alternative 
experimental strategy by delivering 2-CFoDA directly into the striatum of WT mice prior to 
amphetamine challenge. At 5 mg/ml, subtle alterations in the locomotor curve following 
amphetamine administration were observed relative to saline (Figure 7a); however calculations 
of total distance traveled via area under the curve analysis identified no differences between 2-
CFoDA and saline pretreatment condition (Figure 7b). By increasing the pretreatment dose of 2-
CFoDA to 10 mg/ml, we observed significantly different amphetamine locomotor response 
curves (Figure 7c), and total distance traveled via area under the locomotor curve analysis was 
substantially reduced in mice pretreated with 10 mg/ml 2-CFoDA relative to saline (Figure 7d). 
As with prior data in this chapter, this finding of reduced amphetamine-induced locomotion 
following pretreatment with high dose 2-CFoDA must be interpreted judiciously. One 
confounding aspect of the data is that the locomotor curves from the mice pretreated with 10 
mg/ml 2-CFoDA do not resemble control conditions, as their eventual increase in locomotion is 
relatively linear while mice in the saline condition exhibit abrupt and almost exponential 
increases in activity following amphetamine administration. Additionally, the 10 mg/ml curve 
does not resemble amphetamine-induced locomotor curves from subsequent chapters where a 
significant reduction in amphetamine-induced locomotor behavior is observed. Due to the 
relatively high dose and lack of knowledge of the pharmacodynamic profile of 2-CFoDA, the 
inhibitor may have off-target sedative liability. Another consideration is that GLT-1 is reported to 
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be expressed ~100 fold more than EAAT3 (Holmseth et al., 2012). Despite 2-CFoDA’s 
preference for EAAT3 versus GLT-1, we may be observing unforeseen behavioral 
consequences resulting from the inequalities of EAAT3 and GLT-1 expression in the striatum. It 
is also possible inhibition of EAAT3 at an alternative site in the brain would be more impactful in 
inhibiting amphetamine-induced locomotion. Of note, recent studies investigating the molecular 
consequences of amphetamine administration have shown that EAAT3 undergoes endocytosis 
from the neuronal membrane in dopaminergic neurons of the midbrain, which are responsible 
for the release of dopamine into the striatum following amphetamine challenge. Investigation of 
2-CFoDA’s in vivo pharmacodynamic profile and further effective dose studies would be an 
important step towards understanding the potential effectiveness of 2-CFoDA in vivo.  
 The search for efficacious pharmacological agents acting on the glutamatergic system 
has been ongoing ever since dysfunction of the neurotransmitter was identified as a putative 
biomarker for obsessive-compulsive disorder. Many different types of glutamatergic modulators 
have been investigated as novel therapeutic options for the disorder, primarily as augmenting 
agents in refractory OCD cases. These include riluzole (Coric et al., 2005, Grant et al., 2007, 
Grant et al., 2014), a glutamate modulator that inhibits release of the neurotransmitter via 
inhibition of voltage gated Na+-channels, and NMDA blockers including memantine (Pasquini 
and Biondi, 2006, Haghighi et al., 2013), D-cycloserine (Kushner et al., 2007, Storch et al., 
2016), and ketamine (Rodriguez et al., 2011, Bloch et al., 2012, Rodriguez et al., 2013). As is 
the issue with most forms of pharmacotherapy for neuropsychiatric disorders, the treatments 
may be efficacious in certain subsets of the patient population but rarely, if ever, are they 
effective in all. More studies aimed at understanding the underlying cause of the disorder must 
be done in order to isolate specific proteins that are implicated in the disorder. At this time, the 
strongest evidence in OCD is for SLC1A1/EAAT3; however little effort has been put forth to 
develop compounds with the capacity to exert physiological effects in vivo. It is irrational to 
argue that a panacea drug will be found to cure all of the ills of patients suffering from OCD, as 
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the patient population undergoes a diverse set of symptoms. However, until rationally designed 
compounds aimed at modulating strongly implicated protein targets are developed, this patient 
population will continue to be treated with therapeutic strategies aimed at treating only their 
symptoms, not the underlying pathophysiology of the disorder.  
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CHAPTER 4 
 
OCD CANDIDATE GENE SLC1A1/EAAT3 IMPACTS BASAL GANGLIA-MEDIATED 
ACTIVITY AND STEREOTYPIC BEHAVIOR 
 
As published in: OCD candidate gene SLC1A1/EAAT3 impacts basal ganglia-mediated activity 
and stereotypic behavior. Proc Natl Acad Sci USA (2017).  
 
 
Isaac D. Zike, Muhammad O. Chohan, Jared M. Kopelman, Emily Krasnow, Daniel Flicker, 
Katherine M. Nautiyal, Michael Bubser, Christoph Kellendonkj, Carrie K. Jones, Gregg D. 
Stanwood, Kenji F. Tanaka, Holly Moore, Susanne E. Ahmari, Jeremy Veenstra-VanderWeele 
 
Introduction 
 
Obsessive-compulsive disorder (OCD) is a common neuropsychiatric condition that 
ranks among the top ten causes of disability worldwide (Koran et al., 2007, Michael S. Ritsner, 
2007). Primary forms of therapy include serotonin reuptake inhibitors (SRIs) and cognitive 
behavioral therapy; however, only 50-60% of patients exhibit adequate response to current 
treatment approaches, with clinically significant residual symptoms in most patients (Dougherty 
et al., 2004, Koran et al., 2007). Other agents, including antipsychotic medications and 
glutamatergic agents, have been investigated to augment SRIs, but have shown limited 
evidence of efficacy to date (Simpson et al., 2013, Grant et al., 2014, Sarris et al., 2015). 
Surgical intervention with deep-brain stimulation (DBS) in the ventral capsule/ventral striatum or 
subthalamic nucleus shows promise, but is reserved for the most severely ill patients 
(Aouizerate et al., 2004, Fontaine et al., 2004). New treatments based on greater understanding 
of pathophysiology are therefore needed. 
 Multiple lines of evidence indicate that the basal ganglia are critically affected in OCD. 
Structural neuroimaging studies demonstrate altered caudate volume in OCD (Rosenberg et al., 
1997, Radua and Mataix-Cols, 2009), and functional imaging has identified hyperactivity in 
cortico-striatal circuits, both at baseline and with symptom provocation (Menzies et al., 2008). 
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Interestingly, some reports using magnetic resonance spectroscopy (MRS) describe elevated 
striatal glutamatergic signal in the caudate (Whiteside et al., 2006, Starck et al., 2008), 
suggesting increased intracellular glutamate and/or gamma-aminobutyric acid (GABA). Recent 
work in genetic and optogenetic mouse models of SRI-sensitive compulsive-like grooming 
behavior have also implicated cortico-striatal signaling, suggesting relevance of dysfunctional 
basal ganglia signaling to repetitive behavior across species (Welch et al., 2007, Shmelkov et 
al., 2010b, Ahmari et al., 2013, Burguiere et al., 2013). 
 Family studies support a significant role for genetics in OCD, with increased heritability 
in early-onset OCD (Grados and Wilcox, 2007, Pauls, 2008). Suggestive linkage to the 
chromosome region 9p24, which contains SLC1A1, in addition to other genes, was initially 
established in a genome-wide linkage scan of OCD and then independently replicated (Hanna 
et al., 2002b, Willour et al., 2004b). Analysis of SLC1A1, which codes for the neuronal 
glutamate transporter EAAT3 (excitatory amino acid transporter 3), identified significant 
association in the 3’ region, with stronger evidence in males (Veenstra-VanderWeele et al., 
2001, Arnold et al., 2006, Dickel et al., 2006). Some, but not all, subsequent studies also 
identified association with polymorphisms in the 3’ gene region, with the most evidence for 
association with the rs301430C allele (Arnold et al., 2006, Dickel et al., 2006, Stewart et al., 
2007, Shugart et al., 2009, Wendland et al., 2009a, Stewart et al., 2013a), which is linked to 
elevated SLC1A1 expression in lymphoblastoid cells, human postmortem brain, and a luciferase 
reporter assay (Wendland et al., 2009a). Taken together, these data suggest that OCD 
susceptibility may result from elevated SLC1A1 expression, and that decreasing EAAT3 activity 
could therefore be a therapeutic target.  Association findings, gene expression differences, and 
deletions of SLC1A1 have also been reported in schizophrenia and bipolar disorder (Horiuchi et 
al., 2012, Myles-Worsley et al., 2013, Afshari et al., 2015), indicating a potential role for EAAT3 
in a broader array of neuropsychiatric disorders.  
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 SLC1A1 mRNA and EAAT3 protein are strongly expressed in the cortex and the 
striatum, and in mesolimbic and nigrostriatal dopaminergic neurons (Nieoullon et al., 2006, 
Nafia et al., 2008, Holmseth et al., 2012, Underhill et al., 2014, Bjorn-Yoshimoto and Underhill, 
2016). EAAT3 localizes to peri- and postsynaptic regions (Conti et al., 1998a), where it serves 
three apparent functions: 1) buffering glutamate concentrations around peri/extrasynaptic N-
methyl-D-asparate (NMDA) and metabotropic glutamate receptors (Otis et al., 2004); 2) taking 
up glutamate as an intracellular precursor for GABA synthesis (Sepkuty et al., 2002, Mathews 
and Diamond, 2003); and 3) taking up cysteine for glutathione synthesis and protection from 
oxidative stress (Aoyama et al., 2006, Watts et al., 2014).  
One logical place for SLC1A1/EAAT3 to impact cortico-striatal signaling is in the 
GABAergic medium spiny neurons (MSNs) of the striatum, which receive glutamatergic inputs 
from the cortex and provide output to the thalamus via the direct and indirect pathways of the 
basal ganglia. EAAT3 activity limits NR2B-containing NMDA receptor-dependent signaling at 
hippocampal glutamatergic synapses (Scimemi et al., 2009), and could similarly impact post-
synaptic signaling in striatal MSNs (Cahill et al., 2014).  In addition, recent reports suggest that 
EAAT3 is expressed in dopaminergic neurons projecting from the ventral tegmental area (VTA) 
and the substantia nigra (SN) to the ventral and dorsal striatum respectively (Nafia et al., 2008, 
Underhill et al., 2014). It is therefore possible that the subpopulation of EAAT3 in midbrain 
dopaminergic neurons could impact OCD-implicated basal ganglia circuitry via 
neuromodulation. This is especially relevant in light of recent evidence that amphetamine elicits 
endocytosis of EAAT3 and causes elevated signaling at glutamate receptors in dopaminergic 
neurons (Underhill et al., 2014). 
 Despite its genetic association with OCD, no studies have addressed the functional 
impact of Slc1a1/EAAT3 on OCD-relevant brain circuits or on OCD-like behaviors. To explore 
these questions, we used a flexible knock-in approach (Tanaka et al., 2010) to generate mice 
with constitutively reduced Slc1a1/EAAT3 expression (Slc1a1-STOP mice). We hypothesized 
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that these animals would show decreased liability to repetitive behaviors, based on the 
implication of increased SLC1A1 expression in OCD risk. Beyond assessing spontaneous 
repetitive behaviors, which occur at low baseline frequency, we examined sensitivity to 
pharmacologically induced compulsive-like behaviors using amphetamine (which causes 
dopamine efflux and increased synaptic dopamine levels) and the dopamine D1 receptor agonist 
SKF-38393. Our flexible knock-in approach also permitted targeted excision of the STOP 
cassette, allowing us to localize the impact of EAAT3 loss on repetitive behaviors. 
 
Methods 
Slc1a1-STOP Mouse Line Generation 
Generation of targeting vector: We constructed a pNeoSTOPtetO plasmid using BAC 
recombineering (Tanaka et al., 2010). Our targeting vector has a 10kb 5’-homology arm, 
NeoSTOPtetO cassette, 1.7kb 3’-homology arm, and diphtheria toxin A subunit. We inserted the 
STOP-tetO cassette just upstream of the Slc1a1 translation initiation site (Figure 8a). 
Multicloning (MCS) site1 (PacI/NotI/ BamHI), loxP, FRT, PGK-EM7-Neo-HSV thymidine kinase 
poly A minigene, STOP sequence, FRT, tetO sequence, loxP, and MCS2 
(EcoRV/EcoRI/PacI/SalI) were connected in tandem. 400 bp DNA fragments upstream and 
downstream of the translation initiation site were amplified with PCR primers containing 
appropriate restriction enzyme sites, and respectively inserted into each MCS of pNeoSTOP-
tetO plasmid. To perform BAC recombination, the linearized NeoSTOP-tetO cassette with 400 
bp homology arms was transferred into bacteria carrying the pBADTcTypeG plasmid and the 
BAC encompassing the Slc1a1 coding frame; BAC genomic clones containing Slc1a1 promoter 
and regulatory regions were obtained from BacPac (RP23-475B5). The targeting vector was 
isolated from the recombined, kanamycin resistant clone using a retrieving technique into 
pMCS-DTA plasmid.  
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Construct insertion. 8 colonies were found to be kanamycin-resistant, and 2/8 were found to 
contain the NeoSTOP-tetO cassette via colony direct PCR. Expected band sizes based on 
primer positions and location of NeoSTOP-tetO sequence were seen: 685 bp (5’ arm) and 644 
bp (3’ arm).  
Generation of ES Cells: The targeting vector was electroporated into a 129/SvEvTac mouse ES 
cell line in the Duke Embryonic Stem Cell Core. Homologous recombinants were detected using 
PCR for the 3’ arm of the targeting vector using a primer complementary to the 3’ homology 
arm, and an external primer complementary to the genomic sequence located 3’ of the 3’ 
homology arm of the targeting vector. A subset of positive clones were tested by PCR for 
homologous targeting of the 5’ arm. Transgene incorporation was verified using Southern blot 
with probe position from -11,256 to -10,717 bases upstream of the translation initiation site, 
outside the homology arm, which generated the predicted band sizes of 15kb (WT) and 18kb 
(Slc1a1-STOP-tetO). Positive ES clones were injected into C57BL/6J blastocysts to obtain 
chimeric mice, which were crossed to 129S6/SvEvTac females to obtain germline transmission. 
Germline transmitted offspring were then established as Slc1a1 STOP-tetO heterozygous 
knock-ins on a pure 129S6/SvEvTac background.  
 
Quantitative-Real Time Polymerase Chain Reaction 
RNA Isolation 
RNA from fresh striatal tissue was isolated using Qiagen RNeasy Mini 
Kit with DNase I (Qiagen, Valencia, CA, USA) treatment per manufacturer’s instructions. RNA 
quality and yield were assessed by NanoDrop spectrophotometer (Thermo Scientific, Waltham, 
MA, USA).  
 
Quantitative PCR 
For quantitative PCR (qPCR) experiments, cDNA was generated using High Capacity cDNA 
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Reverse Transcription Kit (Life Technologies, Carlsbad, CA, USA) per manufacturer’s 
instructions. qPCR was performed using Slc1a1 (Mm00436590_m1) and Gapdh 
(Mm99999915_g1) TaqMan gene expression assays run on a 7900HT system (Life 
Technologies). All samples were run in triplicate with non-template and reverse transcriptase 
negative controls. Differential gene expression was calculated using the ΔΔCT method with 
Gapdh as the endogenous control. 
 
Immunoblotting Studies  
Brains were harvested from mice following rapid decapitation. Brains were immediately placed 
on an ice-cold metal platform, and the striatum was dissected. Dissected tissue was placed into 
3 mL of homogenization buffer [130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl2, 1.2 mM MgSO4, 1.2 
mM KH2PO4, 10 mM Hepes (pH 7.4), 10 mM glucose, ascorbic acid, and 0.32 M sucrose] and 
homogenized using a Potter Elvehjem homogenizer (Wheaton, Millville, NJ, USA). Protein 
concentrations of all samples were determined by a bicinchoninic acid (BCA) protein assay 
(Thermo Fisher Scientific). Equal amounts of protein were incubated with Laemmli sample 
buffer for 10 min at room temperature and analyzed by using SDS/PAGE and Western blotting. 
EAAT3 protein was visualized in samples blotted to Immobilon-P PVDF membrane (EMD 
Millipore, Billerica, MA, USA) by using a rabbit anti-EAAC1/EAAT3 antibody (EAAC11-A, 
1:1,000 dilution; Alpha Diagnostics, San Antonio, TX, USA). β-actin was visualized by using a 
mouse anti–β-actin antibody (A5316, 1:10,000 dilution; Sigma-Aldrich, St. Louis, MO, USA) as a 
loading control. Appropriate HRP-conjugated, secondary antibodies were obtained from GE 
Healthcare Life Sciences (Pittsburgh, PA, USA). Secondary antibody labeling was detected by 
using Amersham ECL Prime Western Blotting Detection Reagents and visualized via 
chemiluminescence using FluorChem M System (Protein Simple, San Jose, CA, USA). Multiple 
exposures were obtained to ensure linearity of band detection. Western blots were quantified by 
using NIH ImageJ software.  
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Synaptosomal Glutamate and Cysteine Transport Assays.  
Brains were harvested from mice following rapid decapitation and immediately placed on an ice-
cold metal platform so that striatum could be dissected. Striatal tissue samples were placed into 
3 mL of homogenization buffer [130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl2, 1.2 mM MgSO4, 1.2 
mM KH2PO4, 10 mM Hepes (pH 7.4), 10 mM glucose, ascorbic acid, and 0.32 M sucrose] and 
homogenized by using a Potter-Elvehjem homogenizer (Wheaton). Homogenates were 
centrifuged at 500 × g at 4 °C for 10 min. Supernatants were removed and centrifuged at 12,000 
× g at 4 °C for 10 min. The resulting synaptosome-enriched pellets were then resuspended in 
2.5 mL of assay buffer [130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl2, 1.2 mM MgSO4, 1.2 mM 
KH2PO4, 10 mM Hepes (pH 7.4), 10 mM glucose and ascorbic acid], and protein 
concentrations were determined by using the bicinchoninic acid (BCA) Protein Assay (Thermo 
Fisher Scientific). This material (hereafter called synaptosomes) was then diluted to 30 µg of 
total protein per 100 µL. Synaptosomes were incubated with 20 uM of [3 H]-glutamate  (10% 
labeled and 90% unlabeled), 50 uM and 200 uM [35 S]-cysteine (Perkin-Elmer, Waltham, MA, 
USA) (1% labeled and 99% unlabeled). Assays were terminated by rapid filtration over 0.3% 
polyethyleneimine-soaked GF/B glass microfiber filters (Whatman, GE Life Science) and 
washed three times with ice-cold Krebs-Ringers-Hepes buffer [130 mM NaCl, 1.3 mM KCl, 2.2 
mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, and 10 mM Hepes (pH 7.4)]. Filters placed into 
scintillation vials with 7 mL of Ecoscint H (National Diagnostics, Atlanta, GA, USA) scintillation 
fluid, shaken overnight at room temperature, and then radioactivity was quantified by using a 
TriCarb 2900TR scintillation counter (Perkin-Elmer). Specific [3 H]-glutamate and [35 S]-
cysteine transport was assayed in triplicate for all samples.  
 
Behavioral Assays. 
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All behavioral experiments were performed in the Laboratory for Neurobehavior Core Facility at 
Vanderbilt, operated by the Vanderbilt Brain Institute, or the Rodent Neuroanalytical Core, 
operated by the New York State Psychiatric Institute. Behavioral testing was performed between 
10:00 and 16:00 using mice 8-16 wk old. Animals were habituated to testing rooms for 15–20 
min before the start of each experiment.  
 
Spontaneous Locomotor Activity  
Spontaneous locomotor activity in the open field was measured by using 27 x 27 x 20.5 
chambers (Med-Associates, St. Albans, VT, USA) placed within light- and air-controlled sound-
attenuating boxes (64 x 45 x 42 cm). Locomotion was detected by interruption of infrared beams 
by the body of the mouse (16 photocells in each horizontal axis located 1 cm above the activity 
chamber floor, as well as 16 photocells elevated 4 cm above the chamber floor). Data were 
collected and analyzed by Med Associates Activity Monitor software. Mice were acclimated to 
the activity chambers during a 30-min session 2–3 d before data recording began.  
 
Elevated Zero Maze 
Anxiety behaviors were examined by using an elevated zero maze (62.5 cm outer diameter, 5 
cm path width, 15 cm wall height in closed segments; Stoelting, Wood Dale IL, USA) with 
recordings lasting for 5 min. At the start of each trial, mice were placed onto an open portion of 
the maze, adjacent to and facing one of the closed segments. Each session was recorded by a 
ceiling-mounted video camera connected to a computer for digital video acquisition and analysis 
with ANY-maze software (Stoelting). Data analyzed include the percent of time spent in the 
open zone, number of open and closed zones entries, and distance traveled within the maze.  
 
Light-Dark Emergence 
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Light-dark emergence was measured by using 27 x 27 x 20.5 chambers (Med Associates) 
placed within light- and air-controlled sound-attenuating boxes (64 x 45 x 42 cm). An opaque 
black insert is placed into the open- field chamber that creates equal sized light and dark 
compartments with an open door. Mice were placed into the dark chamber through a trap door 
located on top of the insert. Mouse location was detected by interruption of infrared beams by 
the body of the mouse (16 photocells in each horizontal axis located 1 cm above the activity 
chamber floor. The distance traveled in each chamber, the total number of transitions, time 
spent in the each chamber, and latency to enter the light chamber are recorded by the Med 
Associates software.  
 
Acoustic Startle and Prepulse Inhibition 
Acoustic startle response and prepulse inhibition of acoustic startle were measured by using the 
Acoustic Startle Reflex Test Compartments (Med Associates). Mice were acclimated to 
background white noise of 65 dB for 5 min in a Plexiglas holding cylinder. Mice were then 
presented with seven trial types in six discrete, randomized blocks of trials for a total of 42 trials 
with an intertrial interval of 10 to 20 s. One trial measured baseline movement and one trial 
measured response to the 120-dB, 50-ms startle stimulus alone. The other five trials used an 
acoustic prepulse of 74, 78, 82, 86, or 90 dB preceding the acoustic startle stimulus by 100 ms. 
Startle amplitude was measured every millisecond over a 65 ms period beginning at the onset 
of the startle stimulus. The dependent variable was the maximum startle over the sampling 
period. Prepulse inhibition was calculated by dividing the difference between baseline startle 
and startle following prepulse by baseline startle. 
 
Home Cage Scan 
To evaluate possible repetitive behavior, individual mice of each genotype were video-recorded 
alone in their home cage for 24 h while maintaining their 12 h/12 h light/ dark schedule. 
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Automated video analysis was conducted by using HomeCageScan (Clever Sys, Reston, VA, 
USA) to index time spent performing individual behaviors.  
 
Spontaneous Grooming 
Mice were placed in an empty novel cage and allowed to habituate for 30 minutes. Mouse 
behavior was then recorded for 10 minutes. Time spent grooming was then manually 
determined with a stopwatch while observing the video, with the observer blind to genotype. 
 
Amphetamine-Induced Locomotion 
Locomotor activity in the open field was measured by using 27 x 27 x 20.5 cm chambers (Med 
Associates) placed within light- and air-controlled sound-attenuating boxes (64 x 45 x 42 cm). 
Locomotion was detected by interruption of infrared beams by the body of the mouse (16 
photocells in each horizontal axis located 1 cm above the activity chamber floor, as well as 16 
photocells elevated 4 cm above the chamber floor to detect rearing and jumping behaviors). 
Data were collected and analyzed by Med Associates Activity Monitor software. Mice were 
acclimated to the activity chambers during a 30-min session 2–3 d before data recording began. 
On day 1 of the experimental sequence, mice were weighed then placed into activity chambers, 
and activity was monitored for 30 min. The mice were then removed from the activity chambers 
and received an intraperitoneal (I.P.) injection of 0.9% saline or amphetamine (Sigma-Aldrich) 
(1.8, 3, or 8 mg/kg) Mice were returned to the activity chambers and locomotor activity was 
recorded for 60 min. Mice were returned to their home cage for a week to allow for drug wash 
out then given the alternative treatment. Time course data were analyzed by using non-linear 
curve line fit analysis and cumulative measures of behavior (i.e., total distance traveled, time in 
stereotypy, number of stereotype behaviors, time rearing, and number of rearing behaviors) 
during the entire 60-min recording was analyzed.  
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Amphetamine-Induced Stereotypy 
Mice were weighed one hour prior to the beginning of behavioral assay then administered with 8 
mg/kg amphetamine (Sigma Aldrich). Mice were then promptly placed into novel clear empty 
cages and behavior was recorded for 90 minutes with a video camera. Mouse behavior was 
analyzed for a stationary shuffling and sniffing-like stereotypy previously observed in pilot 
experiments. Observers blind to genotype performed analysis by post hoc scoring of video 
recordings. The observer recorded time spent performing this stationary shuffling and sniffing-
like stereotypy manually with a stopwatch. Time spent undergoing stereotypy was analyzed for 
two minutes 50 and 80 min post amphetamine administration.  
 
SKF-38393-Induced Grooming 
Mice were weighed then placed in an open field apparatus measuring by using 27 x 27 x 20.5 
cm chambers (Med Associates) placed within light- and air-controlled sound-attenuating boxes 
(64 x 45 x 42 cm). Mice were allowed to habituate for 30 min then administered saline or SKF-
38393 (10 mg/kg, I.P. Tocris Biosciences, Pittsburgh, PA, USA) and placed back into the open 
field for 60 additional minutes. Behavior was recorded via cameras located above the open field 
for the entirety of the experiment. Following a one-week wash-out period, mice received the 
alternative treatment from week 1. Trained observers, blind to genotype and drug treatment, 
manually scored grooming duration during sample periods (first two minutes of every ten-minute 
bin) for one hour following SKF-38393 administration.  
 
cFos+ Immunohistochemistry  
To measure an indirect marker of neuronal activation, we immunostained coronal slices of 
mouse striatum and nucleus accumbens challenged with amphetamine (3.0 mg/kg, I.P.) or 
saline. Mice were then perfused with 4% paraformaldehype and post-fixed overnight at 4 °C, 
transferred to 30% sucrose in 0.1 M phosphate buffer until sunk, and sectioned on a microtome 
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to a thickness of 40µm. Striatum containing sections were peroxidase quenched in .3% H2O2 in 
methanol for 30 min, blocked in PBS with 5% normal donkey serum and 0.3% Triton X-100 for 2 
hr at room temperature, and incubated in rabbit anti-cFos primary antibody (1:5000; Santa Cruz, 
Dallas, TX, USA) for 72 hr at 4 °C. After washing in PBS with 0.3% Triton X-100, sections were 
incubated in biotinylated donkey anti-rabbit (1:500; Jackson ImmunoResearch, West Grove, PA, 
USA) secondary antibody for 2 hr at room temperature. Washed sections were incubated with 
ABC reagent and DAB substrate (Vector Labs, Burlingame, CA, USA) per manufacturer’s 
instruction for visualization of stained cells.  
 
cFos+ Cell Quantification 
cFos immunostaining was identified using StereoInvestigator software (MBF Biosciences, 
Williston, VT, USA) and an Axio Imager M2 microscope (Zeiss) with a 10X objective coupled to 
a Retiga 2000R camera (Qimaging). 3-4 coronal brain sections corresponding to dorsal medial 
striatum (A/P +0.9 mm, M/L ±1.5 mm, D/V -3 mm relative to bregma), nucleus accumbens core 
(A/P +1.2 mm, M/L ±0.75 mm, D/V -4.5 mm relative to bregma) and nucleus accumbens shell 
(A/P +1.2 mm, M/L ±0.5 mm, D/V -4.5 mm relative to bregma), and somatosensory cortex (AP 
+0.9 mm, M/L ±3.0 mm, DV -3.0 mm relative to bregma) were identified for each treatment 
condition and matched between genotypes using the Allen Brain Atlas.(Franklin and Paxinos, 
2013) For each animal (n=6 DS WT and ST, n=4 NAc WT and ST), the total number of cFos+ 
cells within a unilateral region of interest was estimated using a sampling frame (dorsal striatum 
90 x 67.5 uM; NAcc, and somatosensory cortex 35 x 35 uM) and the cell counter plugin for 
ImageJ (NIH). For each mouse, total number of cFos+ cells within the counting frame were 
counted, averaged within subject, and then normalized within genotype to the saline condition. 
Analysis was performed using two-way ANOVA’s to identify interactions between drug and 
genotype as well as main effects. All quantification was done blind to genotype and treatment. 
Raw counts are included in Table 1. 
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Binding 
Fresh striatal tissue was dissected and frozen as noted above then placed in 2 mL of binding 
buffer [50 mM Tris (pH 7.4), 5 mM MgCl2, 5 mM KCl, 1 mM EDTA, and 120 mM NaCl] and 
homogenized by using an Omni-Tip handheld homogenizer (Omni International) at 10,000–
12,000 rpm for 10–15 s. Homogenates were then centrifuged at 20,000 × g at 4 °C for 20 min. 
Membrane pellets were resuspended in 3 mL of binding buffer and homogenized again as 
described above. Homogenates were preincubated at 37 °C for 15 min and then centrifuged at 
20,000 × g at 4 °C for 20 min. Membrane pellets were again resuspended in 3 mL of binding 
buffer and homogenized as described above. Protein concentration was determined by BCA 
protein assay (Thermo Fisher Scientific). Samples were stored at −80 °C until used for binding 
assays. Membrane samples were then thawed and (100–150 µg for striatum) incubated in a 
final reaction volume of 1 mL at room temperature for 75 min in the presence of 3 nM [3 H]-SCH 
23390 (D1R assays; 84.3 Ci/mmol; Perkin-Elmer) or 90 min in the presence of 3 nM [3 H]-
methylspiperone (D2R assays; 84.3 Ci/mmol; Perkin-Elmer). Binding reactions were terminated 
by the addition of 8 mL of ice-cold wash buffer [50 mM Tris (pH 7.4)] followed by rapid filtration 
over water-moistened S&S (#5) (Schleicher and Schuell Bioscience) or Whatman GF/B 
(Whatman) glass fiber filter by using a Millipore vacuum manifold. Each filter was then washed 
two times with 8 mL of ice-cold wash buffer. Filters were placed in scintillation vials, and 10 mL 
of Biosafe II scintillation fluid (Research Products International, Mt. Prospect, IL, USA) was 
added to each vial. Vials were shaken overnight at room temperature, and then radioactivity 
was counted by using a TriCarb 2900TR scintillation counter (Perkin-Elmer). Nonspecific 
binding was determined by using parallel incubations as above with the addition of 2 µM 
butaclamol to samples with binding values from these samples subtracted from radioligand-only 
samples to determine specific binding. All samples (total and nonspecific binding) were assayed 
in triplicate.  
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Microdialysis 
Anesthetized (isoflurane) 6-8 week old mice were implanted unilaterally with Microdialysis Guide 
Cannula MBR-5 (BASi, MBR-2255) using standard stereotactic techniques (AP +0.9 mm, ML 
1.7 mm, DV -2.0 mm; relative to bregma). Microdialysis was performed following a recovery 
period of 3 days. On the day of microdialysis a Microdialysis Probe MBR-2-5 (BASi, MB-2212) 
with a confirmed in vitro recovery of > 7% was lowered into the guide cannula. The probe was 
then perfused with an artificial cerebral spinal fluid (aCSF; 145 mM NaCl, 2.7 mM KCl, 1.0 mM 
MgCl2, 1.2 mM CaCl2, pH 7.4) at a rate of 1 µL/min for a period of 120 mins prior to collecting 
the first sample. Following this equilibration period, dialysis samples were collected into vials 
containing 5 µl of HeGA preservative every 40 min. Once stable basal dopamine levels were 
established four different concentrations of dopamine (0, 1, 10, 20 nM) in aCSF were perfused 
in a random order and loss or gain of dopamine was measured. Following completion of this no 
net flux protocol, aCSF was again perfused until steady levels of dopamine were established; at 
which point 3 mg/kg amphetamine was administered (i.p). Four 40 mins samples were then 
collected. Dialysis samples were immediately analyzed using HPLC using a 100mm long 
column (Pursuit XRs C18 100 x 3.0mm, Agilent Technologies) and a mobile phase consisting of 
1.5% acetonitrile, 7% methanol, 75 mM sodium phosphate monobasic monohydrate, 25 µM 
EGTA, 2.28 mM 1-octanesulfonic acid soap with a pH of 3.9 prepared no more than 24hrs 
before the run. DA and metabolite peaks were detected using an electrochemical microdialysis 
cell (ESA, model 5014B) coupled to a CoulArray detector (ESA, model 5600A) with CoulArray 
software. After the experiments, mice were deeply anesthetized and transcardially perfused, 
brains sliced and probe positions confirmed.  
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DAT and Cre Immunohistochemistry  
Mice (12 weeks for DAT and 16-24 weeks for Cre) were perfused with 4% paraformaldehype 
and post-fixed overnight at 4°C, transferred to 30% sucrose in 0.1 M phosphate buffer until 
sunk, and sectioned on a cryostat to a thickness of 40µm. Midbrain containing sections were 
washed with PBS and 0.3% Triton X-100 3 times for ten minutes, peroxidase quenched in 0.3% 
H2O2 in methanol for 30 min, and then blocked in PBS with 5% normal donkey serum and 0.3% 
Triton X-100 for 1 hr at room temperature. Sections were then incubated overnight at 4°C with 
either rat anti-DAT (1:1000, Millipore, Billerica, MA, USA) or mouse anti-Cre (1:1000, Millipore) 
antibody. After washing in PBS with 0.3% Triton X-100, sections were incubated in biotinylated 
donkey anti-Mouse (Cre,1:500; Jackson Immuno Research, West Grove, PA, USA) or 
biotinylated donkey anti-Rat (DAT, 1:500; Jackson Immuno Research) secondary antibody for 2 
hr at room temperature. Washed sections were incubated with ABC reagent and DAB substrate 
(Vector Labs, Burlingame, CA, USA) per manufacturer’s instruction for visualization of stained 
cells. DAT and Cre immunostaining was identified using StereoInvestigator software (MBF 
Biosciences, Williston, VT, USA) and an Axio Imager M2 microscope (Zeiss) coupled to a 
Retiga 2000R camera (Qimaging). Areas corresponding to VTA (AP -2.9 -.3.4 mm; ML ± 0.4 
mm; DV -4.5 mm relative to bregma) were identified (Allen Brain Atlas) (Franklin and Paxinos, 
2013).  
 
DAT Stereological Quantification 
Unbiased stereology was used to estimate mean total number of DAT+ neurons in the midbrain 
via the optical fractionator method (Pakkenberg and Gundersen, 1989, Furness et al., 2008, 
Gondre-Lewis et al., 2016) This design-based method allows an estimation of cell number that 
is independent of volume estimates. Data collection was performed using the StereoInvestigator 
program (MBF Biosciences). The system used an X-Y-Z motorized stage. The program was 
integrated with an Axio Imager M2 microscope (Zeiss) with coupled to a Retiga 2000R camera 
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(Qimaging). Region of interest was outlined at low power using a 2.5X objective. ROIs were 
determined based on stereotactic coordinates provided by Paxinos and Franklin atlas (Franklin 
and Paxinos, 2013) at -2.9 - -3.5 mm from bregma for the midbrain (VTA and SNc). Cells were 
counted using a 20X objective (N.A.= 0.5). Sampling scheme, sampling grid sizes (170 uM x 
170 uM) and counting frames (45 uM x 45 uM), were optimized to obtain individual estimates of 
DAT+ neuron number with a mean Gundersen coefficient of error (CE) ≤ 0.1(Pakkenberg and 
Gundersen, 1989). Four mice per genotype (WT and Slc1a1-STOP), obtained via heterozygous 
breeding, were analyzed using StereoInvestigator. Sampling parameters are listed below. 15 
sections per animal were used for estimates with the first section being selected randomly within 
the first three sections. Section thickness was measured at every fifth sampling location, and the 
mean thickness was used for computation of DAT+ neuron estimates. At each sampling 
location, microscope was focused down through the dissector sample to count any cell 
according to dissector counting rules. Since the fractionator method does not require a  
measurement of tissue volume or any other dimensional quality, the cell number estimate is 
valid, even if the tissue volume changes during processing.(West et al., 1991, West et al., 1996)  
 
Sampling Parameters 
HPLC Analysis of Tissue Biogenic Amines 
Neurochemical measures were obtained in the Neurochemistry Core Facility at Vanderbilt 
University Medical Center operated by the Vanderbilt Brain Institute. Brain regions, harvested 
 
Number of 
Mouse 
Sections 
Section 
Evaluation 
Interval 
Distance 
Between 
Sections 
(uM) 
Sampling 
Grid Area 
(uM) 
Counting 
Frame 
(uM) 
Dissector 
Height 
(uM) 
Guard 
Zones 
(uM) 
Average 
Section 
Thickness 
(uM; range) 
CE 
(m=1) 
Wildtype 15 3 40 170 x 170 45 x 45 14 2 18 (16-19.6) 0.10 
Slc1a1 -
STOP 
15 3 40 170 x 170 45 x 45 14 2 
17.8 (15-
19.5) 
0.09 
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and dissected as noted above, were flash-frozen in liquid nitrogen and stored at −80 °C. Frozen 
brain tissue was homogenized by using a tissue dismembrator (Misonix XL-2000; Qsonica, 
Newtown, CT, USA) in 100–750 µL of a solution containing 100 mM TCA, 10 mM NaC2H3O2, 
100 µM EDTA, 5 ng/mL isoproterenol (an internal standard), and 10.5% (vol/vol) methanol (pH 
3.8). Samples were spun in a microcentrifuge at 10,000 × g for 20 min, and the supernatants 
were stored at −80 °C until assayed. Before assay, thawed supernatants were centrifuged at 
10,000 × g for 20 min before being analyzed by HPLC. Twenty microliters of each sample were 
injected by using a Waters 2707 autosampler onto a Phenomenex Kintex (2.6 µm, 100 A) C18 
HPLC column (100 × 4.6 mm). Biogenic amines were eluted with a mobile phase [89.5% 100 
mM TCA, 10 mM NaC2H3O2, 100 µM EDTA, and 10.5% methanol (pH 3.8)] delivered at 0.6 
mL/min by using a Waters 515 HPLC pump. Analytes were detected by using an Antec Decade 
II (oxidation: 0.4) (3 mm GC WE, HYREF) electrochemical detector operated at 33 °C. HPLC 
instrument control and data acquisition was managed by Empower software.  
 
In Vivo Viral Infusion 
Stereotaxic surgery was performed followed standard procedures, under sterile conditions. 
Adult male (8-12 week old) Slc1a1-STOP homozygous and wildtype controls were anesthetized 
with an i.p. injection of xylazine (10 mg/kg; Sigma Aldrich) and ketamine (100 mg/kg; Hospira, 
Lake Forest, IL, USA) and place into a mouse stereotaxic apparatus. A 5-uL Hamilton syringe 
(Hamilton, Reno NV, USA) attached to a nano syringe pump (KDS310; KD Scientific, Holliston, 
MA, USA) was lowered through a skull burr hole into the ventral tagmental area or dorsal 
striatum at the coordinates: VTA (AP -3.3 mm; ML ±0.4 mm; DV -4.5 mm relative to bregma; 
dorsal striatum (AP +0.9 mm; ML ±1.7 mm; -2.5 mm relative to bregma) with reference to the 
mouse brain atlas of Paxinos (Franklin and Paxinos, 2013). A total of 0.3 uL of virus was infused 
bilaterally at a flow rate of 0.1 uL/min. The syringe was left in place for 10 min after completion 
of infusion to eliminate backflow and then slowly withdrawn. This process was repeated on the 
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other side to produce bilateral viral injections. Cranial incision was closed with Vetbond (3M, 
Maplewood, MN, USA) and mice were returned to their home cage for a minimum of 2 weeks 
postsurgery. Mice received either AAVrh10.CMV.PI.Cre.rBG (University of Pennsylvania Vector 
Core, Philadelphia, PA, USA) or AAVrh10.CMV.PI.eGFP.WPRE.bGH (University of 
Pennsylvania Vector Core) at a titer of 1 x 1013 genomic copies per milliliter. 
 
Statistical Analysis 
Data were analyzed using Prism (GraphPad, La Jolla, CA, USA). Two-tailed, unpaired Student 
t-test or two-way ANOVA with Sidak’s post-tests were used to analyze the primary data, except 
for locomotor data, which was analyzed using non-linear curve fit analysis. Specific statistical 
analyses for each data set are described in results and in the figure legends.  In the text and 
figures, all data are reported as the mean ± standard error of the mean. Bar graphs depict the 
mean ± standard error of the mean. 	  
 
Results 
Slc1a1/EAAT3 Expression and Transporter Function is Reduced in Slc1a1-STOP Mice 
To investigate the functional impact of Slc1a1/EAAT3 expression in OCD-relevant 
behavioral assays, we used the Flexible Accelerated STOP Tetracycline operator knock-in 
(FAST) system (Tanaka et al., 2010) to create a knock-in mouse with globally reduced 
Slc1a1/EAAT3 expression (Figure 8a). As expected, Slc1a1 mRNA was reduced in Slc1a1-
STOP (ST) mice relative to wildtype (WT) littermate controls (Figure 8b) via qRT-PCR of the 
dorsal striatum (unpaired t-test; P<0.0001, n=5 per genotype). Immunoblots of whole striatum 
synaptosomes also demonstrated ablated EAAT3 protein expression in Slc1a1-STOP mice 
compared to WT littermate controls (P=0.0001, n=6 per genotype) (Figure 8c). 
 We next probed the functional consequences of reduced EAAT3 expression using 
striatal synaptosome transport assays (Nieoullon et al., 2006). Because EAAT3 is the primary  
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Figure 8. Slc1a1-STOP mice have reduced Slc1a1/EAAT3 protein expression and function 
(A) Slc1a1-STOP construct schematic. Closed triangles represent flippase recognition target 
sequences and open triangles represent LoxP sites. STOP: Stop signal. Neo: PGK-EM7-NEO 
minigene. tetO: tetracycline operon. 
(B) Slc1a1-STOP mice have reduced Slc1a1 mRNA expression	  as measured by qRT-PCR of dorsal 
striatum. (unpaired t-test; t=11.81, ****P<0.0001, n=5 per genotype)  
 (C) EAAT3 protein expression is reduced in striatal synaptosome preparations from Slc1a1-STOP 
(ST, Lane 2 and 4) mice, relative to wildtype (WT, Lane 1 and 3) mice. (unpaired t-test; t=8.84, 
***P=0.0001, n=6 per genotype. Figure is representative of three separate experiments). Average 
protein expression is demonstrated in bar graph.  
 (D) Na+-dependent uptake of L-cysteine (50 uM) is abolished in striatal synaptosome preparations 
from Slc1a1-STOP (ST) mice. Non-selective EAAT inhibitor threo-β-benzyloxyaspartate (TBOA) 
(100 uM) reduced wildtype (WT) synaptosome uptake but did not affect uptake from ST 
synaptosomes. (two-way ANOVA; inhibitor x genotype F(1,20)=8.361, **P=0.009; inhibitor 
F(1,20)=15.7, ***P=0.0008; genotype F(1,20)=25.34, ****P<0.0001, n=6 per genotype; post hoc 
Sidak’s multiple comparison test ***P<0.05). Figure is representative of three separate experiments. 	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source for neuronal cysteine (Watts et al., 2014), [35S]-cysteine was used as the substrate for 
EAAT3 synaptosome uptake. Na+-dependent uptake of cysteine in synaptosomes prepared 
from Slc1a1-STOP mice was ablated relative to WT synaptosomes (Figure 8d; two-way 
ANOVA; inhibitor x genotype F(1,20)=8.361, P=0.009; inhibitor F(1,20)=15.7, P=0.0008; 
genotype F(1,20)=25.34, P<0.0001, n=6 per genotype; post hoc Sidak’s multiple comparison 
test P<0.05). As expected from previous reports (Holmseth et al., 2012), we were unable to 
detect a difference in Na+-dependent glutamate uptake in striatal synaptosomes from Slc1a1-
STOP mice relative to WT littermate controls in either the presence or absence of the EAAT 
inhibitor dihydrokainic acid (DHK) (Supplementary Figure 4a).  
 
Slc1a1-STOP Mice Show No Changes in Spontaneous Behavior  
Slc1a1-STOP mice and littermate controls were subjected to a battery of behavioral 
tasks to determine if baseline behavioral differences were present. No anxiety-like phenotypes, 
compulsive-like phenotypes, or deficits in sensorimotor gating (Ahmari et al., 2012) were 
observed in Slc1a1-STOP mice as measured by changes in open field activity, time spent in the 
open arms of the elevated zero maze, light-dark emergence, prepulse inhibition, or spontaneous 
grooming relative to wildtype littermate controls (Supplementary Figure 5).  
 
Pharmacological Probing of Basal Ganglia Circuitry Reveals Reductions in Basal 
Ganglia-Dependent Repetitive Behavior in Slc1a1-STOP Mice  
To induce basal ganglia-mediated locomotor and repetitive behaviors, D-amphetamine 
was administered acutely in Slc1a1-STOP and WT littermate controls. At a moderate dose (1.8 
mg/kg), amphetamine-induced locomotion was significantly attenuated in Slc1a1-STOP mice 
relative to controls (Figure 9a; Curve fit analysis; F(4,496)=6.89, P<0.0001). A higher dose (3.0 
mg/kg) further accentuated this difference (Figure 9b; Curve fit analysis; F(4,496)=13.32, 
P<0.0001). At the highest amphetamine dose tested (8.0 mg/kg), at which stereotypic behavior  
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Figure 9. Slc1a1-STOP mice have attenuated behavioral response to amphetamine and SKF-
38393 challenge 
(A-B) Following acute D-amphetamine challenge (1.8 and 3.0 mg/kg), WT and Slc1a1-STOP mice 
demonstrate locomotor hyperactivity, which was attenuated in Slc1a1-STOP mice at both 1.8 mg/kg 
(A: curve fit analysis T=30-90; F(4,496)=6.891, ****P<0.0001, n=14 per genotype) and 3.0 mg/kg (B: 
curve fit analysis T=30-90; F(4,496)=13.32, ****P<0.0001, n=14 per genotype). 
(C) A main effect of genotype is observed on stereotypy following high dose amphetamine challenge 
(8.0 mg/kg) in Slc1a1-STOP mice and wildtype littermate controls. Stereotypic behavior was scored 
by trained blind independent observers at 50 and 80 minutes post challenge (two-way ANOVA; 
genotype F(1,42)=12.09, **P=0.001, n=12 per genotype).  
(D) SKF-38393 challenge reveals a main effect of drug and genotype for grooming behavior 
following agonist challenge in Slc1a1-STOP and wildtype controls. Grooming behavior was scored 
by a trained blind independent observers (two-way repeated measures ANOVA; drug x genotype, 
F(1,26)=0.74, P=0.40; drug, F(1,26)=28.5, ***P<0.0001; genotype, F(1,26)=7.95, **P=0.0091; n=14 
per genotype)	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dominates over locomotion (Castellan Baldan et al., 2014), there were no differences in overall 
locomotor behavior (Supplementary Figure 6a). However, when a separate cohort of animals 
was tested at this 8.0 mg/kg dose, blinded video scoring of stereotypic behavior at 50 and 80 
minutes post amphetamine revealed a main effect of genotype in Slc1a1-STOP and WT 
littermate controls (Figure 9c; two-way ANOVA; genotype F(1,42)=12.09, P=0.0012, n=12 per 
genotype). Mice did not undergo stereotypic behavior following saline challenge (Supplementary 
Figure 6b). 
To examine the impact of ablated EAAT3 expression independent of pre-synaptic 
dopamine release triggered by amphetamine administration, we acutely challenged Slc1a1-
STOP mice with the dopamine D1 receptor (D1) agonist SKF-38393 (SKF) (10 mg/kg, IP) to 
induce perseverative grooming (Starr and Starr, 1986, Taylor et al., 2010). Via two-way ANOVA, 
a main effect of genotype was identified following SKF challenge in Slc1a1-STOP mice and 
controls (Figure 9d; two-way Repeated Measures ANOVA; Drug, F(1,26)=28.5, P<0.0001; 
Genotype, F(1,26)=7.95, P=0.0091, n=14 per genotype).  
 
Amphetamine Dependent cFos+ Induction is Decreased in the Dorsal Striatum of Slc1a1-
STOP mice  
Amphetamine-induced locomotion and stereotypy are dependent on discrete subregions 
of the striatum (Rebec et al., 1997, Ikemoto, 2002). We therefore quantified cFos 
immunoreactivity in the dorsal striatum and the nucleus accumbens core and shell in response 
to amphetamine (3.0 mg/kg). In the dorsal striatum, a main effect of genotype was observed in 
cFos+ cells, with an amphetamine-induced increase in cFos+ cells in WT littermate controls that 
was absent in Slc1a1-STOP mice (Figure 10a, Supplementary Figure  7a; two-way ANOVA; 
drug x genotype; F(1,17)=9.91, P=0.006; genotype; F(1,17)=9.91, P=0.006; n=5-6 per 
genotype; post hoc Sidak’s multiple comparison test, P<0.05). A similar but less robust main 
effect of amphetamine was observed in the nucleus accumbens (NAc) core (Figure 10b, 
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Supplementary Figure 7b; two-way ANOVA; drug x genotype; F(1,12)=1.55, P=0.24; drug; 
F(1,12)=17.52, P=0.001; n=4 per genotype) and shell (Figure 10c, Supplementary Figure 7c; 
two-way ANOVA; drug x genotype F(1,12)=4.74, P=0.05; drug F(1,12)=13.59, P<0.003; n=4 per 
genotype) in WT and Slc1a1-STOP mice.  
 
Dopamine Receptor Density is Reduced in Striatal Membranes of Slc1a1-STOP Mice 
 To assess whether the blunted dopamine agonist response in Slc1a1-STOP mice could 
be explained by changes in striatal dopamine receptor density, we performed binding 
experiments in striatal membrane preparations from both dorsal and ventral striatum using a 
dopamine D1 receptor (D1) antagonist, [3H]-SCH-23390. D1 binding was decreased in Slc1a1-
STOP membranes isolated from dorsal striatum relative to WT littermate controls (Figure 10d; 
unpaired t-test; P=0.008, n=6 WT, n=8 ST) however, binding estimates of D1 density in the 
ventral striatum were not affected (Supplementary Figure 8a). We also measured dorsal striatal 
membrane binding of the D2 receptor using a D2 antagonist, [3H]-methylspiperone (NMSP) and 
observed a trend towards decreased binding (Supplementary Figure 8b; unpaired t-test; 
P=0.058, n=6 WT, n=8 ST). 
 
Decreased striatal dopaminergic transmission in Slc1a1-STOP mice 
 To corroborate a previous report of no change in dopamine neuron numbers or 
morphology in Slc1a1 null mice at 3 months of age (Berman et al., 2011), we performed 
dopamine transporter immunohistochemistry in the midbrain of 10-12 week old Slc1a1-STOP 
mice and littermate controls and found no differences in stereological DAT+ cell number 
estimates (Supplementary Figure 9a-c). In order to explore pre-synaptic mechanisms that could 
account for altered response to dopamine agonists in the Slc1a1-STOP mice, we measured 
tissue levels of dopamine and its major metabolite, 3,4-Dihydroxyphenylacetic acid (DOPAC), 
30 minutes after amphetamine (3.0 mg/kg IP) or saline injection. Via two-way ANOVA, 
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significant drug effects were observed on substantia nigra (SN) dopamine and DOPAC, VTA 
DOPAC, and dorsal striatum dopamine (Supplementary Figure 10). A main effect of genotype 
was only observed in substantia nigra DOPAC (Supplementary Figure 10). 
We next investigated if extracellular striatal dopamine levels were altered in Slc1a1-
STOP mice relative to wildtype controls. Basal, steady-state extracellular dopamine levels were 
first measured using the quantitative technique of “no net flux” microdialysis (Chefer et al., 
2006). In freely moving mice, dorsal striatal extracellular dopamine levels were found to be 
significantly lower in Slc1a1-STOP mice than in WT littermate controls (Figure 10e; unpaired t-
test; P=0.0006, n=6 per genotype). No differences were observed in dopamine clearance as 
measured by the slope of no net flux regression line (Supplementary Figure 11a). Conventional 
microdialysis revealed a significant elevation in dopamine levels following amphetamine (3 
mg/kg, IP) in both WT and Slc1a1-STOP mice compared to baseline levels. However, absolute 
levels of dopamine after amphetamine were significantly reduced in Slc1a1-STOP mice 
compared to wildtype controls (Figure 10f; repeated measures two-way ANOVA; time x 
genotype, F(7,70)=2.52, P=0.0226; genotype F(1,10)=9.34, P=0.01; Sidak’s multiple 
comparison; P<0.001; *P<0.05; n=6 per genotype). No genotypic differences were seen in 
dopamine metabolite levels at baseline or in response to amphetamine challenge 
(Supplementary Figure 11b-c).  
 
Viral-Mediated Rescue of Slc1a1/EAAT3 in the Midbrain Attenuates Amphetamine-
Induced Behavioral Deficits in Slc1a1-STOP Mice 
 To test the hypothesis that our findings could be explained by the impact of EAAT3 
ablation on midbrain dopaminergic neurons, we took advantage of the FAST construct to 
restore Slc1a1/EAAT3 expression in the midbrain of Slc1a1-STOP mice via Cre-Lox 
recombination. Slc1A1-STOP mice were bilaterally infused with either AAVrh10-CMV.Cre 
(ST:Cre) or AAVrh10-CMV.eGFP (ST:GFP) in the central midbrain (-3.3 mm AP, ±0.4 mm ML, - 
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Figure 10. EAAT3 loss affects amphetamine induced cFos expression, dopamine receptor 
membrane density, and extracellular dopamine concentrations in the dorsal striatum  
Quantification of cFos+ cells was performed in the dorsal striatum (left), nucleus accumbens (NAc) 
core, (middle), and shell (right).  
(A) Staining for cFos+ cells reveals an amphetamine (3.0 mg/kg, IP) dependent increase in the dorsal 
striatum (DS) of WT mice that is absent in Slc1a1-STOP mice. (Two-way ANOVA; drug x genotype; 
F(1,17)=9.91, **P=0.006; genotype; F(1,17)=9.91, **P=0.006; n=5-6 per genotype; post hoc Sidak’s 
multiple comparison test, *P<0.05). 
(B) Staining for cFos+ cells reveals a main effect of amphetamine on cFos+ cells in the nucleus 
accumbens (NAc) core of WT and STOP mice. (Two-way ANOVA; drug; F(1,12)=17.52, **P<0.01; n=4 
per genotype)   
(C) Staining for cFos+ cells reveals a main effect of amphetamine on cFos+ cells in the NAc shell of 
WT and STOP mice and a trend level interaction and genotype effect. (Two-way ANOVA; drug x 
genotype and genotype F(1,12)=4.74, ^P=0.05; drug F(1,12)=13.59, **P<0.01; n=4 per genotype) 
(D) Dopamine D1 receptor density estimated with [3H]-SCH-23390 binding in dorsal striatum 
membrane preparations (unpaired t-test; t=3.1, **P=0.008, n=8 wildtype, n=6 STOP). 
(E) Slc1a1-STOP mice have significantly lowered dopamine levels at baseline as measured by the 
extrapolation of linear regression using no-net flux microdialysis (unpaired-test, t=4.89, ***P=0.0006, 
n= 6 per genotype). 
(F) Dorsal striatal dopamine levels are significantly reduced in Slc1a1-STOP mice relative to wildtype 
controls following systemic administration of amphetamine (3 mg/kg, IP) (Repeated Measures Two-
way ANOVA; time x genotype, F(7,70)=2.52, *P=0.0226; genotype F(1,10)=9.34, *P=0.01; Sidak’s 
Multiple Comparison; ***P<0.001,*P<0.05; n=6 per genotype).   	  
	   110	  
4.5 mm DV), and wildtype littermate controls were bilaterally infused with AAVrh10-CMV.Cre 
(WT-Cre) (Figure 11a). After a two week incubation period, we found that ST:Cre animals 
showed a greater locomotor response to amphetamine (3.0 mg/kg) compared to ST:GFP 
control animals (Figure 11b; curve fit analysis; F(4,478)=6.84, P<0.0001, n=12 ST:GFP, n=15 
ST:Cre); however, their locomotor response remained less than wildtype animals. We also 
observed a significant main effect of Cre virus in ST:Cre and ST:GFP controls following high 
dose amphetamine-induced stereotypy (8.0 mg/kg) (Figure 11c; two-way ANOVA; Cre virus 
F(1,46)=9.45, P=0.0035). No difference in perseverative grooming was observed between 
ST:GFP and ST:Cre mice after injection of the D1 agonist, SKF (Figure 11d; two-way ANOVA; 
drug, F(1,50)=19.2, P<0.0001; virus, F(1,50)=0.13, P=0.72;  n=12 ST:GFP, n=15 ST:Cre). 
Rescue of EAAT3 expression and viral spread in the midbrain of ST:Cre mice was confirmed via 
western blot (Supplementary Figure 12a-b) and immunohistochemistry (Supplementary Figure 
13).To verify the specificity of midbrain rescue, we assessed the impact of viral Cre-mediated 
restoration of EAAT3 in the dorsal striatum, and found no differences in amphetamine- or SKF-
mediated repetitive behavior in comparison to GFP controls (Supplementary Figure 14).  
 
Discussion 
 Multiple studies have identified linkage and association of SLC1A1/EAAT3 with 
obsessive-compulsive disorder (Veenstra-VanderWeele et al., 2001, Arnold et al., 2006, Dickel 
et al., 2006, Stewart et al., 2007, Shugart et al., 2009, Wendland et al., 2009a, Samuels et al., 
2011, Veenstra-VanderWeele et al., 2012); however, this is the first in vivo study to assess 
whether changes in EAAT3 expression affect repetitive behavior. By using amphetamine as well 
as a dopamine D1 receptor agonist, we were able to probe the effects of EAAT3 ablation on 
basal ganglia-mediated behavior. As hypothesized, we detected a decrease in hyperlocomotion, 
stereotypic behavior, and striatal dopamine concentrations in response to these drugs in 
Slc1a1-STOP mice (Figure 9-10). Coupled with our findings of partial Cre-mediated rescue in  
	   111	    
Figure 11. Viral Cre-mediated rescue of midbrain Slc1a1/EAAT3 expression rescues 
amphetamine but not SKF-38393 phenotypes in Slc1a1-STOP mice  
 (A) Schematic of Cre-mediated excision of the neo-STOP-tetO cassette in Slc1a1-STOP mice, 
leading to endogenous Slc1a1/EAAT3 expression. Blue triangles represent LoxP sites. Reference 
section indicates injection position in the central midbrain of Slc1a1-STOP and wildtype controls (-3.3 
mm AP, ±0.4 mm ML, -4.5 mm DV). 
(B) Slc1a1-STOP mice injected with AAV-Cre (ST:Cre) exhibit increased hyperlocomotor response to 
3.0 mg/kg amphetamine in comparison to Slc1a1-STOP littermate controls injected with AAV-GFP 
(ST:GFP) (curve fit analysis T=30-90; F(4,478)=6.84, ****P<0.0001; n=12 ST:GFP, n=15 ST:Cre).  
(C) A main effect of Cre virus is observed on stereotypy following high dose amphetamine challenge 
(8.0 mg/kg) in ST:Cre and ST:GFP controls. Stereotypic behavior was scored by trained blind 
independent observers at 50 and 80 minutes post challenge (two-way ANOVA; Cre virus, 
F(1,46)=9.453, **P=0.0035; n=12 ST:GFP, n=14 ST:Cre). 
(D) ST:Cre mice showed no difference in stereotyped grooming behavior in response to 10 mg/kg 
SKF-38393 in comparison to ST:GFP littermate controls (two-way ANOVA; drug, F(1,50)=19.2, 
P<0.0001; virus, F(1,50)=0.13, P=0.72;  n=12 ST:GFP, n=15 ST:Cre).  	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the midbrain, this is consistent with multiple previous lines of evidence supporting a role for 
dopaminergic pathology in compulsive-like behavior. Most immediately relevant to our findings, 
the Hdc null mouse model, based upon a family demonstrating a complex neuropsychiatric 
phenotype including complete penetrance for Tourette syndrome and partial penetrance for 
OCD, displayed elevated stereotypy in response to amphetamine challenge (Castellan Baldan 
et al., 2014). In humans, dopamine agonists, including amphetamine and the dopamine 
precursor L-DOPA, are well-known triggers of repetitive behavior, from simple motor 
movements to frankly compulsive behavior in disorders linked to altered dopamine homeostasis 
(Varley et al., 2001, Parraga et al., 2007, Voon et al., 2009, Madruga-Garrido and Mir, 2013). 
Indirect evidence also suggests an interaction between the dopamine system and SLC1A1 in 
humans. Atypical antipsychotic medications, which act in part as dopamine receptor 
antagonists, trigger OC symptoms in some patients, and recent evidence suggests that 
polymorphisms in SLC1A1 moderate susceptibility to this uncommon drug-induced compulsivity 
(Kwon et al., 2009, Cai et al., 2013). 
Our data show that EAAT3 ablation leads to decreased immediate early gene activation 
in dorsal striatal neurons in response to amphetamine (Figure 10a), in addition to reductions in 
extracellular dopamine concentrations in the striatum at baseline and following amphetamine 
challenge (Figure 10e-f).  These data are consistent with a change in pre-synaptic dopaminergic 
neuron function as a result of EAAT3 loss, and align with a recent study demonstrating that 
EAAT3 impacts glutamatergic input onto midbrain dopaminergic neurons (Underhill et al., 2014). 
Specifically, Underhill and colleagues found that EAAT3 is internalized in response to 
amphetamine, resulting in increased glutamate exposure and potentiation of AMPA and NMDA 
glutamate receptor-mediated synaptic transmission in midbrain dopamine neurons (Underhill et 
al., 2014). Based on these convergent data, we hypothesized that chronic increases in peri-
synaptic glutamate levels at dopaminergic neurons may elicit a homeostatic mechanism in 
Slc1a1-STOP mice that underlies the attenuated response to amphetamine. In support of this 
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idea, we found that viral-mediated rescue of midbrain Slc1a1/EAAT3 resulted in increased 
amphetamine-induced locomotor and stereotypy behavior compared to Slc1a1-STOP mice 
infused with a control virus (Figure 11b-c). This contrasted with rescue of Slc1a1/EAAT3 in the 
striatum of Slc1a1-STOP mice, which had no impact on amphetamine-induced behavior 
(Supplementary Figure 14). Importantly, the lack of complete rescue of amphetamine response, 
as well as lack of change in D1 agonist response, suggests that EAAT3 ablation in dopaminergic 
neurons (at least in adult animals) may not be the only mechanism impacting response to 
dopamine agonists in Slc1a1-STOP mice. Further study of EAAT3 ablation, restoration, and 
overexpression will be needed to dissect its importance in specific brain regions, neuronal 
subtypes, and importantly, within particular developmental windows. 
Of note, the initial published evaluation of Slc1a1/EAAT3 null mice reported decreased 
activity in the open field, although this was not consistent with a later report, which described no 
baseline differences but found impaired Morris Water Maze performance in aged animals due 
oxidative stress-mediated neuronal loss (Peghini et al., 1997, Aoyama et al., 2006). In our 
baseline assessment of activity, anxiety-like behavior, and compulsive-like behavior, we found 
no significant changes in the Slc1a1-STOP animals. This is consistent with some data 
suggesting that the OCD-associated SLC1A1 alleles lead to increased, not decreased, 
expression; however, postmortem studies are needed to clarify the direction of SLC1A1 
expression change in OCD (Wendland et al., 2009a, Porton et al., 2013). Examining the impact 
of SLC1A1 overexpression on OCD-relevant behaviors in mice would also more directly assess 
this hypothesis. These data may also indicate the difficulty of detecting a potential decrease in 
low levels of spontaneous compulsive-like behavior (Wendland et al., 2009a). In addition, one 
subsequent report in Slc1a1/EAAT3 null mice described oxidative stress-mediated loss of 
dopamine neurons in animals at 12 months of age but no differences at 3 months (Berman et 
al., 2011). Even though our model does retain some degree of preserved EAAT3 function 
(Figure 8), we therefore restricted our work to younger animals and ruled out decreases in 
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dopamine transporter immunohistochemistry (Supplementary Figure 9) or diminished dopamine 
or DOPAC levels in the midbrain (Supplementary Figure 10). Furthermore, the results of our 
midbrain viral rescue (Figure 11) are not consistent with dopamine neuron loss as a mechanism 
of altered response to amphetamine or SKF-38393. 
As with many studies aimed at unraveling pathophysiology in a preclinical context, it is 
important not to over-interpret these data in relation to the human condition. We therefore 
believe that the Slc1a1-STOP mouse should be considered as a putative model of reduced 
liability to dopamine-induced and basal ganglia-mediated repetitive behaviors (Castellan Baldan 
et al., 2014). Although heterozygous SLC1A1 deletions have been reported in schizophrenia 
and schizoaffective disorder (Myles-Worsley et al., 2013, Afshari et al., 2015), our findings do 
not clearly indicate a psychosis-like phenotype, due to no observed changes in baseline 
behavior or prepulse inhibition. In the context of psychotic disorders, our observation of 
decreased sensitivity to amphetamine could be considered opposite to what might be expected, 
since amphetamine can induce psychosis in humans (Murray et al., 2013). Because of this 
apparent contradiction, further work using the Slc1a1-STOP mice, including heterozygous 
animals, is warranted to better understand the potential contribution of SLC1A1 deletions to risk 
of psychosis. 
In summary, we report the first evaluation of the OCD candidate gene Slc1a1/EAAT3 in 
relation to OCD-relevant circuitry and behavior in an animal model. Using dopaminergic 
agonism as a probe, we demonstrate the relevance of EAAT3 to striatal dopaminergic 
neurotransmission and to repetitive behavior. The partial rescue of dopamine agonist response 
by restoration of EAAT3 expression in the midbrain demonstrates an in vivo functional impact 
that matches previous cell model and ex vivo reports of EAAT3 effects in dopaminergic 
neurons. More work is needed to examine the effects of manipulating EAAT3 expression in 
other proposed models of striatally-mediated repetitive behavior (Welch et al., 2007, Shmelkov 
et al., 2010b) and in cognitive tasks relevant to OCD (Dittrich and Johansen, 2013, Krebs and 
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Heyman, 2015). Our results also suggest that EAAT3 antagonists should be evaluated in 
relation to dopamine agonist response and, perhaps, more broadly in relation to basal ganglia-
mediated repetitive behavior across species. 
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CHAPTER 5 
 
SUMMARY, DISCUSSION, AND FUTURE DIRECTIONS 
 
 Glutamate is the primary excitatory neurotransmitter in the CNS and is critical for 
behavior, cognition, memory, and learning (Zhou and Danbolt, 2014b). Glutamatergic 
dysfunction has been identified in many neurological disorders including epilepsy (Tanaka et al., 
1997), schizophrenia (McCullumsmith and Meador-Woodruff, 2002, Nudmamud-Thanoi et al., 
2007, Hu et al., 2015), amyotrophic lateral sclerosis (Blasco et al., 2014), Parkinson’s disease 
(Gardoni and Di Luca, 2015), addiction (Tzschentke and Schmidt, 2003) and obsessive-
compulsive disorder (Pittenger et al., 2011, Pittenger, 2015). In the Veenstra-VanderWeele lab, 
our primary focus has been on investigating the impact of glutamatergic dysfunction in 
obsessive-compulsive disorder. Glutamatergic deficits in OCD have been identified in the CSTC 
circuit (Rosenberg et al., 2001, Rosenberg et al., 2004, MacMaster et al., 2008, Starck et al., 
2008), the same brain region previously implicated in OCD via structural imaging analysis 
(Saxena et al., 1998, Saxena et al., 2001, Maia et al., 2008, Rotge et al., 2008). The 
combination of these findings and evidence from other studies of the CSTC circuit (Rauch et al., 
1997, Rauch et al., 2001, Harrison et al., 2009, Beucke et al., 2013) led to a preliminary model 
where hyperactivity of the direct pathway or hypoactivity of the indirect pathway may lead to 
overall elevated activity of the CSTC circuit and subsequent emergence of OCD symptoms.  
 Following the identification of glutamatergic dysfunction in the CSTC circuit as a putative 
biomarker of OCD, evidence from subsequent genetic analysis relevant to the glutamate system 
became of particular interest. Fitting with the glutamatergic hypothesis, the most consistently 
implicated gene in OCD is SLC1A1, which codes for the neuronal glutamate transporter 
excitatory amino acid transporter 3 (EAAT3, also known as EAAC1). SLC1A1 was initially 
suspected in OCD based on a genome-wide linkage study, which uncovered a peak on 
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chromosome 9p24, where the gene is located (Hanna et al., 2002b, Willour et al., 2004b). A 
number of studies subsequently identified association between polymorphisms in and around 
SLC1A1 in OCD (Arnold et al., 2006, Dickel et al., 2006, Kwon et al., 2009, Shugart et al., 2009, 
Samuels et al., 2011, Veenstra-VanderWeele et al., 2012, Stewart et al., 2013a). Of note, recent 
investigation of SLC1A1 suggests that polymorphisms within the gene are also associated with 
de novo obsessive-compulsive symptoms induced by antipsychotic medication in schizophrenia 
(Kwon et al., 2009, Ryu et al., 2011, Schirmbeck et al., 2012, Cai et al., 2013), implying that 
there is an interaction between the dopamine and glutamate system relevant to repetitive 
behavior.  
 Accurate preclinical modeling of neuropsychiatric disorders is always difficult, especially 
in the case of OCD where rare genetic variants eliciting a large effect are unavailable and 
genome-wide association studies have yet to identify common variants that reach genome-wide 
significance. Consistent identification of SLC1A1 in association studies provides support for 
SLC1A1 as a putative risk gene for OCD; however little evidence is available to identify how 
alterations in its expression or function may lead to dysfunction of the CSTC circuit or to 
compulsive behavior. My work in the Veenstra-VanderWeele lab used genetic and 
pharmacological manipulations in mice to understand whether altered SLC1A1/EAAT3 
expression or function could explain the convergence of neurochemical and genetic data 
implicating the glutamate system generally and this gene specifically in compulsive behavior 
and its underlying neural circuitry.  
 
Summary of Results 
Initial efforts to identify abnormal expression and/or function of EAAT3 in models of 
repetitive behavior and dysfunctional glutamatergic neurotransmission focused on Sapap3 null 
mice. These mice exhibit excessive SRI-responsive grooming and exhibit deficits in cortical-
striatal glutamatergic neurotransmission. We identified increases in EAAT3 expression in striatal 
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synaptosomes of Sapap3 null mice relative to WT controls; however this increase was not 
mirrored in ex vivo assays of striatal EAAT3 function, albeit with low statistical power 
(Supplementary Figure 4). We next transitioned to examining the capabilities of a novel EAAT3 
inhibitor (NBI-59159), previously shown to attenuate amphetamine-induced hyperlocomotion, a 
basal ganglia dependent behavior (Dunlop and Marquis, 2006), to alleviate the grooming 
phenotype observed in Sapap3 null mice. Despite the prior reports of the inhibitors in vivo 
efficacy, acute pretreatment of Sapap3 null and wildtype littermate controls with NBI-59159 prior 
to assessment of spontaneous grooming had no effect on grooming behavior, regardless of 
genotype. It is possible that more thorough investigation of the behavioral consequences of NBI-
59159 dosing on Sapap3 null phenotypic behavior would have resulted in data supporting the 
compounds efficacy; however we were only able to acquire a limited amount of the compound, 
allowing for a small pilot study at the dose reported to impact behavior in a previous study.  
Recent reports using Sapap3 null mice suggest that increased local glutamate 
concentration around EAAT3 due to pharmacological inhibition might not be expected to 
alleviate repetitive grooming behavior. Using pharmacological techniques, the Calakos lab 
found that Sapap3 null mice show persistent activation of the metabotropic glutamate receptor 
mGlu5, leading to repetitive behavior (Ade et al., 2016). Since mGluR5 colocalizes to the 
extrasynaptic space surrounding synapses, along with EAAT3, increasing the local glutamate 
concentration via inhibition of EAAT3 seems unlikely to rescue the repetitive behavior grooming 
phenotype observed in Sapap3 null mice.  
 To date, the striatum has been repeatedly implicated in OCD via numerous experimental 
approaches ranging from neuroimaging of patients (Rosenberg et al., 2000, Whiteside et al., 
2006, Starck et al., 2008) to optogenetic rodent models (Ahmari et al., 2013, Burguiere et al., 
2013). Taking note of this, we sought to directly probe the striatum pharmacologically to assess 
the in vivo efficacy of a novel EAAT3 inhibitor, 2-CFoDA, as had been reported previously with 
NBI-59159 (Dunlop and Marquis, 2006). Acute administration of systemic amphetamine causes 
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a robust increase in striatal synaptic dopamine concentrations, resulting in increased activation 
of dopamine receptors and overall disinhibition of the basal ganglia. Using amphetamine to 
induce  basal ganglia dependent locomotor behavior enabled us to determine how blockade of 
EAAT3 function may affect behavior dependent on a node of the CSTC circuit. The initial 
characterization of 2-CFoDA in the Bridges lab was primarily focused on assessing its efficacy 
in vitro. Thus, the compound’s in vivo profile was not well understood. We opted to deliver the 
compound into the CSF of WT mice via ICV injection in an attempt to bypass the blood brain 
barrier to deliver the drug throughout the brain. Despite prior reports of NBI-59159’s capability to 
attenuate amphetamine induce locomotor behavior; we did not observe any differences in 
locomotor behavior following amphetamine administration at any of the doses of 2-CFoDA 
delivered ICV (Figure 6). It is possible that delivery of 2-CFoDA into the CSF did not allow for 
the inhibitor to reach its intended site of action in the striatum. Thus, we then transitioned to 
direct striatal administration of 2-CFoDA. At a moderate dose of 2-CFoDA, no in vivo efficacy 
was observed (Figure 7); however we found that a high dose of the inhibitor did reduce 
amphetamine-induced locomotor behavior (Figure 7). However, these data suggested sedating 
effects at this high dose because minimal overall activity was observed in 2-CFoDA pretreated 
mice following amphetamine challenge.  
Taken together, the data from our behavioral pharmacology studies with EAAT3 
inhibitors were unable to shed light on the potential utility of EAAT3 targeting compounds for 
impacting behavior dependent on the basal ganglia. In the time since SLC1A1/EAAT3 has been 
identified as a potential candidate risk gene for OCD, development of compounds efficacious in 
vivo has not been a priority for drug development groups for a few reasons. First, establishing 
specificity for EAAT3 versus other glutamate transporters has proven challenging, and even 
modest off-target effects at GLT-1 could generate substantial adverse effects. Second, the 
observed association in OCD has been with common variants that have uncertain impact on 
SLC1A1 expression or function, and rare variants have not yet been clearly implicated in OCD. 
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Third, previous studies have not clarified how EAAT3 function may impact glutamatergic 
signaling in the specific brain regions relevant to the OCD. Until more is known about EAAT3’s 
role in local glutamatergic signaling and how modulation of transporter function may impact 
OCD-relevant brain regions, there is little motivation to invest substantial resources into the 
development of compounds effectively targeting EAAT3 in vivo.  
 Despite the convergence of evidence from putative glutamatergic biomarker analysis 
and consistent genetic association studies implicating of the gene, no studies had focused on 
assessing the functional impact of Slc1a1/EAAT3 on OCD-relevant circuits or behavior. In an 
effort to understand whether alteration of Slc1a1/EAAT3 expression may affect OCD-relevant 
behavior or neural circuitry, the Veenstra-VanderWeele lab, along with our collaborators from 
the Ahmari lab at the University of Pittsburgh, developed an Slc1a1/EAAT3 transgenic mouse 
line, termed Slc1a1-STOP mice. Slc1a1-STOP mice were made via homologous recombination 
to introduce a FAST construct (Tanaka et al., 2010), including a floxed-Neo-STOP cassette, 
upstream of the native Slc1a1 locus, resulting in a constitutive model of reduced Slc1a1/EAAT3 
expression (Figure 8a). Slc1a1-STOP mice were biochemically characterized by assessing 
Slc1a1/EAAT3 expression and function. Both Slc1a1 and EAAT3 expression was reduced to 
negligible levels in striatal tissue of Slc1a1-STOP mice relative to WT mice (Figure 8b-c). 
EAAT3 function, examined via [35S]-cysteine synaptosome uptake assays, was completely 
absent in synaptosomes isolated from Slc1a1-STOP mice compared to WT synaptosomes 
(Figure 8d).  
 Next, the spontaneous behavior of Slc1a1-STOP mice was assessed via a battery of 
assays aimed at identifying any baseline behavioral phenotypes. No anxiety-like phenotypes, 
compulsive-like phenotypes, or deficits in sensorimotor gating were observed in Slc1a1-STOP 
mice (Supplementary Figure 5). This is consistent with preliminary evidence suggesting that 
OCD-associated SLC1A1 alleles cause increased, not decreased, expression (Wendland et al., 
2009a). We could also have observed a floor effect, since reductions in OCD-relevant behavior 
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are unlikely to be seen in Slc1a1-STOP mice in tasks where WT mice exhibit low levels of 
spontaneous OCD-relevant behavior. 
 Based on these initial data, our hypothesis was that Slc1a1-STOP mice could represent 
an animal model of reduced liability to the induction of basal ganglia mediated repetitive or 
stereotypic behavior. To test this hypothesis, amphetamine was administered to induce basal 
ganglia mediated locomotor and repetitive behavior. Slc1a1-STOP mice exhibited reductions in 
amphetamine-induced locomotion at low and intermediate doses relative to WT mice, 
supporting our hypothesis (Figure 9a-b). We also measured locomotor behavior at high dose 
amphetamine; however no genotype differences were observed, perhaps because at this dose 
mice transition to a non-locomotor stereotypic behavior (Supplementary Figure 6). Conversely, 
when high dose amphetamine-induced stereotypy was measured by video scoring, reductions 
in repetitive stereotypic behavior were identified in Slc1a1-STOP mice (Figure 9c). We also 
explored the impact of ablated Slc1a1/EAAT3 expression on dopaminergic signaling in the 
striatum independent of pre-synaptic dopamine release by challenging mice with the dopamine 
D1 receptor agonist SKF-38393, which causes perseverative grooming/scratching behavior. This 
face valid OCD-relevant behavior was blunted in Slc1a1-STOP mice relative to WT littermate 
controls, mirroring the results from the amphetamine-induced behavior (Figure 9d). These were 
the first OCD-relevant behavioral findings suggesting that alteration of Slc1a1/EAAT3 has a 
functional impact on face valid behavior dependent on the neural circuitry implicated in OCD. 
 Since the striatum has distinct subregions that are linked to amphetamine-induced 
locomotion and stereotypy specifically (Rebec et al., 1997, Ikemoto, 2002), we next quantified 
the activation of the immediate early gene cFos by amphetamine in the dorsal striatum and the 
nucleus accumbens core and shell. As expected, our data showed that ablation of EAAT3 
expression in Slc1a1-STOP mice results in reduced cFos+ immunoreactivity broadly in all striatal 
subregions measured following amphetamine challenge, as well as reductions in dorsal striatal 
dopamine receptor binding in adult mice (Figure 11a). These data support the hypothesis that 
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EAAT3 loss primarily affects striatal MSNs; however they are also consistent with potential 
changes in pre-synaptic dopaminergic neuron function. 
 In order to address the possibility of changes in pre-synaptic dopaminergic neuronal 
function and to corroborate a previous report of no change in dopamine neuron numbers or 
morphology in Slc1a1 null mice at 3 months of age (Berman et al., 2011), we performed 
dopamine transporter immunohistochemistry. No differences in stereological DAT+ cell number 
estimates were identified in the midbrain of young adult Slc1a1-STOP mice relative to wildtype 
littermate controls (Supplementary Figure 9). To further explore pre-synaptic mechanisms that 
could account for altered response to dopamine agonists in the Slc1a1-STOP mice, we 
measured tissue levels of dopamine and its major metabolite, 3,4-Dihydroxyphenylacetic acid 
(DOPAC), 30 minutes after amphetamine (3.0 mg/kg IP) or saline injection. Via two-way 
ANOVA, significant drug effects were observed on substantia nigra (SN) dopamine and 
DOPAC, VTA DOPAC, and dorsal striatum dopamine. A main effect of genotype was only 
observed in substantia nigra DOPAC.  
We next investigated if extracellular striatal dopamine levels were altered in Slc1a1-
STOP mice relative to wildtype controls. Basal, steady-state extracellular dopamine levels were 
first measured using the quantitative technique of “no net flux” microdialysis (Chefer et al., 
2006). In freely moving mice, dorsal striatal extracellular dopamine levels were found to be 
significantly lower in Slc1a1-STOP mice than in WT littermate controls (Figure 10e). Absolute 
levels of dopamine after amphetamine challenge were also significantly reduced in Slc1a1-
STOP mice compared to wildtype controls (Figure 10f).  
Based on these findings indicating that EAAT3 loss influences striatal dopamine levels, 
as well as recent reports of amphetamine-induced endocytosis of EAAT3 impacting glutamate 
receptor mediated neurotransmission in the midbrain (Underhill et al., 2014), we hypothesized 
that EAAT3 loss in midbrain dopaminergic neurons accounted for the change in amphetamine 
sensitivity. We therefore utilized the loxP sites surrounding the STOP-tetO cassette in the 
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Slc1a1-STOP mice to restore Slc1a1/EAAT3 expression in the midbrain using a viral based 
expression rescue strategy. After injection of an AAV-Cre virus into the midbrain, Slc1a1-STOP 
mice underwent Cre-Lox recombination, and expression of Slc1a1/EAAT3 was restored 
(Supplementary Figure 12-13). Restoration of midbrain Slc1a1/EAAT3 expression in Slc1a1-
STOP mice led to increases in locomotion and stereotypy at moderate and high doses of 
amphetamine respectively when compared to Slc1a1-STOP mice injected with a control GFP 
virus (Figure 11b-c). It is of note however that their response remained less than that of WT 
mice treated with the same AAV-Cre virus. Furthermore, induction of perseverative grooming 
behavior via SKF-38393 was not affected by restoration of midbrain EAAT3 expression. The 
inability to rescue the D1-agonist induced grooming phenotype by restoring midbrain expression 
of Slc1a1/EAAT3 implies that there are alternative mechanisms involving EAAT3 and the 
behavioral response to dopaminergic agents that are responsible for the reduced SKF induced 
grooming observed in Slc1a1-STOP mice. 
 
Interpretation 
Our work is the first known attempt to examine how changes in Slc1a1/EAAT3 
expression affect the dopaminergic system and repetitive behavior dependent on the striatum. 
Experimental evidence supports our hypothesis that reduced Slc1a1/EAAT3 expression 
attenuates induced striatal-dependent repetitive and stereotypic behavior, which our data 
suggest is driven, at least in part, by reductions in dopamine concentrations in the striatum of 
Slc1a1-STOP mice. Identifying a link between midbrain EAAT3 expression and amphetamine-
induced repetitive behavior was an unexpected finding; although previous evidence did support 
a role of dopamine in compulsive-like behavior (Szechtman et al., 1998, Denys et al., 2004, 
Voon et al., 2009, Denys et al., 2013, Schmidt et al., 2013, Castellan Baldan et al., 2014). Since 
all of the observed OCD-relevant behavioral deficits observed in Slc1a1-STOP mice were  
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Table 1. Summary of Results 
Included above are results from biochemical and behavioral assays for wildtype, Slc1a1-STOP, 
Slc1a1-STOP Cre (midbrain), and Slc1a1-STOP Cre (striatum) mice.  
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dependent on dopaminergic agents, it would be imprudent to not consider the interdependence 
of Slc1a1/EAAT3 and dopamine in relation to OCD.  
Another mouse model was recently reported to have altered response to dopaminergic 
agents as a potential model of OC-spectrum disorders. The histidine decarboxylase (Hdc) null 
mouse was studied based upon a family with an apparent dominant negative mutation in HDC 
exhibiting complex neuropsychiatric phenotypes including full penetrance for Tourette syndrome 
(TS) and partial penetrance for OCD. Hdc null mice exhibited augmented striatal cFos+ 
immunoreactivity, baseline striatal dopamine concentrations, and amphetamine-induced 
stereotypic behavior (Castellan Baldan et al., 2014). Although these data are in the opposite 
direction from the amphetamine-induced behavioral deficits observed in Slc1a1-STOP mice, 
they complement our findings because the Hdc null mouse was designed to recapitulate the 
molecular consequences of rare mutations found in TS, while Slc1a1-STOP mice were 
hypothesized to be a model of reduced liability to basal ganglia dependent repetitive behavior. 
There are considerable similarities between TS and OCD, including clinical 
symptomology, genetics, implicated brain structures, and treatment strategies. Despite these 
shared characteristics, it is unknown to what extent the underlying pathogenic mechanisms of 
the disorders overlap. Dopamine receptor antagonists are an effective monotherapy for the 
treatment of TS and have been used as adjunct strategy to SRIs in OCD (Vulink et al., 2005, 
Denys, 2006). Furthermore, dopamine agonists, including amphetamine and the dopamine 
precursor L-DOPA, have been reported to elicit tics and induce obsessive-compulsive 
symptoms (Varley et al., 2001, Parraga et al., 2007, Voon et al., 2009, Madruga-Garrido and 
Mir, 2013, Shakeri et al., 2016). Of particular interest to our efforts, certain second generation 
antipsychotic medications, such as clozapine, which acts at dopamine and serotonin receptors, 
can also induce obsessive-compulsive symptoms, and recent evidence indicates that 
polymorphisms in SLC1A1 may moderate susceptibility to this drug-induced compulsivity (Kwon 
et al., 2009, Ryu et al., 2011, Cai et al., 2013). 
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 Though the data in Chapter 4 are the first to link functional alterations of Slc1a1/EAAT3 
to OCD-relevant behavior and the dopaminergic system in vivo, prior evidence has linked 
EAAT3 and dopaminergic neurons. EAAT3 has been of particular interest to researchers 
investigating disorders involving degeneration of dopaminergic neurons, specifically Parkinson’s 
disease. Dopaminergic neurons, which are inherently more susceptible to oxidative stress, are 
preferentially affected when cysteine transport via EAAT3 is inhibited in vitro (Nafia et al., 2008). 
Further, in vivo investigation showed that acute intranigral injection of a pan-EAAT inhibitor 
selectively caused degeneration of substantia nigra pars compacta dopaminergic neurons and 
that coinjection of NMDA receptor antagonists was protective for dopaminergic neurons, 
suggesting that inhibiting mechanisms of glutamate uptake results in increased, toxic NMDA 
receptor activity in the substantia nigra (Assous et al., 2014). Even more pertinent to our efforts, 
a report using EAAT3 null mice identified a ~40% loss in dopaminergic neurons in the 
substantia nigra par compacta in aged mice (but not in younger mice that parallel our study 
subjects) that was not observed in a separate group of EAAT3 null mice chronically dosed with 
the glutathione precursor N-acetylcysteine (Berman et al., 2011), which bypasses EAAT3. 
When considered in relation to our data, specifically the amphetamine-induced behavioral data, 
a potential explanation could have been that Slc1a1-STOP mice were losing dopaminergic 
neurons in the midbrain leading to reductions in amphetamine dependent behavior. For this 
reason, we investigated DAT staining in the midbrain of young adult Slc1a1-STOP and WT mice 
using stereology, which did not identify any significant differences in estimates of the 
dopaminergic neuron population (Supplementary Figure 9).  
A recent publication from the Amara lab identified reductions in cell membrane levels of 
EAAT3 in dopaminergic neurons of the VTA following acute administration of amphetamine 
(Underhill et al., 2014). Interestingly, they report augmented glutamatergic neurotransmission at 
glutamate receptors in dopaminergic neurons of the midbrain following amphetamine-driven 
endocytosis of EAAT3, primarily due to NR2B-containing NMDA receptors (Li et al., 2017). 
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While these and prior studies investigating EAAT3’s impact on glutamatergic signaling in 
midbrain dopaminergic neurons show that acute alteration of EAAT3 function affects 
glutamatergic neurotransmission (Assous et al., 2014, Underhill et al., 2014, Li et al., 2017), it 
was previously unclear how chronic loss of glutamate uptake via EAAT3 would affect 
dopaminergic neuron function over the longer term. Based on our data, it is most likely that the 
deficits observed in amphetamine response in Slc1a1-STOP mice are driven by our observation 
of reduced striatal dopamine levels both at baseline and in response to the psychostimulant.  
 One distinct difficulty in constructing a mechanistic explanation of our behavioral results 
in Slc1a1-STOP mice is that prior published data involved acute inhibition of EAAT3 function in 
wildtype mice; whereas EAAT3 function in the dopaminergic neurons of Slc1a1-STOP mice is 
chronically absent. Inherently, it is unclear how many of the insights gleaned from these distinct 
experiments may overlap to help us understand our results. In particular, it is challenging to 
explain how hypothetical chronic increases in local glutamate receptor exposure in the 
dopaminergic neurons of the midbrain may result in reduced dopamine concentrations in the 
striatum, both at baseline and after amphetamine administration.  
 The findings from the Amara and Assous groups showing the consequences of acute 
EAAT3 loss in dopaminergic neurons offer two logical hypotheses for extrapolation into Slc1a1-
STOP mice. The first would be that chronically increased local glutamate concentrations in the 
midbrain of Slc1a1-STOP mice lead to an activity-dependent downregulation of glutamate 
receptor expression or signaling in the midbrain. Previous data show that increased glutamate 
signaling and resultant elevations in intracellular Ca2+ can lead to NMDA receptors trafficking 
away from the membrane, presumably as a homeostatic mechanism to prevent excitotoxicity 
(Hardingham and Bading, 2010, Wild et al., 2014). Within the context of the midbrain of Slc1a1-
STOP mice, increased signaling at NMDA receptors over time could hypothetically lead to 
compensatory reductions in the cell membrane population of glutamate receptors. This chronic 
reduction of cell membrane NMDA receptors available to respond to glutamate may help explain 
	   128	  
the dopaminergic deficits in the striatum and the observed attenuated amphetamine-induced 
behavioral responses observed in Slc1a1-STOP mice. A potential issue with this explanation is 
that Wild and colleagues (2014), used high frequency stimulation of substantia nigra pars 
compacta neurons to induce this activity-dependent trafficking of NMDA receptors off of the 
cellular membrane. In contrast, EAAT3 is thought to be largely responsible for the uptake of 
extra-synaptic and peri-synaptic glutamate, with relatively minor contributions to the removal of 
glutamate from the synapse (Holmseth et al., 2012). These high frequency stimulation data 
therefore may not offer an ideal parallel for changes in chronic glutamate concentration in 
Slc1a1-STOP mice. Although preliminary, no alterations in cell membrane levels of glutamate 
receptors in the midbrain of Slc1a1-STOP mice have been identified (data not shown). This 
explanation also does not account for the observed reductions in dopamine receptor density 
detected in the striatum of Slc1a1-STOP mice.  
The second hypothesis that could explain the discrepancy in acute versus chronic 
effects of EAAT3 loss is that consistently increased ambient glutamate acting upon midbrain DA 
neurons leads to alterations in development of the dopaminergic system. A chronic increase in 
glutamate receptor activation may lead to increased extracellular dopamine in early 
developmental stages that leads to compensatory changes in the dopaminergic system over 
time. Potential compensatory mechanisms include increased autoreceptor activity, which could 
drive reductions in basal striatal extracellular dopamine levels (Figure 10e-f). Developmental 
increase in extracellular dopamine levels could also potentially result in a homeostatic decrease 
in membrane density of dopamine receptors in the striatum, as we observe in Slc1a1-STOP 
mice (Figure 10d). Due to the relatively small portion of glutamate that EAAT3 is responsible for 
removing from the glutamatergic synapse relative to GLT-1, synaptic DA levels would 
hypothetically be moderately affected and alterations in relevant baseline behaviors would not 
be expected, as is the case for Slc1a1-STOP mice. This explanation of increased tonic DA 
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Figure 12. Theoretical alterations in midbrain and striatal signaling throughout development in 
Slc1a1-STOP mice. 
(A) Schematic displaying increased glutamate exposure in the midbrain of Slc1a1-STOP mice during 
development due to the lack of EAAT3 expression. Hypothetically, chronic elevations in glutamate 
exposure of dopaminergic neurons may lead to increased dopamine release in the striatum during 
development compared to wildtype mice. 
(B) Schematic displaying observed reductions in striatal cell membrane levels of dopamine receptors 
and extracellular dopamine of adult Slc1a1-STOP mice. These reductions may represent a 
compensatory mechanism driven by excessive midbrain glutamate receptor exposure throughout 
development due to a lack of functional EAAT3 in Slc1a1-STOP mice. 	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release resulting in compensatory changes of the dopaminergic system across development 
also matches our findings of attenuated amphetamine-induced behavior and striatal cFos+ 
immunoreactivity in adult Slc1a1-STOP mice relative to WT controls.  
In addition to the deficits observed in amphetamine induced repetitive behavior, a 
blunted behavioral response to SKF-38393 was found in Slc1a1-STOP mice. Our finding of 
reduced membrane density of the D1 dopamine receptor in the dorsal striatum of these mice 
relative to controls likely explains this. These data are also consistent with our hypothesis that 
loss of EAAT3 in dopaminergic neurons results in compensatory changes in the dopaminergic 
system, which in turn leads to adaptive changes in receptor expression and reduced response 
to dopamine receptor agonists in the striatum. With regard to our data showing that our Slc1a1-
STOP:Cre midbrain viral injection does not rescue of SKF-38393 induced grooming, we 
hypothesize that compensatory changes yielding reduced striatal cell membrane density of 
dopamine receptors occur at an early developmental stage and that partial rescue of midbrain 
Slc1a1/EAAT3 expression in adult mice therefore does not rescue SKF-38393 induced 
repetitive grooming phenotypes in Slc1a1-STOP:Cre (midbrain) mice. It is also possible that 
EAAT3 expression is necessary in both the dopaminergic cells of the midbrain and the striatal 
MSNs to generate wildtype-like behavior in response to the D1 agonist, as we have shown that 
rescued expression of Slc1a1/EAAT3 in either site alone does not rescue this particular 
behavior. 
At this point, it is unclear how these fascinating and thought-provoking data fit into the 
glutamate hypothesis of OCD and how they may complement other animal models of repetitive 
behavior. As we have described, Slc1a1-STOP mice do not seem to recapitulate any behaviors 
commonly associated with animal models of spontaneous OCD-like behavior. Instead, Slc1a1-
STOP mice may be thought of as an “anti-model” of basal ganglia induced repetitive behavior. 
We would hypothesize that EAAT3 ablation or blockade could alleviate repetitive behavior in 
preclinical models relevant to OCD such as SAPAP3, SLITRK5, or Hdc null mice.  
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Dopamine, Glutamate, and OCD Risk 
Our data on altered dopamine system function in mice with reduced expression of a 
neuronal glutamate transporter add further to accumulating evidence pointing to an interaction 
between the glutamatergic and dopamine systems, including in relation to OCD risk and OCD 
treatment (Fonseka et al., 2014, Dold et al., 2015). Despite the evidence for glutamatergic 
dysfunction of the CSTC circuit in OCD, it is likely that the disorder involves dysfunction in 
modulatory neurotransmitters as well, based on the degree to which the dopamine and 
serotonin systems impact this circuit. For example, serotonin reuptake inhibitors, the primary 
pharmacotherapy for OCD at this point, normalize glutamatergic signal in the striatum and the 
cingulate cortex in neuroimaging studies (Moore et al., 1998, Rosenberg et al., 2000, Hansen et 
al., 2002). Further, dopamine receptor antagonists are an effective augmentation strategy in 
OCD (Li et al., 2005, Bloch et al., 2006, Skapinakis et al., 2007, Veale et al., 2014, Dold et al., 
2015). It is likely that alterations in protein function derived from abnormalities in multiple 
serotoninergic, dopaminergic, or glutamatergic risk genes may result in abnormal signaling 
within the CSTC circuit, thereby leading to compulsive behavior.     
 
Future Directions 
 Based on our initial findings using a mixed genetic and behavioral pharmacology 
approach in the Slc1a1-STOP mouse, many avenues are available to better understand how 
loss of Slc1a1/EAAT3 function affects signaling in the midbrain and striatum, the two brain 
regions that we hypothesize are most impacted in the Slc1a1-STOP mouse. Future work 
focused on delineating the glutamatergic and dopaminergic changes that lead to the 
amphetamine-dependent behavioral phenotypes described in Slc1a1-STOP mice are 
imperative. Currently, the most plausible explanation of how loss of EAAT3 function affects 
amphetamine-dependent repetitive behavior based on our data is that increased ambient 
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glutamate in the midbrain during development leads to the observed reductions of striatal 
dopamine levels in adult mice, both at baseline and after amphetamine, which we believe 
underlie the observed behavioral phenotypes. Overall reductions in extracellular dopamine 
levels in the striatum may then explain the attenuation of repetitive amphetamine-induced 
behaviors identified in Slc1a1-STOP mice as well as reductions in cFos+ immunoreactivity in the 
striatum following amphetamine challenge.  
 Based on preliminary data obtained using a genetic strategy to rescue Slc1a1/EAAT3 
expression in either D1 dopamine receptor or DAT expressing neurons (Appendix 3), the 
hypothesized developmental mechanism underlying the observed behavioral deficits in Slc1a1-
STOP mice most likely includes both dopaminergic neurons and other neurons in the CSTC 
circuit, most likely MSNs. Exclusive expression of Slc1a1/EAAT3 in either neuronal population 
referenced above is unable to rescue amphetamine induced locomotor phenotypes of Slc1a1-
STOP mice, suggesting that expression of EAAT3 is necessary in both neuronal populations 
throughout development for wildtype-like behavioral response. Use of a D1-Cre and DAT-Cre 
double rescue strategy may be a viable alternative to alleviate the observed phenotypes in 
Slc1a1-STOP mice and would provide more insight into how amphetamine induced behavior is 
affected by EAAT3 function in these neuronal populations during development.  
In order to more fully elucidate EAAT3’s role in the striatum, our collaborators in the 
Ahmari lab at the University of Pittsburgh have strategically designed experiments to 
understand how global loss of Slc1a1/EAAT3 impacts striatal neuron function. They have 
stereotactically injected Ca2+ indicators into the dorsal striatum of Slc1a1-STOP mice and WT 
controls in order to visualize changes in neuronal activity with microendoscopy in response to 
amphetamine and SKF-38393, while concurrently monitoring locomotor and repetitive behavior. 
The findings of these experiments will reveal any alterations in independent or synchronized 
firing of Slc1a1-STOP MSNs that may explain our observed reductions in dopaminergic agent 
induced repetitive behavior.  
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To further isolate where loss of EAAT3 has an impact on glutamatergic signaling 
abnormalities in Slc1a1-STOP mice leading to the observed phenotypes, identification of 
potential alterations of AMPA and NMDA glutamate receptor activity in the midbrain of Slc1a1-
STOP mice would be helpful. Electrophysiological experiments aimed at isolating glutamate 
receptor specific components of the post-synaptic response in dopaminergic neurons of the 
midbrain in Slc1a1-STOP mice and controls revealed through the use of AMPAR and NR2B-
selective antagonists would allow us to determine how loss of EAAT3 affects their activation 
profiles. Such a change could potentially help to explain the decrease in extracellular dopamine 
in the striatum at baseline. Alternatively, this same experiment could also be performed in the 
MSNs of the striatum in order to understand whether the absence of EAAT3 has a similar effect 
at other sites in the CSTC circuitry.  
It would also be useful to investigate if there are electrophysiological changes following 
amphetamine challenge that could explain the behavioral phenotypes observed in Slc1a1-STOP 
mice. This could be tested in two different ways. First, bath application could identify the acute 
effects of amphetamine on dopamine neuron firing in the absence of EAAT3. Second, 
administering amphetamine to the animal prior to harvesting neural tissue could identify whether 
EAAT3 loss alters adaptive changes in dopaminergic neurons, allowing an assessment of 
Underhill and colleagues’ findings that EAAT3 internalization mediates an increase in glutamate 
sensitivity following amphetamine administration. Alternatively, if more efficacious and selective 
EAAT3 inhibitors were available, it would also be useful to understand whether acute or chronic 
pharmacological blockade of the transporter impacts glutamatergic signaling, either in the 
striatum and midbrain. In particular, it would be interesting to compare the effects of chronic 
absence of EAAT3 with the effects of acute EAAT3 blockade, which we might expect to differ 
based upon our failure to restore D1 agonist response with Cre-mediated viral rescue of EAAT3 
expression in the midbrain. Currently, the impact of reduced EAAT3 function in 
electrophysiological studies has only been assessed via amphetamine-induced endocytosis of 
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the transporter. Acute application of selective EAAT3 inhibitors would allow for a clearer 
understanding of how short-term loss of EAAT3 function may impact glutamatergic signaling in 
the absence of other adaptive changes that might be expected following amphetamine 
administration.  
 While no identifiable abnormalities of baseline dopaminergic activity in the midbrain of 
anesthetized Slc1a1-STOP mice were identified via single unit recordings (Chohan, et al, in 
preparation), further investigation could focus on dopaminergic activity of these mice. For 
example, application of NMDA or ifenprodil, an NR2B-specific inhibitor, during these recordings 
may detect inherent differences of dopaminergic neuronal firing that are dependent on NR2B-
containing NMDA receptors. Further, systemically administering amphetamine at both high and 
low doses while assessing activity of dopaminergic neurons would help to determine whether 
challenge with the psychostimulant impacts neuronal firing, including whether this impact is 
evenly distributed across midbrain dopaminergic nuclei or is biased toward the substantia nigra 
or ventral tegmental area.  
 As noted above, an OCD-linked polymorphism, rs301430C, is associated with increased 
SLC1A1 expression in lymphoblastoid cells, human postmortem tissue, and a luciferase 
reporter assay (Wendland et al., 2009a). These data indicate that overexpression of 
SLC1A1/EAAT3, particularly in males with early-onset OCD (Dickel et al., 2006), may contribute 
to OCD susceptibility. By taking advantage of the FAST construct in Slc1a1-STOP mice, we 
could drive overexpression of Slc1a1/EAAT3 and investigate how augmenting expression 
affects baseline and drug-induced OCD-relevant behavior. Via cross-breeding strategies, we 
removed the NeoSTOP cassette in Slc1a1-STOP mice, yielding Slc1a1-tetO mice that we 
subsequently crossed with a CaMKIIa-tTA (tet-OFF) line. These Slc1a1-tetO:CaMKIIa-tTA mice 
drastically overexpress EAAT3 in the striatum, confirming that our experimental system results 
in effective tTA-mediated overexpression of EAAT3. Our priority would be to focus initially on 
animals with overexpression in dopaminergic neurons using a TH-tTA driver, since our viral 
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rescue data localize to the midbrain. The Slc1a1-tetO:CamKIIA-tTA animals may allow us to 
pursue a parallel overexpression experiment emphasizing the striatum, based upon previous 
work from the Kellendonk lab. Both lines of animals could be evaluated for baseline OCD-
relevant behavior, such as baseline and spray-induced grooming, marble burying, nestlet 
shredding, prepulse inhibition, and reversal learning. Based upon the human genetic data and 
our mouse studies, we would hypothesize that overexpression of Slc1a1/EAAT3 will result in 
increased spontaneous OCD-relevant behavior. It is also possible that no overt behavioral 
phenotypes emerge in either line of Slc1a1 overexpressing mice, since overexpression is 
associated with OCD risk but is unlikely to act in a deterministic way but likely requires the 
presence of other genetic or environmental risk factors to result in compulsive behavior. In this 
case, we would evaluate response to dopaminergic agonists, paralleling our work in the Slc1a1-
STOP mice.  
Based on our current hypothesis that constitutive loss of Slc1a1/EAAT3 expression 
results in compensatory changes in the dopaminergic system that underlie the observed 
behavioral phenotypes in Slc1a1-STOP mice, it would also be useful to understand how loss of 
Slc1a1/EAAT3 expression or function exclusively in adulthood impacts OCD-relevant behavior. 
Using currently available resources, alternative strategies utilizing tetracycline trans-suppressor 
(tTS)-mediated reduction of Slc1a1/EAAT3 expression would also be beneficial, as little work 
has been done investigating the developmental impact of Slc1a1/EAAT3 expression on OCD-
relevant behavior. Due to the scarcity of cell type specific tTS lines, examining the impact of 
Slc1a1/EAAT3 loss in exclusive developmental stages could also be achieved by using an 
inducible knockout mouse line containing a LoxP bound Slc1a1 crossed with an inducible Cre 
recombinase. Due to the complexity of neural development and the described impact of EAAT3 
function on the dopamine system, it is possible that temporally controlled global or cell-type 
specific tTS- or Cre-mediated reductions in Slc1a1/EAAT3 expression could have a different 
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effect on the glutamatergic and dopaminergic systems and provide further understanding of the 
EAAT3’s role in OCD-relevant behavior. 
 Alternatively, if a selective, potent, and bioavailable EAAT3 inhibitor was readily 
available, temporally controlled chronic loss of EAAT3 function could also be achieved 
pharmacologically. By using such a pharmacological tool in a chronic dosing strategy, we would 
be able to investigate similar questions as above; however fewer resources would need to be 
invested if the compound was already developed and its properties were well understood. 
Importantly, it is not uncommon for psychiatric pharmacotherapies to reach efficacy only upon 
chronic administration, as is the case for SRIs in both preclinical models of OCD-like behavior 
and in treatment of OCD patients. If chronic loss of EAAT3 function via pharmacological 
inhibition normalized OCD-relevant behavior in induced or spontaneous preclinical models, 
strong support would be provided for the potential utility of EAAT3 inhibitors in OCD treatment.  
 
Potential for EAAT3 Inhibitors in Psychiatric Disorders 
 The majority of the OCD patient population is left with significant impairment following 
the primary forms of pharmacotherapy and behavioral therapy. Alternative rationally designed 
therapeutics that impact the underlying mechanism of the disorder are needed to better serve 
the patient population. As discussed previously, an ancillary aim of this project was to 
preliminarily ascertain whether EAAT3 could be an appropriate target for novel therapeutics in 
OCD. Our data are the first to evaluate whether ablating this leading OCD candidate gene 
reverses behavior relevant to the disorder. The two novel EAAT3 inhibitors utilized in Chapter 3, 
NBI-59159 and 2-CFoDA, were previously uncharacterized in vivo, and it was uncertain how 
effective they would be in rodent models of repetitive behavior and glutamatergic dysfunction. 
Based on our data indicating a lack of efficacy or significant off-target side effects in vivo for 
these compounds, at least at the doses we were able to test, it is clear that alternative 
	   138	  
compounds are needed to investigate the value of EAAT3 inhibition in a preclinical OCD-
relevant context.  
 Currently, the lack of effective preclinical in vivo EAAT3 inhibitors for use in induced 
models of repetitive behavior is understandable. Preliminary data implicating Slc1a1/EAAT3 in 
OCD had been confined predominantly to human genetic analysis, while functional investigation 
of altered EAAT3 function in animal models has focused on its role in the supply of cysteine to 
neurons for the production of glutathione and downstream effects on oxidative stress. Outside of 
our findings describing the striatal dopaminergic deficits and amphetamine-induced behavioral 
deficits incurred by reduced Slc1a1/EAAT3 expression, no other group has adequately 
investigated how altered EAAT3 function may impact repetitive behavior or the neural circuitry 
relevant to OCD. Due to this previous lack of significant preclinical data, it is understandable 
that development efforts are at their earlier stages, however more potent, selective, and 
bioavailable compounds to inhibit EAAT3 function are being developed.  
 We hope that our data using a genetic model of EAAT3 loss will help motivate further 
development of EAAT3 inhibitors. If a compound with a desirable pharmacodynamic and 
metabolic profile were available, it would be of substantial benefit to the field. First, a potent 
inhibitor of EAAT3 would be useful in studies aimed at understanding how EAAT3 contributes to 
glutamatergic signaling via electrophysiology. Current studies attempting to understand this are 
primarily constrained to using pan-EAAT inhibitors, thus they are unable to delineate the 
signaling consequences of individual EAAT blockade in brain regions with concurrent 
expression of multiple EAATs. Previous work has suggested that alteration in EAAT3 function 
affects AMPA, NMDA, and mGluR5 receptor activity but have not isolated the EAAT3 specific 
contributions to baseline glutamatergic signaling in normal conditions (Otis et al., 2004, 
Underhill et al., 2014, Li et al., 2017). Further study using specific EAAT3 inhibitors would help 
the field understand how changes in transporter function may contribute to alterations in 
glutamatergic signaling and thereby confer OCD risk. Furthermore, EAAT3 inhibitors could also 
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be utilized in vivo in preclinical animal models of genetic, spontaneous, or drug-induced models 
OCD-like behavior (See Chapter 2). Despite the majority of these models having limited 
construct validity, they have been behaviorally characterized and in some cases, have 
demonstrated abnormalities in CSTC signaling. Examining the ability of EAAT3 blockade to 
rescue behavior or signaling abnormalities in these animal models would provide strong 
evidence for clinical EAAT3 inhibitor development aimed at testing alternative treatment 
strategies for OCD patients.   
 As is the case for any theoretical experimental strategy, there are important points of 
concern to address as well. Achieving in vivo specificity for EAAT3 versus other EAAT proteins 
is a significant hurdle. While the structure of EAATs has been extrapolated from an analogous 
asparate transporter found in Pyrococcus horikoshii (Boudker et al., 2007), the exact structure 
of mammalian EAATs has yet to be been resolved. It is unlikely that there are significant 
structural differences across the protein family with regard to their orthosteric site, therefore 
making specificity difficult. It is likely that strategies aimed at allosteric modulation of EAAT3, as 
has been done in the mGluR protein family (Conn et al., 2009), may be more practical. The 
drastic expression difference in EAAT3 relative to other EAATs also makes specificity of 
inhibitors paramount. In addition to an effective pharmacodynamic profile, a potential EAAT3 
inhibitor also needs to possess a suitable pharmacokinetic and metabolic profile. If the 
compound is unable to reach its intended site of action, then it becomes less useful outside of in 
vitro or ex vivo experimental strategies. Potential off-target effects would also need to be 
addressed, specifically with regard to increased oxidative stress due to loss of cysteine 
transport.  As noted above, treatment with N-acetylcysteine could be used to bypass EAAT3 
and serve as a substrate for glutathione synthesis, potentially preventing any impact on 
oxidative stress susceptibility due to an EAAT3 inhibitor. Loss of function mutations of SLC1A1 
lead to dicarboxylic aminoaciduria (Bailey et al., 2011), which would be expected to also arise 
from a chronic dosing regimen of an EAAT3 inhibitor. Neither glutamate nor asparate is an 
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essential amino acid, and individuals with dicarboxylic aminoaciduria did not appear to have 
other significant medical problems, so this effect of EAAT3 inhibition likely does not interfere 
with drug development. Of note, if a compound capable of effectively inhibiting EAAT3 function 
while maintaining a desirable pharmacokinetic profile was developed, it is possible that it could 
be of use in other psychiatric disorders as well.  
Outside of the data supporting glutamatergic dysfunction in OCD, evidence has also 
implicated glutamatergic dysfunction in schizophrenia, substance abuse, mood disorders, 
Alzheimer’s disease, and autism spectrum disorder (Moghaddam and Javitt, 2012).  Previously 
reported links between polymorphisms in SLC1A1 and increased susceptibility to second 
generation antipsychotic-induced obsessive-compulsive symptoms, as well as our reports of 
dopaminergic alterations in Slc1a1-STOP mice, are of particular interest when thinking about 
additional disorders in which EAAT3 inhibition may be advantageous. It is also of note that 
association of GRIN2B polymorphisms to schizophrenia has been reported (Qin et al., 2005, 
Martucci et al., 2006, Allen et al., 2008), in addition to data identifying overall NMDA receptor 
hypofunction in the disorder (Coyle, 2012). GRIN2B codes for the NR2B subunit of NMDA 
receptors, and its activity is impacted by EAAT3 function specifically (Scimemi et al., 2009, 
Jarzylo and Man, 2012). It is possible that EAAT3 inhibition may have beneficial effects by 
increasing ambient glutamate concentrations around NR2B-containing NMDA receptors and 
facilitating NMDA receptor mediated neurotransmission.  
Our data linking altered Slc1a1/EAAT3 expression and function to the dopaminergic 
system also suggests that pharmacological blockade of the transporter may be useful for 
studying disorders connected to dopamine signaling, including Parkinson’s disease, 
schizophrenia, mood disorders, and Tourette syndrome (Goto and Grace, 2007, Taylor et al., 
2010, Denys et al., 2013, Castellan Baldan et al., 2014, Gardoni and Di Luca, 2015, Goto et al., 
2016). The phenotypic and genetic overlap between OCD and TS has previously been well 
described (Grados, 2010). Of particular interest, a recent investigation of the casual relationship 
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between a rare histidine decarboxylase (Hdc) mutation and TS-relevant behavior stemmed from 
the identification of a hypomorphic Hdc mutation in a family that included nine members with 
Tourette syndrome, four of whom had comorbid OCD symptoms (Castellan Baldan et al., 2014). 
The authors identified abnormalities in dopaminergic modulation of the basal ganglia, including 
elevations in basal striatal dopamine levels, amphetamine-induced striatal cFos+ 
immunoreactivity and repetitive stereotypy in mice expressing a nonsense Hdc mutation. These 
findings seem to be the mirror image of those identified in Slc1a1-STOP mice, further 
supporting the potential utility of EAAT3 inhibitors in preclinical models of psychiatric disorders 
characterized by aberrant dopaminergic function. Use of novel EAAT3 inhibitors in animal 
models of schizophrenia, Tourette syndrome or any alternative psychiatric condition purportedly 
exhibiting glutamatergic and/or dopaminergic dysfunction is an exciting opportunity that may 
improve our understanding of the mechanisms underlying these debilitating disorders, leading to 
improved therapeutic options. Of note, a genetic approach could also be taken by crossing 
Slc1a1-STOP mice with Hdc null mice or other models of dopamine-dependent behavior. 
 In conclusion, the data described and discussed herein are the first attempts to 
understand how alterations in EAAT3 function affect repetitive behavior and the neural circuitry 
relevant to OCD. Up to this point, the field of OCD research has largely been confined to human 
genetic and neuroimaging strategies that have yet to be strategically integrated to provide 
mechanistic understanding of pathophysiology. Despite substantial evidence separately 
implicating SLC1A1, glutamatergic and dopaminergic signaling, and hyperactivity of the basal 
ganglia in OCD, there has been a distinct lack of functional investigation linking all three of 
these pieces of human data using in vivo models. Our data in the Slc1a1-STOP mouse allows 
us to connect Slc1a1/EAAT3 to basal ganglia-dependent repetitive behavior and the 
dopaminergic system. These findings now frame further investigation of SLC1A1/EAAT3’s role 
in the pathophysiology of OCD. Specifically, we hypothesize that EAAT3 function impacts 
striatal-dependent repetitive behavior by modulating neurotransmission at extrasynaptic 
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receptors in dopaminergic neurons, thereby affecting both baseline striatal dopamine levels and 
response to dopamine agonists. Continued investigation of Slc1a1-STOP-tetO mice offers a 
unique opportunity to understand the role of EAAT3 function in OCD-implicated neural circuits, 
potentially motivating the development of a new, rationally-designed treatment for the OCD 
patient population.  
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SUPPLEMENTAL FIGURES  
NBI-59159 2-CFoDA 
Supplementary Figure 1. Chemical Structures of EAAT3 Inhibitors 
(A) Chemical structure of the EAAT3 inhibitor, NBI-59159, used in SAPAP3 null mouse repetitive 
grooming experiments. 
(B) Chemical structure of the EAAT3 inhibitor, 2-CFoDA, used in ICV and direct striatal injection 
amphetamine challenge experiments.  
A B 
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Supplementary Figure 2. NBI-59159 attenuates amphetamine-Induced locomotor behavior 
A) NBI-59159 was administered to mice 15 minutes prior to amphetamine (3 mg/kg, subcutaneous) 
challenge. Overall time versus treatment effect was observed (P=0.018). Post-hoc analysis revealed a 
significant effect for the 5 mg/kg dose at 25-50 minutes. Figure was adapted from Glutamate Transport 
Inhibitors as Targets for Treating Psychosis (Dunlop, 2006). 
A 
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Supplementary Figure 3. Injection sites for examining the behavioral consequences 
of EAAT3 Inhibitors in amphetamine-induced locomotor behavioral assays. 
A) Site of intracerebroventicular (ICV) injection cannula (AP 0.0 mm, ML ±0.75 mm, DV -2.0 
mm, all relative to bregma).  
B) Site of direct striatal injection site (AP +0.5 mm, ML ±1.5 mm, DV -3.5 mm, all relative to 
bregma). 
A B 
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Supplementary Figure 4.  
No differences in glutamate uptake between wildtype and Slc1a1-STOP mice; high 
concentration cysteine reveals abolished transporter function in Slc1a1-STOP mice. 
(A) Na+-dependent uptake of L-glutamate (100 uM) is not altered in synaptosome preparations from 
Slc1a1-STOP mice. EAAT inhibitor: dihydrokainic acid (DHK) (100 uM) (two-way ANOVA; genotype 
F(1,8)=0.02, P=0.9, n=3; Figure is representative of three separate experiments). 
(B) Na+-dependent uptake of L-cysteine (200 uM) is absent in striatal synaptosome preparations from 
Slc1a1-STOP (ST) mice (two-way ANOVA; genotype F(1,20)=10.89, P=0.0036, n=6 per genotype). 
Figure is representative of three separate experiments.  	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Supplementary Figure 5.  
Slc1a1-STOP mice show no changes in spontaneous behavior. 
Slc1a1-STOP (STOP) mice display no behavioral abnormalities in assays relevant to anxiety or OCD-
like behavior.  
(A) Spontaneous locomotor behavior (two-way ANOVA; genotype F(1,53)=0.4378; P=0.44. n=14 per 
genotype). 
(B) Elevated zero maze (unpaired t-test; t=1.3, P=0.20. n=14 per genotype). 
(C) Light-dark emergence (unpaired t-test; t=0.5, P=0.63. n=14 per genotype). 
(D) Prepulse Inhibition (two-way ANOVA; genotype F(1,91)=0.05; P=0.83, n=14 per genotype). 
(E) Home Cage Scan (unpaired t-test; grooming P=0.08, p>0.05 for all other behaviors analyzed 
separately, n=14 per genotype). 
(F) Spontaneous Grooming (unpaired t-test; t=0.5, p=0.62, n=14 per genotype). 	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Supplementary Figure 6. 
High-dose amphetamine locomotor response is not altered in STOP mice relative to WT, and 
stereotypic behavior is not observed following saline administration 
Following acute D-amphetamine challenge (8.0 mg/kg), WT and STOP mice initially underwent 
locomotor activation and then transitioned to stationary stereotypy.  
(A) 8.0 mg/kg D-amphetamine (IP) (curve-Fit Analysis; F(4,496)=1.17, P=0.32, n=14 per genotype). 
Saline treated mice do not undergo phenotypic shuffling or sniffing stereotypy behavior. All mice in 
panels B and C are vehicle treated (i.e. receive only saline).  
(B) Saline induced stereotypy (Two way ANOVA: time x genotype F(1,44)=0.75, P=0.39; time 
F(1,44)=0.41, P=0.52, genotype F(1,44)=0.42, P=0.42; n=12 per genotype) 
(C) Saline induced stereotypy (Two way ANOVA; time x virus F(1,50)=0.32, P=0.58; time 
F(1,50)=0.89, P=0.35; virus F(1,50)=0.69, n=12 ST:GFP, 15 ST:Cre).  
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Supplementary Figure 7. 
Representative coronal sections of dorsal striatum, nucleus accumbens, and somatosensory 
cortex for cFos+ Quantification post-amphetamine challenge 
Low and high magnification images are in the left and right columns, respectively. Wildtype (top) and 
Slc1a1-STOP (bottom) mice were challenged with saline (left) and amphetamine (right), and then 
subjected to cFos+ immunohistochemistry. Region of quantification is indicated with black box in low 
magnification images. Scale bars are 250 uM and 15 uM on low and high magnification images 
respectively. 
(A) Dorsal striatum (A/P +0.9 mm, M/L ±1.5 mm, D/V -3 mm)  
(B) Nucleus Accumbens Core (A/P +1.2 mm, M/L ±0.75 mm, D/V -4.5 mm) 
(C) Nucleus Accumbens Shell (A/P +1.2 mm, M/L) ±0.5 mm, D/V -4.5 mm) 
(D) Analysis of cFos+ staining in the somatosensory cortex (A/P +0.9 mm, M/L ±3.0 mm, D/V -3.0 mm) 
was performed as a negative control for both amphetamine and genotype. Analysis reveals no main 
effects on cFos+ cells in the somatosensory cortex of WT and STOP mice. (Two-way ANOVA; drug x 
genotype F(1,12)=0.36, P=0.56; drug F(1,12)=0.13, P=0.72; genotype F(1,12)=0.36, P=0.56; n=4 per 
genotype) 	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Supplementary Figure 8. 
D1-receptor density is not affected in the ventral striatum of Slc1a1-STOP mice, while D2-
receptor density is reduced at a trend level in the dorsal striatum 
(A) Dopamine D1 receptor density estimated with [3H]-SCH-23390 binding in ventral striatum 
membrane preparations (unpaired T-test; t=0.39, P=0.7,  n=9 WT, n=7 STOP). 
(B) Dopamine D2 receptor density estimated with [3H]-methylspiperone (NMSP) binding in dorsal 
striatum membrane preparations (unpaired t-test; t=2.1, ^P=0.06, n=9 wildtype, n=6 STOP). 	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Supplementary Figure 9.  
No differences were identified in DAT staining or population estimates in the midbrain of STOP 
mice 
(A-B) Representative midbrain coronal sections of DAT staining in WT (A) and Slc1a1-STOP (B) mice. 
AP -3.1 mm. Scale bar: 500 uM. 
(C) Stereological analysis of DAT+ revealed no difference in the midbrain of WT and Slc1a1-STOP 
mice using the optical fractionator method. Coronal midbrain sections used for analysis of DAT 
staining were from -2.9 – -3.4 mm relative to bregma, (N=4 WT and Slc1a1-STOP). 	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Supplementary Figure 10. 
Effects of amphetamine on tissue levels of dopamine and DOPAC in Slc1a1-STOP mice 
(A) A main effect of amphetamine is observed in a two-way ANOVA of amphetamine’s effect on DA 
levels in the substantia nigra (SN) of WT and Slc1a1-STOP mice. (two-way ANOVA; drug x genotype 
F(1,23)=0.05, P=0.83; drug F(1,23)=7.95, P<0.01; genotype F(1,23)=3.29, P=0.08. n=7 per genotype 
per treatment). 
(B) A main effect of amphetamine and genotype is observed in a two-way ANOVA of amphetamine’s 
effect on DOPAC levels in the substantia nigra (SN) of WT and Slc1a1-STOP mice (two-way ANOVA; 
drug x genotype, F(1,23)=0.78, P=0.39; drug F(1,23)=13.54, P<0.01, genotype F(1,23)=4.35, P<0.05. 
n=7 per genotype per treatment). 
(C) Neither amphetamine nor genotype had a significant effect on tissue levels of dopamine in the 
ventral tegmental area (VTA) (two-way ANOVA; drug x genotype F(1,23)=0.99, P=0.33; 
genotype  F(1,23)=0.1294, P=0.72, n= 7 per genotype per treatment) 
(D) A main effect of amphetamine is observed in a two-way ANOVA of amphetamine’s effect on 
DOPAC levels in the VTA of WT and Slc1a1-STOP mice. (two-way ANOVA; drug x genotype 
F(1,23)<0.0001, P=0.99; drug F(1,23)=10.3, P<0.01, n= 7 per genotype per treatment) 
(E) A main effect of amphetamine is observed in a two-way ANOVA of amphetamine’s effect on DA 
levels in the dorsal striatum (DS) of WT and Slc1a1-STOP mice. (two-way ANOVA; drug x genotype 
F(1,24)=1.13, P=0.30; drug F(1,24)=6.8,P=0.01; genotype F(1,24)=3.92, P=0.06; n=7 per genotype 
per treatment). 
(F) Neither amphetamine nor genotype had a significant effect on DS DOPAC levels (two-way 
ANOVA; drug x genotype F(1,24)=0.01, P=0.92; genotype F(1,24)=0.11, P=0.74, n=7 per genotype 
per treatment). 
(G) Neither amphetamine nor genotype had a significant effect on nucleus accumbens (NAcc) DA 
tissue levels (two-way ANOVA; drug x genotype F(1,24)=0.2, P=0.65; drug F(1.24)=3.43, P=0.08; 
genotype F(1,23)=0.51, P=0.48, n=7 per genotype per treatment). 
(H) Neither amphetamine nor genotype had a significant effect on NAcc DOPAC tissue levels (two-
way ANOVA; drug x genotype F(1,24)=0.03, P=0.87; genotype F(1,24)=0.11, P=0.75, n=7 per 
genotype per treatment). 	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Supplementary Figure 11. 
Slc1a1-STOP mice have reduced baseline dopamine as measured via no-net flux microdialysis, 
and the main dopamine metabolites are not affected by amphetamine challenge. 
(A) Slc1a1-STOP mice have significantly lowered dopamine levels at baseline as measured by the 
extrapolation of linear regression using no-net flux microdialysis. (WT slope=0.92±0.03, x-
intercept=3.17; STOP slope=0.94±0.19, x-intercept=1.52; Slope comparison F(1,44)=0.44, P=0.51; 
n=6 per genotype) 
(B-C) Dorsal striatal levels of the dopamine metabolites HVA (B) and DOPAC (C) are are not different 
in Slc1a1-STOP mice relative to wildtype controls following systemic administration of amphetamine (3 
mg/kg, IP) (B) Repeated measures two-way ANOVA; time x genotype, F(7,70)=0.96, P=0.47; (C) 
Repeated measures two-way ANOVA; time x genotype F(7,70)=0.12; n=6 per genotype). 	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Supplementary Figure 12. 
Injection of an AAV-Cre into the midbrain of Slc1a1-STOP mice results in increased EAAT3 
expression 
(A) EAAT3 protein expression is increased in midbrain synaptosome preparations from Slc1a1-STOP 
mice injected with Cre virus (ST:Cre, Lane 2), relative to Slc1a1-STOP mice injected with GFP 
(ST:GFP, Lane 1). (Unpaired t-test; t=14.6, ***P=0.0001, n=3 per virus. Figure is representative of 
three separate experiments). Average protein expression ± SEM is demonstrated in bar graph.  	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Supplementary Figure 13. 
Cre expression is detected in the midbrain and striatum of Slc1a1-STOP mice injected with an 
AAV-Cre. 
(A-B) Cre expression is detected in the midbrain and striatum of Slc1a1-STOP mice injected with an 
AAV-Cre. Representative coronal sections are shown for both midbrain (-3 - -3.4 mm AP relative to 
bregma) and striatum (1.1 – 0.7 mm AP relative to bregma). High magnification images were taken at 
20X, scale bar is 100 uM. 	  
	   158	  	  
Supplementary Figure 14.  
Viral Cre-mediated rescue of dorsal striatum Slc1a1/EAAT3 expression does not rescue any of 
the dopaminergic agent behavioral phenotypes observed in Slc1a1-STOP mice  
(A) Cre-mediated excision of the Flexible Accelerated STOP-tetO knock-in in Slc1a1-STOP mice, 
leading to endogenous Slc1a1/EAAT3 expression. Blue triangles represent LoxP sites. Reference 
section indicates injection position in the dorsal striatum of Slc1a1-STOP and wildtype controls (A/P 
+0.9 mm, M/L ±1.5 mm, D/V -3 mm). 
(B) Slc1a1-STOP mice injected with AAV-Cre (ST:Cre) in the dorsal striatum exhibit a similar 
hyperlocomotor response to 3.0 mg/kg amphetamine in comparison to Slc1a1-STOP littermate 
controls injected with AAV-GFP (ST:GFP) (Curve fit analysis T=0-60; F(4,370)=0.83, P=0.50, n=9 
ST:GFP, n=12 ST:Cre).  
(C) Stereotyped behavior in ST:Cre mice in response to 8.0 mg/kg amphetamine is not different in 
comparison to ST:GFP littermate controls (Two-way ANOVA; Time x Virus, F(1,32)=0.14, P=0.71; 
Time, F(1,32)=0.68, P=0.42; Virus,  F(1,32)=1.95, P=0.17; n=9 ST:GFP, n=10 ST:Cre).   
(D) ST:Cre mice showed no difference in stereotyped grooming behavior in response to 10 mg/kg 
SKF-38393 in comparison to ST:GFP littermate controls (Two-way ANOVA; Drug x Virus 
F(1,32)=0.45, P=0.51; Drug , F(1,32)=29.74, P<0.0001; Virus, F(1,32)<0.0001, P=0.99;  n=9 ST:GFP, 
n=10 ST:Cre).  	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APPENDICES 
 In addition to the data presented in the previous chapters, which has been submitted for 
publication, I have pursued numerous other studies. Although these findings are not published, 
they have informed previous and ongoing efforts in the Veenstra-VanderWeele lab. 
 
Appendix 1: Neurochemical Characterization of Glutamate, GABA, and Cysteine in Slc1a1-
STOP Mice 
 
Appendix 2: Slc1a1-STOP mice exhibit no baseline behavioral phenotypes in OCD-relevant 
specific assays 
 
Appendix 3: Consequences of D1-Cre and DAT-IRES-Cre Based Rescue of Slc1a1/EAAT3 
Expression on Amphetamine Induced Locomotor Behavior 
 
Appendix 4: Implications of a Muscarinic Acetylcholine Receptor M4 Positive Allosteric 
Modulator in a Preclinical Model of OCD-Relevant Behavior 
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APPENDIX 1 
 
Neurochemical Characterization of Glutamate, GABA, and Cysteine in Slc1a1-STOP Mice 
 
Alterations in the concentration of glutamate, GABA, and cysteine have been observed 
in the human OCD population and in studies investigating the downstream impact of altered 
EAAT3 function (Moore et al., 1998, Sepkuty et al., 2002, Mathews and Diamond, 2003, 
Rosenberg et al., 2004, Chakrabarty et al., 2005a, Aoyama et al., 2006, Whiteside et al., 2006, 
Yucel et al., 2008, Bailey et al., 2011, Aoyama and Nakaki, 2013, Watts et al., 2014). EAAT3 is 
strongly expressed in the cortico-striatal regions implicated in these studies and is proposed to 
have three functions: 1) regulate extrasynaptic glutamate levels; 2) uptake of GABA to provide a 
substrate for GABA synthesis in GABAergic neurons; and 3) uptake of cysteine for glutathione 
synthesis (Nieoullon et al., 2006). In order to determine how disrupted function of EAAT3 affects 
these functions in striatum, medial prefrontal cortex, and hippocampus of Slc1a1-STOP mice, 
fresh tissue was isolated from each region and submitted for analysis of the aforementioned 
amino acids via high performance liquid chromatography. No abnormal tissue concentrations for 
were identified in for the amino acids analyzed in any of brain regions (Appendix Figure 1). Due 
to our previous data showing that cysteine uptake is absent in synaptosomes of Slc1a1-STOP 
mice relative to wildtype mice (Chapter 4) and previous reports of EAAT3 null mice having 
increased levels of oxidative-stress and lower levels of the anti-oxidant glutathione (Aoyama et 
al., 2006, Aoyama and Nakaki, 2013), we also performed a colorimetric based assay to quantify 
glutathione levels in striatal tissue of Slc1a1-STOP mice. A reduction of ~23% of total striatal 
glutathione was identified in Slc1a1-STOP mice relative to wildtype controls (Appendix Figure 
2). These data support our previous functional data showing that baseline glutamate uptake is 
not affected in ex vivo preparations as well as agreeing with reports from other groups showing 
that downstream products of EAAT3 function are affected as a result of reduced EAAT3 
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expression in the striatum. As glutathione deficiencies resulting from a lack of EAAT3 function 
are exacerbated in aged EAAT3 null mice (Aoyama et al., 2006), future work related to these 
efforts in Slc1a1-STOP mice may look at more specific and prolonged time points to garner 
further insight into the consequences of disrupted EAAT3 function on downstream biochemical 
processes.  
 
 
Appendix Figure 1. No differences were observed in (A) glutamate, (B) GABA, or (C) cysteine tissue 
concentrations in the striatum (STR), medial prefrontal cortex (mPFC), or in the hippocampus (HPC) of 
Slc1a1-STOP mice relative to controls (t-test, P > 0.05; n=5 per genotype per region).  
Appendix Figure 2. Total striatal glutathione levels are reduced in Slc1a1-STOP mice normalized to 
wildtype controls (t-test; t=2.66, *P=0.023, n=6 per genotype, each sample was analyzed in triplicate).  
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Appendix 2 
Slc1a1-STOP mice exhibit no baseline  
behavioral phenotypes in OCD-relevant specific assays 
 
 In order to assess any baseline behavior deficits relevant to OCD, Slc1a1-STOP mice 
were assayed in behavioral assays believed to be more pertinent of the disorder. As with many 
preclinical animal behavioral models of psychiatric disorders, symptoms observed in the human 
population are unable to be tested in rodent models and individual assay’s validity (Chapter 2) 
may be subject to discussion with regards to the relevance to the disorder they are sought to be 
modeling.  
Marble Burying 
 Initial analysis of marble burying by rodents was performed as a manner to test novel 
compounds for anxiolytic activity as rodents commonly use bedding to bury novel objects 
(Andersen et al., 2010). However, upon the finding that SRIs reduced this behavior, and SRIs 
known therapeutic effect in OCD patients, marble burying has thus been used as a screen to 
test novel preclinical models of the disorder. Briefly, twenty marbles in a four by five grid were 
laid out in a novel cage with clean bedding. Slc1a1-STOP mice and wildtype controls were 
placed into the novel cage alone for thirty minutes. At the end of the assay, mice were removed 
and pictures were taken to score the number of buried marbles by two scorers blind to 
genotype. No differences were observed in the total number of marbles buried by Slc1a1-STOP 
mice relative to wildtype controls, suggesting a lack of OCD-relevant behavioral phenotype in 
this assay (Appendix Figure 3a).  
 
Nestlet Shredding 
 Nestlet shredding is another behavioral assay that takes advantage of rodent’s natural 
behavior to shred materials in order to construct a nest. As with marble burying, nestlet 
shredding is believed to be a relatively high throughput behavioral assay relevant to OCD based 
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on the observed effectiveness of SRIs to limit the behavior in mouse models (Li et al., 2006, 
Angoa-Perez et al., 2013). One mouse was placed into a cage with clean bedding along with a 
single preweighed nestlet and left undisturbed for thirty minutes. Following the completion of the 
thirty minutes, mice were removed and the unshredded nestlet was allowed to dry overnight 
then weighed. As with the marble burying, no observed differences were identified in Slc1a1-
STOP mice relative to wildtype controls (Appendix Figure 3b).  
 
It is important to point out that while marble burying and nestlet shredding are commonly 
used due to their purported relevance to OCD, many drugs, which are ineffective in the 
treatment of OCD, have shown efficacy in these assays, lessening these assay’s predictive 
validity (Angoa-Perez et al., 2013).  
 
Water Spray Induced Grooming 
 Increased spontaneous grooming is a commonly observed behavioral phenotype 
observed in mouse models reported to be relevant to OCD (Welch et al., 2007, Shmelkov et al., 
2010b, Ahmari et al., 2013). However, as previously described (Chapter 4), Slc1a1-STOP mice 
exhibit no clear spontaneous grooming phenotypes at baseline. As the majority of the 
behavioral deficits in Slc1a1-STOP mice were induced, I wanted to examine if Slc1a1-STOP 
mice also displayed reduced induced behavior, which is suggested to be relevant to OCD. Mice 
were placed into an empty novel cage and allowed to habituate for five minutes. Mice were then 
videotaped for five minutes then removed from the cage and lightly misted with water from a 
hand spray bottle at a distance of twelve inches three times to coat the mouse’s dorsal surface. 
Mice were then placed back into the cage and videotaped for another five minutes. Following 
the completion of the assay, two observers blind to genotype scored grooming behavior. As with 
baseline grooming, no differences in spontaneous or water spray induced grooming in Slc1a1-
STOP mice relative to wildtype littermate controls (Appendix Figure 3c). Initially, it may be 
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surprising that no behavioral abnormalities were identified in Slc1a1-STOP mice following the 
induction of a behavior reported to be relevant to OCD, as many of the behavioral deficits 
previously described were induced behaviors. However, it is important to point out that all of the 
previous behavioral phenotypes were induced pharmacologically by probing the dopamine 
system while the induction of grooming in the manner described has not been reported to affect 
any specific neurotransmitter system. 
 
 
 
 
 
 
 
 
 
Appendix Figure 3. Slc1a1-STOP mice do not exhibit OCD-relevant behavioral phenotypes at 
baseline or when induced via water spray. 
(A) No differences were observed in number of marbles buried by Slc1a1-STOP mice relative to 
wildtype controls (t-test, t=0.16, P=0.87, n=10 WT, 12 STOP). 
(B) No differences were observed in nestlet shredding behavior by Slc1a1-STOP mice relative to 
wildtype controls (t-test, t=0.25, P=0.81, n=10 WT, 12 STOP). 
(C) Grooming behavior was unchanged in Slc1a1-STOP mice exclusively in no spray (NS) or water-
spray induced (S) behavioral paradigms relative to wildtype controls (Two-way ANOVA, Spray; 
F(1,40)=99.3; P<0.0001; Genotype F(1,40)=0.008, P=0.92; n=10 WT and 12 STOP). 
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Appendix 3  
Consequences of D1-Cre and DAT-IRES-Cre Based Rescue of  
Slc1a1/EAAT3 Expression on Amphetamine Induced Locomotor Behavior 
 
D1-Cre 
 Prior to the AAV-Cre (midbrain) dependent findings of partial rescue of amphetamine 
induced behaviors in Slc1a1-STOP mice (Chapter 4), an alternative experimental strategy was 
used to attempt to rescue the behavioral phenotypes observed in Slc1a1-STOP mice. Having 
identified initial reductions in both dopamine D1R agonist sensitivity via SKF-38393 challenge 
and reduced density estimates of the receptor in the striatal cell membrane preparations in 
Slc1a1-STOP mice (Chapter 4), I wanted to ascertain if cell-type specific rescue of 
Slc1a1/EAAT3 in D1R expressing neurons throughout development would rescue the 
amphetamine induced locomotor phenotypes of Slc1a1-STOP mice. Mice carrying a dopamine 
D1R specific cre-recombinase were crossbred with Slc1a1-STOP mice to yield mice 
heterozygous for D1R-Cre and homozygous for Slc1a1-STOP mice (Slc1a1-STOP:D1-Cre). 
Female Slc1a1-STOP:D1-Cre mice were then bred with male Slc1a1-STOP mice to yield 
littermate pairs to be used for behavioral characterization. Rescued expression of Slc1a1 was 
confirmed via qRT-PCR in striatal tissue samples (Appendix Figure 4a, One-way ANOVA; 
F(2,5)=18.4, P=0.0049, n=3 per genotype; Tukey’s multiple comparison test Slc1a1-STOP vs. 
Slc1a1-STOP:D1-Cre, P<0.05). As in previous amphetamine-induced locomotor assays, mice 
were placed into locomotor chambers, allowed to habituate for thirty minutes then challenged 
with amphetamine (3.0 mg/kg, IP). I found that rescue of Slc1a1/EAAT3 expression in D1R 
expressing cells did affect amphetamine-induced locomotion, unexpectedly however, it led to an 
exaggerated reduced behavioral locomotor phenotype relative to Slc1a1-STOP mice (Appendix 
Figure 4b, Non-linear curve fit analysis, F(4,280)=6.64, P<0.0001; n=9 per genotype).  
I also tested how rescued expression of Slc1a1/EAAT3 in D1R-expressing neurons 
affects D1R agonist behavioral sensitivity as I hypothesized that rescued expression of EAAT3 
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in D1R-MSNs of the striatum may effect SKF-38393 induced grooming behavior despite the 
results observed in response to amphetamine. A main effect of SKF on grooming behavior was 
identified however no genotypes differences were observed when Slc1a1-STOP:D1-Cre mice 
were challenged with the D1R agonist relative to Slc1a1-STOP controls (Appendix Figure 4c; 
Two-way ANOVA; SKF-38393 F(1,30)=27.56, P<0.0001; n=9 per genotype).  
These data were certainly intriguing however they were unexpected. They suggest that 
the observed behavioral deficits observed in Slc1a1-STOP mice were not dependent exclusively 
on EAAT3 function in D1R-expressing neurons and that EAAT3 expression has an impact on 
dopamine dependent behaviors outside of the striatum. Second, these data also show that 
expression of EAAT3 in the D1R-expressing cells alone does not underlie the reductions in D1R 
cell membrane estimates or behavioral sensitivity to SKF-38393. Due to the amplified reduction 
of amphetamine induced locomotion observed in Slc1a1-STOP:D1-Cre mice relative to Slc1a1-
STOP mice, it can also be hypothesized that EAAT3 plays an important development role on 
the neurocircuitry involved in amphetamine dependent behaviors.   
 
DAT-IRES-Cre 
 Following the behavioral results identified in Chapter 4 showing that AAV-Cre mediated 
rescue of Slc1a1/EAAT3 in the midbrain led to partial rescue of amphetamine dependent 
behavior in Slc1a1-STOP mice, I followed up on that study by using another transgenic line, 
DAT-IRES-Cre, to rescue Slc1a1/EAAT3 expression in DAT expressing neurons throughout 
development. Slc1a1-STOP:DAT-Cre mice were generated as above. It was my hypothesis that 
rescuing Slc1a1/EAAT3 expression in dopaminergic neurons throughout development would 
completely rescue the amphetamine dependent behavioral phenotypes previously described in 
Slc1a1-STOP mice. Amphetamine induced locomotor behavioral assays were performed as 
previously described (3.0 mg/kg, IP) in Slc1a1-STOP:DAT-Cre mice and Slc1a1-STOP controls. 
Interestingly, as previously observed in Slc1a1-STOP:D1-Cre mice, amphetamine challenge led 
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to reduced locomotor behavior in Slc1a1-STOP:DAT-Cre mice relative to Slc1a1-STOP controls 
(Appendix Figure 5; Non-linear curve fit analysis; F(4,406)=11.49, P<0.0001, n=12 per 
genotype). 
 More comprehensive discussion of the implications of this work is included in Chapter 5 
however brief discussion and interpretation is included here. The results of these studies are 
quite fascinating however their implications on the underlying mechanisms that elicit reduced 
amphetamine and basal ganglia dependent behavioral phenotypes in Slc1a1-STOP mice are 
relatively unclear. First, when the results from our viral and transgenic rescue studies are 
interpreted comprehensively, it can be deduced that there is a significant developmental aspect 
of Slc1a1-STOP mice’s behavioral phenotypes. Hypothetically, it may be that the underlying 
mechanisms leading to reduced dopamine driven behaviors in Slc1a1-STOP mice occur early 
during development and are dependent on EAAT3 function in both presynaptic DAergic and 
postsynaptic MSNs.  
The comparison between the midbrain viral Cre and DAT-Cre rescue studies also bring 
about other questions. How can rescued expression of Slc1a1/EAAT3 in the midbrain 
exclusively in adulthood partially rescue amphetamine induced locomotion however D1-Cre or 
DAT-Cre driven rescued expression of Slc1a1/EAAT3 cause an opposite behavioral effect? It is 
possible that rescue of midbrain EAAT3 expression and function in adult mice affects DAergic 
neurotransmission in an alternative manner that is not intrinsically related to the cause of the 
observed phenotypes in Slc1a1-STOP mice regardless of the intervention’s ability to moderately 
mitigate the amphetamine-induced behavioral phenotypes. Further examination of loss of 
EAAT3 function on dopaminergic and glutamatergic neurotransmission in each of the implicated 
nodes of dopamine dependent behavior are necessary in order to more fully comprehend 
potential underlying signaling deficits related to the behavioral phenotypes observed in Slc1a1-
STOP mice.  
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Appendix Figure 4. D1-Cre driven rescue of Slc1a1/EAAT3 Expression leads to reductions in 
amphetamine induced locomotion but does not affect SKF-38393 induced grooming. 
(A) Slc1a1 expression is partially rescued in tissue samples harvested from the striatum of Slc1a1-
STOP:D1-Cre mice relative to Slc1a1-STOP littermate controls (One-way ANOVA; F(2,5)=18.4, 
**P=0.0049, n=3 per genotype; Tukey’s multiple comparison test, *P<0.05). 
(B) Amphetamine (3.0 mg/kg, IP) causes minimal locomotor activation in Slc1a1-STOP:D1-Cre mice 
relative to Slc1a1-STOP littermate controls (Non-linear curve fit analysis, F(4,280)=6.64, P<0.0001; 
n=9 per genotype). 
(C) No genotype effect is observed following SKF-38393 challenge in Slc1a1-STOP:D1-Cre mice 
relative to Slc1a1-STOP littermate controls (Two-way ANOVA; SKF-38393 F(1,30)=27.56, P<0.0001; 
Genotype F(1,30)=0.04, P=0.85; n=9 per genotype 
Appendix Figure 5. DAT-Cre driven rescue of Slc1a1/EAAT3 Expression leads to reductions in 
amphetamine induced locomotion. 
Amphetamine (3.0 mg/kg, IP) causes minimal locomotor activation in Slc1a1-STOP:DAT-Cre mice 
relative to Slc1a1-STOP littermate controls (Non-linear curve fit analysis, F(4,406)=11.49, 
***P<0.0001; n=12 per genotype). 
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Appendix 4 
 
Implications of a Muscarinic Acetylcholine Receptor M4 Positive  
Allosteric Modulator in a Preclinical Model of OCD-Relevant Behavior 
 
 In collaboration with the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) 
and as an alternative to my work in Slc1a1-STOP mice, I also performed behavioral 
pharmacology in Sapap3 null mice, a previously described preclinical model of repetitive and 
anxiety like behavior (Chapter 2 and 3). Briefly, Sapap3 null mice exhibit cortico-striatal 
signaling deficits, increased anxiety-like behavior, and SRI responsive perseverative grooming 
behavior (Welch et al., 2007, Zuchner et al., 2009). While the overall human genetic data 
implicating the human ortholog of Sapap3, DLGAP3, in OCD is largely speculative; the Sapap3 
nulls are a useful model for preliminary screening of compounds thought to impact repetitive-like 
behavior. In collaboration with the VCNDD, I sought to determine if the robust behavioral 
phenotypes observed in Sapap3 null mice would respond to a novel positive allosteric 
modulator (PAM) of the M4 muscarinic acetylcholine receptor (M4R), VU-154. Previous work 
from the VCNDD showed the VU-154 was able to reverse behavioral and cognitive deficits 
induced by the noncompetitive NMDAR antagonist, MK-801 (Bubser et al., 2014). 
Physiologically, it was also shown that that potentiation of M4R via VU-154 administration 
impacts glutamate release from cortico-striatal terminals (Pancani et al., 2014), suggesting that 
VU-154 may also be effective in ameliorating the behavioral phenotypes observed in Sapap3 
null mice.  
 To test this hypothesis, VU-154 was used in behavioral assays to examine its ability to 
attenuate both repetitive grooming and anxiety-like phenotypes described in Sapap3 null mice. 
Spontaneous grooming was assessed by placing single mice into novel clean cages where their 
behavior was recorded via videotape then subsequently analyzed for total time spent grooming 
by independent observers blind to genotype. Thirty minute pretreatment of Sapap3 null mice 
with VU-154 (3.0 mg/kg, IP) led a reduction in perseverative grooming behavior that was not 
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observed in wildtype littermate controls (Appendix Figure 6a; Two-way ANOVA; VU-154 x 
Genotype F(1,24)=7.28, P=0.01; VU-154 F(1,24)=8.92, P=0.005; Genotype F(1,24)=18.67, 
P=0.0001; Multiple Comparisons ***P<0.001, n=7 per genotype).  
 As in the grooming assays, thirty minute pretreatment of Sapap3 nulls and wildtype 
littermate controls with VU-154 was utilized to determine the M4R PAMs ability to reduce 
anxiety-like behavior in Sapap3 null mice in the elevated zero maze. Via two-way ANOVA, a 
significant VU-154 by genotype interaction was observed with Sapap3 nulls exhibiting a VU-154 
responsive anxiety-like behavioral phenotype relative to wildtype controls (Appendix Figure 6b; 
Two-way ANOVA; VU-154 x Genotype F(1,18)=32.67, P<0.0001; Multiple Comparisons 
***P<0.001, *P<0.05; n=5 WT, 7 Sapap3 null).  
While these behavioral assays were relatively low-powered, they do indicate the 
potential utility of cortico-striatal normalizing compounds in the preclinical models of repetitive 
and anxiety-like behavior. Future efforts investigating VU-154’s effect on alternative models of 
OCD-relevant behavior with improved construct validity relative to Sapap3 nulls are important to 
garner further insight into the potential efficacy of the M4R PAMs as a novel therapeutic option 
in the treatment of OCD and related disorders. 
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Appendix Figure 6. M4R PAM VU-154 attenuates repetitive and anxiety-like behavioral 
phenotypes in Sapap3 null mice. 
(A) Perseverative grooming behavior is attenuated by VU-154 treatment in Sapap3 null mice (Two-
way ANOVA; VU-154 x Genotype F(1,24)=7.28, **P=0.01; VU-154 F(1,24)=8.92, **P=0.005; 
Genotype F(1,24)=18.67, ***P=0.0001; Multiple Comparisons ***P<0.001, n=7 per genotype). 
(B) Percent time spent in open arms of elevated zero maze is increased by VU-154 treatment in 
Sapap3 null mice (Two-way ANOVA; VU-154 x Genotype F(1,18)=32.67, ***P<0.0001; Multiple 
Comparisons ***P<0.001, *P<0.05; n=5 WT, 7 Sapap3 null). 
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